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Abstract
The mechanisms of parasite clearance in falciparum malaria are still unclear but 
the spleen is considered to be the major site of parasite removal. The process of 
removing intraerythrocytic parasites leaving the host erythrocyte intact is termed 
“pitting”. We have investigated several possible mechanisms for parasite clearance. 
Using monoclonal antibodies to Ring Erythrocyte Surface antigen, (RESA or Pf 155) 
an early antigen expressed on the erythrocyte surface and staining for 
intraerythrocytic plasmodial DNA we have demonstrated that removal of intracellular 
parasites by host phagocytes leaving the erythrocyte intact, occurs in vivo. During 
acute falciparum malaria infection, red blood cells (RBC) containing abundant RESA, 
but no intracellular parasites, are present in the circulation. These RESA-positive 
parasite-negative RBC are not seen in parasite cultures in vitro. This indicates that in 
acute falciparum malaria there is active removal of intra-erythrocytic parasites by a 
host mechanism in vivo (probably the spleen) without destruction of the parasitized 
RBC.
The ability of parasites to form rosettes has been considered a marker of 
pathogenicity in malaria and those parasites with a greater potential for this phe­
nomenon were considered inherently more pathogenic. We have reported resetting in 
a Thai patient with Plasmodium ovale infection suggesting that resetting is in fact a 
common property of all plasmodia.
Using a laser diffraction technique, we measured red blood cell (RBC) 
deformability over a range of shear stresses and related this to the severity of anemia 
in 36 adults with severe falciparum malaria. The RBC deformability at a high shear 
stress of 30 Pa, similar to that encountered in the splenic sinusoids, showed a 
significant positive correlation with the nadir hemoglobin concentration during
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hospitalization (r = 0.49, P < 0.002). Reduction in RBC deformability resulted mainly 
from changes in non-parasitised erythrocytes.
Since reduced red blood cell deformability (RBC-D) can also contribute to 
impaired microcirculatory flow, RBC-D was measured and compared in 23 patients 
with severe falciparum malaria (seven of whom subsequently died), 30 patients with 
uncomplicated malaria, and 17 healthy controls. The RBC-D was significantly 
reduced in severe malaria and was particularly low in all fatal cases. At a low shear 
stress of 1.7 Pascal (Pa), a red blood cell elongation index less than 0.21 on admission 
to the hospital predicted fatal outcome with a sensitivity of 100% (confidence interval 
[Cl] 59 - 100%) and a specificity of 88% (Cl = 61- 98%). The reduction in the RBC- 
D appeared to result mainly from changes in unparasitized erythrocytes. This finding 
may provide a rationale for the use of exchange transfusion in severe malaria since 
this process will replace rigid cells with more deformable cells.
It has been suggested that nitric oxide (NO) plays an important but still rather 
unclear role in the pathogenesis of severe falciparum malaria. We measured plasma 
nitrate and nitrite concentrations in 70 Ghanaian children with malaria (54 with severe 
malaria) and 48 control subjects (33 with medical conditions and 15 surgical 
patients). We also studied 24 adults with severe malaria on the Thai-Burmese border 
and compared those who survived with those who died. After correction for renal 
function in the adults, there was no correlation between plasma or CSF NOx levels, or 
the total amount of NOx excreted in the urine, and disease severity. In the children 
mean nitrogen oxide concentrations were not significantly different in the 2 outcome 
categories and were not related to depth of coma. In children whose cerebrospinal 
fluid (CSF) was examined, lactate concentrations but not CSF NOx levels were 
elevated in fatal cases compared with survivors (P=0-032). Plasma nitrogen oxide
concentrations were negatively correlated with admission parasitaemia (r=-041, 
72=70; P<0-0001). In these two populations, elevations of plasma lactate, but not 
nitrite or nitrate, reflected disease severity.
Lactic acidosis and hypoglycaemia frequently complicate severe malaria in 
African children, and lactate is a strong independent predictor of mortality. To study 
these metabolic derangements we sequentially allocated 21 children with severe 
falciparum malaria and capillary lactate concentrations > 5 mmol/1 to receive quinine 
or artesunate, as antimalarial therapy, and dichloroacetate (DCA), an activator of 
pyruvate dehydrogenase or saline placebo for lactic acidosis. We then administered a 
primed infusion (90 min) of L - [S-^^Ci] sodium lactate and D-[6,6-D2] glucose to 
determine the kinetics of these substrates. Nineteen surviving children were 
comparable at entry to the study. The mean (SD) glucose disposal rate in all patients 
was 56(16) pmol/kg/min and geometric mean (range) lactate disposal rate was 
100(66-177) pmol/kg/min. Glucose and lactate disposal rates were positively 
correlated (r=0.62, p=0.005). Artesunate was associated with faster parasite clearance, 
lower insulin/glucose ratios and higher glucose disposal rates than quinine. Lactate 
disposal was positively correlated with plasma lactate concentrations (r=0 .66; 
p=0.002) and time to recovery from coma (r=0.82, p<0.001; n=15). We have shown 
that elevated glucose turnover in severe malaria results mainly from enhanced 
anaerobic glycolysis and that increased lactate production is the most important 
determinant of lactic acidosis. Quinine differs from artesunate in its effects on glucose 
kinetics and basal lactate disposal rates are increased with dichloroacetate.
We also tested the hypothesis that DCA rapidly reduces hyperlactataemia in this 
patient population. Eighteen children with severe malaria and capillary plasma lactate 
> 5 mM were randomised to receive either intramuscular quinine plus a single 50
mg/kg intravenous infusion of DCA in saline, or quinine plus intravenous saline 
alone. Thirty minutes after treatment, the mean plasma lactate was 28% below pre­
treatment baseline values in the DCA group, but was unchanged in the placebo group. 
Throughout the first 4 h after treatment, mean plasma lactate in the DCA-treated 
patients was significantly less than that in controls (p= 0.003). Thereafter, mean 
plasma lactate declined in both groups and was <2 mM 10 h after treatment. DCA 
was well tolerated and did not alter quinine pharmacokinetics. A single intravenous 
dose of DCA rapidly improved lactic acidosis in African children with severe malaria, 
suggesting that DCA may be a useful adjunct in the initial treatment of these patients, 
and may increase their chance of survival by improving a major complication of their 
illness.
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1.1 Introduction
“The best blood will at some time get into a fool or a mosquito. ” Austin 
O ’Malley
Malaria is a common tropical disease. It is a protozoal infection caused by one 
or more of four species of protozoa; Plasmodium falciparum, P. vivax, P. ovale and P. 
malariae and is most commonly transmitted through the bite of an infected female 
anopheline mosquito. Only P. malariae has an animal reservoir (Bruce-Chwatt 1985). 
Of approximately 400 species of Anopheles throughout the world, only about 60 are 
vectors of malaria under natural conditions, 30 of which are of major importance. 
Malaria can also be transmitted by blood transfusion (Williamson et al. 1999) by 
contaminated needles and syringes {as unfortunately reported recently in a 
nosocomial outbreak in Nottingham} (Evans 1997) and from mother to child before 
and/or during birth (Fischer 1997).
1.2 Epidemiology
Malaria is a public health problem in 90 countries worldwide, inhabited by 36% 
of the world population, i.e. over 2 billion people are at risk. It has been estimated that 
the incidence of malaria in the world may be in the order of 300-500 million clinical 
cases each year. Estimates of malaria mortality vary from 1.5 to 2.7 million deaths 
worldwide per year. Snow et al estimate that eighty per cent of the cases occur in 
tropical Africa, malaria accounts for 10% to 30% of all hospital admissions and is 
responsible for 15% to 25% of all deaths of children under the age of five especially
in remote rural areas with poor access to health services. Around 800,000 children 
under the age of five die from malaria every year and it is one of the major causes of 
infant and juvenile mortality (Snow et al. 1999). Other high-risk groups include 
women during pregnancy, and non-immune travellers, refugees, displaced persons, or 
labour forces entering endemic areas.
Malaria thus has disastrous social consequences and is a heavy burden on 
economic development. It is estimated that a single bout of malaria costs a sum 
equivalent to over 10 working days in Africa. The cost of treatment is between $US 
0.08 and $US 5.3 according to the type of drugs prescribed as determined by local 
drug resistance. In 1987, the total "cost" of malaria - health care, treatment, lost 
production, etc. was estimated to be $US 800 million for tropical Africa and to be 
more than $US 1,800 million by 1995 (World Health Organisation 1998). In other 
parts of the world, the distribution of malaria varies greatly from country to country 
and within the countries themselves. In 1990, 75% of all recorded cases outside of 
Africa were concentrated in nine countries; India and Brazil (50%), Afghanistan, Sri 
Lanka, China, Indonesia, Viet Nam, Cambodia and Thailand. Within countries there 
are also marked differences in the distribution of the disease from one area to another. 
For example in India, the majority of reported cases occur in nine states and in Brazil, 
80% of all cases occur in three states (World Health Organisation 1993). In Thailand 
it is mainly found on the western Thai-Burmese border particularly amongst the 
Burmese refugees (Luxemburger et al. 1996).
1.3 Historical perspective
“Prehistoric man in the Old World was subject to malaria. It is probable that 
the disease originated in Africa, which is believed to be the cradle o f the human race. 
Fossil mosquitoes were found in geological strata. 30 million years old and there is no 
doubt that they have spread the infection through the warmer regions o f the globe, 
long before the dawn o f  history!' (Bruce-Chwatt, 1985)
Hippocrates is credited with early clinical descriptions of malaria and the 
symptoms of malaria have been known since time immemorial, although it was a long 
time before the actual causes were well understood. It was previously thought that 
"miasma" (bad air or "mal aria") emanating from swamps caused the disease. There is 
evidence that some ancient treatments were remarkably effective. The prescription of 
an infusion of qinghao {Artemisia annua) has been used in China for at least the last 
2000 years, its active ingredient qinghaosu (artemisinin) having only recently been 
identified as a potent anti-malarial (Klayman 1985). Development of derivatives of 
these compounds in particular artemether and artesunate have shown them to be the 
most potent and well tolerated anti-malarial drugs ever discovered.
In Peru, the antifebrile properties of the bitter bark of the cinchona tree 
(Cinchvona ledgeriana) were known by local populations well before the 15th 
century as the “Jesuit’s bark". Quinine was isolated from this in 1820 by the 
pharmacists, Pelletier and Caventou.
Although in the past people were unaware of the origin of the recurring fevers 
and their mode of transmission, protective measures against mosquito bites have been 
used for many hundreds of years. Herodotus (485-425 BC) noted that in the swampy
region of Egypt, some people slept in tower-like structures out of the reach of the 
mosquitoes, whereas others slept under nets. Recent studies in the Gambia have 
rediscovered the importance of bed nets particularly when impregnated with an 
insecticide (D'Alessandro et al. 1995) although they are not applicable to all regions 
including for example, Thailand due to differences in the biting habits of local vectors 
(Dolan et al. 1993).
Systematic malaria control started after the discovery of the malaria parasite by 
Laveran, a French army surgeon in Algeria in 1880 (for which he was awarded the 
Nobel Prize for medicine in 1907), and the demonstration by Ronald Ross, a Scottish 
army doctor in India in 1897 that the mosquito was the vector of malaria (Bruce- 
Chwatt, 1985; Desowitz, 1991). These findings quickly led to control strategies and, 
with the discovery during the World War II of the powerful insecticidal effect of 
DDT, the notion of eradication. Effective and inexpensive antimalarial drugs of the 4- 
aminoquinoline chloroquine group were also synthesised during this period. However 
resistance to chloroquine was first identified in Cambodia in the 1960’s and spread 
rapidly throughout South East Asia.
Between 1955 and 1969, the WHO Global Malaria Eradication Programme 
launched a series of campaigns aimed at spraying the inside of homes with 
insecticide. The initiative proved successful in large areas of North America, 
Southern Europe, the former Soviet Union and some territories of Asia and South 
America where transmission was halted and malaria was eradicated.
In Latin America and most Asian countries however, results varied and the 
disease persisted especially with the increase of drug resistance. The problems and 
logistics associated with malaria control were considered beyond the scope of the vast
majority of African countries, and large-scale eradication was never attempted. 
Epidemics frequently broke out in Central America and South East Asia - culminating 
in a massive epidemic in 1968 in Sri Lanka, where malaria was thought to have been 
eradicated. They also occurred in some parts of Africa, as in 1988 in Madagascar 
when 25,000 people died from malaria (Desowitz, 1991).
Mefloquine was developed by the US army in the early 1970’s and again 
resistance has been observed since the early 1980s particularly on the Thai/Cambodia 
and Thai/Burmese borders (Desowitz, 1991). Halofantrine was also developed by the 
US army and marketed by SmithKline Beecham in the 1990s but cross-resistance 
with mefloquine and side-effects (particularly cardiac dysrhythmias) (Nosten et al 
1993) have been observed. It is also too expensive for use in countries where the 
average health expenditure is $10 per annum. The Chinese have developed the latest 
class of antimalarial the artemisinin derivatives artemether and artesunate (Klayman 
1985). These are potent rapidly acting and relatively cheap. Some Western drug 
companies have now begun marketing these drugs for use in multi-drug resistant 
falciparum malaria.
The hope of global eradication of malaria was finally abandoned in 1969. 
Previous efforts had at least demonstrated that it was utopian to envisage eradication 
of the disease by campaigns based on a single strategy. It is now clear that to be 
effective, control programmes need to be adapted to local conditions and involve the 
community at large, the general health services and those involved in development. 
Malaria is a “Disease under Surveillance” by W.H.O., as it is considered an essential 
element of the world strategy of primary health care. National health administrations 
are expected to notify W.H.O. twice a year of those areas originally malarious with no
present risk of infection, those malaria cases imported into areas in the maintenance 
phase of eradication, those areas with chloroquine resistant strains of parasites, and 
those international ports and airports free of malaria. The new “Roll back Malaria” 
program, “a global partnership for halving the burden of malaria by 2010” and the 
“Medicines for Malaria Venture” a private-public co-operation to develop new drugs 
are key plans of the new director of WHO Dr Gro Harlem Brundtland. The outlook 
for new drugs in malaria, however, is rather bleak and the costs involved in 
developing them are huge with little prospect of a return for drug companies for their 
investment (White et al, 1999).
1.4 Life cycle o f Plasmodium falciparum
Falciparum malaria is transmitted by the bite of a female Anopheles mosquito. 
While taking a blood meal the mosquito injects saliva, which contains analgesic as 
well as anti-coagulant substances into the wound through her proboscis. The malaria 
sporozoites are injected in the saliva. They travel through the bloodstream to the liver 
within 45 minutes where they may mature and multiply asexually for 5 up to 28 days 
(Bruce-Chwatt, 1985) until they are released by hepatocyte rupture with as many as
30,000 uninucleate merozoites. These invade mature red blood coipuscles directly. 
There is a specific receptor/ligand interaction for invasion. This induces a calcium 
influx that activates calpain, a cytoplasmic protease that remodels the cytoskeleton. 
This alters the red cell deformability (Cranston et al. 1983). We have studied the 
clinical consequences of this altered red cell deformability in both the risk of severe 
disease and the development of anaemia (Chapter 3). The parasite probably enters the 
cell by attachment, re-orientation and active invasion using an actin myosin complex
(Finder et al 2000). Once inside the merozoite rapidly expresses proteins that hijack 
the cellular metabolism of the erythrocyte. There is no intracellular defence 
mechanism within erythrocytes. The process of maturation then begins over a period 
of 48 hours with a large metabolic energy requirement. The merozoite forms tiny 
rings within a few hours. These are the first visible signs of infection under the 
microscope. These enlarge to become small and then large rings. The appearance of 
malaria pigment (haemozoin) marks histologically the trophozoite stage at around 26 
hours. Haemozoin is the result of parasite polymerisation of haem since the parasite 
metabolises the globin part of haemoglobin in the host cell. Intracellular haem is toxic 
to the parasite and is polymerised by a still unknown mechanism into inert (3-pleated 
sheets (Taramelli et al 1999). This process is the target of most anti-malarial drugs 
probably by binding to cysteine or aspartate proteases although for most the 
mechanism of action is still unclear (Krishna and White 1996). These proteases, 
falcipain and plasmepsin have been characterized and explored recently as drug 
targets (Singh and Rosenthal 2001).
The trophozoite matures through mid-trophozoite to late trophozoite. Then the 
cells divide into > 20 daughter cells producing a schizont. The schizont ruptures after 
48 hours and releases daughter merozoites to start direct red cell invasion again.
Some of the parasites undergo meiosis to become gametocytes. Sexual 
development takes 10-12 days. Normally a variable number of cycles of asexual 
erythrocytic schizogony occur before any gametocytes are produced. The trigger for 
the switch to sexual reproduction is unknown but may relate to parasite density. The 
gametocytes form male and female gametes. Once drawn into the mosquito during a 
blood meal, the gametocytes increase in volume and escape the erythrocyte.
Microgametes are formed by 3 mitotic divisions within the microgamete, and are 
expelled explosively (Day et al, 1998). No further changes affect the female 
macrogamete until fertilisation where the plasmalemmas of male and female gametes 
fuse and the nucleus of the microgamete enters the female cytoplasm. After 
fertilisation, the zygote is a motionless globular cell, but after 18 to 24 hours it 
becomes elongated and motile, containing micronemes and a pellicle. The cell 
invades the microvillus border, passes through the midgut cells, and lies beneath the 
basement membrane. The ookinete then becomes a static oocyst, between the basal 
lamina and the basement cell membrane, and bounded by a thick plasmalemma. The 
chief source of nutrients is the haemolymph in which the oocyst develops. Sporoblasts 
form, and sporozoites bud off (Shahabuddin 1998).
After the cyst ruptures, the sporozoites escape into the haemocoele and migrate 
to and penetrate salivary gland cells where they lie in vacuoles for up to 59 days. 
These sporozoites develop and become up to 1000 times more infective than when in 
the oocyst. They are more antigenic, and bear circumsporozoite polypeptide (CSP) on 
their plasmalemma. Sporozoite motility is involved in their invasion of salivary gland 
cells and escape from the salivary gland (Day et al 1998). The sporozoites are about 
12pm long and 1pm across, with a single nucleus, anterior to which lie micronemes, 
and posterior to which lies ER and mitochondria. They possess a complex pellicle, 
which is responsible for motility, and contains circumsporozoite protein. The apical 
penetrating region contains extensions of the microneme ducts that release an agent 
that interacts with host cell plasma membrane during penetration. A biting mosquito 
transfers about 10% of its sporozoite load into the human host’s capillaries or 
perivascular tissue.
1.5 Pathogenesis and Host Responses
When the parasite reaches 18 hours of age the trophozoite also changes the cell 
surface with the appearance of electron dense “knob proteins”. These are the ligands 
that allow for the main pathogenic characteristic of falciparum that is termed 
“sequestration.” Sequestration describes the ability of the parasitized erythrocytes to 
become “sticky” and adhere to endothelial cells, letting them settle in deep tissues 
such as the brain, the liver, the kidneys and skeletal muscle. They adhere to the 
endothelium in the post-capillary venules causing slowing of the microcirculation. 
This allows the parasitized erythrocyte to avoid travelling to the spleen where the 
mechanism normally used to remove “old” uninfected rigid red cells would non- 
specifically remove the parasitized cell (Lewis and Swirsky, 1996). The parasitised 
red cell is more rigid than unparasitized red cells and can be recognised as it tries to 
squeeze through the splenic sinusoids. This will be discussed further in studies that 
we have performed relating to the rheological properties of the parasitized red blood 
cell (Chapter 3).
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The malaria transm ission cycle.
The appearance of malarial parasite proteins on the surface causes another 
problem for the parasite. These foreign antigens can be recognised by the host. In 
order to escape immune detection the parasite varies these proteins, called variable 
surface antigens (VSA) or P. falciparum erythrocyte membrane protein-1 (PfEMP-1). 
In order to do this it uses a gene rearrangement of the variable, var genes on 
chromosomes 2 and 3 near to the teleomere. This switching on and off of the genes 
allows PfEMP-1 variation to occur in up to 2% of the parasite population per life 
cycle (Newbold 1999). Different VS As probably differ in their pathogenic properties 
(Newbold 1999), for example high binding to intercellular adhesion molecule-1
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(ICAM-1) on brain endothelium may lead to cerebral malaria (Turner et al. 1994) 
whereas adhesion to chondroitin sulphate A is important in malaria in pregnancy 
(Fried et al. 1998). The loss of acquired immunity to malaria that occurs amongst 
primigravida was shown to correlate with an absence of antibodies that block the 
binding of parasites to chondroitin sulphate A on the placenta which appear in 
subsequent pregnancies (Fried et al. 1998). VS As may also be important in the 
property of “resetting” when parasitised red cells stick to other unparasitised red cells. 
The role of this property of resetting in pathogenesis will be discussed further in the 
text (Chapter 3).
Immunity to malaria in man is complex and not properly understood. Immunity 
to pre-erythrocytic stage antigens is largely mediated via CD8+ T cells and involves 
IFN-, nitric oxide, IL-12 and natural killer cells (Lalvani and Hill 1998). Immunity to 
erythrocytic stage antigens varies (in different hosts and with different parasites) but 
is largely mediated by antibody, helper CD4+ T cells, nitric oxide, cytokines and T 
cells. However the situation in man is not as well understood as in animals (Troye- 
Blomberg et al. 1999).
The role of nitric oxide is also controversial even in animal models since 
although it has an antiparasite effect which is reversible with NO synthetase inhibitors 
in P. chabaudi infection (Balmer et al. 2000), inhibitors of the inducible nitric oxide 
synthase do not reduce the antiparasite effect of adoptively transferred P. chabaudi- 
specific CD4+ T cells (Taylor-Robinson et al. 1993). We have performed clinical 
studies to measure the association if any with total nitrite excretion and severity of 
disease (Chapter 4). Killing of parasites probably occurs primarily in the spleen and in 
experiments where immune spleens were transplanted into naive recipients in the rat
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model of P. berghei it was confirmed that the bulk of killing did occur there (Favila- 
Castillo et al. 1996). Asplenic patients suffer from more severe disease 
(Looareesuwan et al. 1987a). We have described red cells expressing malaria antigens 
and therefore infected but without plasmodia nucleic acid (Chapter 3). These parasites 
are thought to have been removed or “pitted” in the spleen.
Host factors also play a role with variation in susceptibility to severe malaria 
associated with tumour-necrosis factor a  promoter gene polymorphisms (McGuire et 
al. 1994) and HLA type (Hill 1999).
1.6 Pathophysiology o f  severe disease
Severe falciparum malaria is defined by a combination of clinical and 
laboratory criteria as set out by the World Health Organisation. (Figure 2) It is 
associated with a much higher mortality than uncomplicated malaria (20% versus < 
3%). The main defining features are as shown in Figure 2. My studies have 
concentrated on three main aspects of severe disease; lactic acidosis, cerebral malaria 
and anaemia.
Acidosis Metabolic acidosis is a common cause of death in severe malaria. 
Lactate concentration is proportionally related to disease severity and the risk of death 
(Krishna et al. 1994b; White and Ho 1992), is multi-factorial and exacerbated by 
hypoxia, anaemia and malnutrition (Newton and Krishna 1998). It is associated with 
other metabolic disturbances such as hypoglycaemia. Lactate is generated by host and 
parasite anaerobic glycolysis (Zolg et al. 1984) with the majority from the host in the 
form of L (+) lactate and approximately 7% in the form of the laevorotatory enatomer 
D (-) lactate from the parasite (Jagt et al. 1990). In normal subjects the liver and
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kidneys rapidly clear lactate. However in severe malaria both hepatic 
(Pukrittayakamee et al. 1991) and renal (van Velthuysen and Florquin 2000) function 
are impaired. In general terms accumulation in plasma Z-lactate may be secondary to 
tissue hypoxia (type A) through circulatory insufficiency, severe anaemia, 
mitochondrial enzyme defects and inhibitors (carbon monoxide, cyanide) - or in 
which overproduction and/or decreased hepatic removal of lactate can occur (type B) 
through hypoglycaemia, glycogen storage diseases, seizures, diabetes mellitus, 
ethanol, hepatic failure, malignancy, and salicylate overdose (DuBose 1999). In 
severe malaria there is obviously a combination of many of these factors and lactic 
acidosis can be further exacerbated by thiamine deficiency (Krishna et al. 1999). 
Hypoglycaemia in malaria results from a failure of hepatic gluconeogenesis and an 
increase in the consumption of glucose by both host and parasite. This is worsened by 
the hyperinsulinaemic effect of quinine.
In our studies we used a stable isotope technique to measure both glucose and 
lactate turnover in children with severe malaria. By using artesunate, an artemisinin 
derivative to treat our patients we avoided the potentially confounding effects of 
quinine induced hyperinsulinaemic hypoglycaemia that was present in previous 
studies.
Dichloracetate (DCA) is a simple chemical that activates pyruvate 
dehydrogenase and so reduces lactic acidosis (Stacpoole, 1989). It has been used in 
intensive care patients with lactic acidosis due to a variety of causes and also in 
patients with mitochondrial myopathies (Stacpoole, 1992; Stacpoole 1993). We 
performed pilot studies to establish the safety and efficacy of DCA in children with 
severe malaria and measured the pharmacokinetics and dynamics.
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Figure 2. Criteria for the diagnosis of severe falciparum malaria. Adapted from (World 
Health Organization 1990)
Cerebral malaria Glasgow 
coma score <10
Pulmonary oedema
Hypotension and shock
Severe anaemia 
Haemoglobin < 5g/dlAcute renal failure
M ( M }
Severe haemolysis 
(Blackwater fever)
Hypoglycaemia BM<2.2 
Acidosis pH<7.2 
Hyperparasitaemia > 5%
Severe jaundice 
Hyperthermia >40oC 
Disemminated Intra-vascular Coagulopathy 
Extreme Pronation
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Cerebral malaria Neurological impairment in malaria can be permanent, 
especially if associated with prolonged hypoglycaemia (Nguyen et al. 1996). Altered 
consciousness and coma in malaria can also be the result of seizures that are 
commoner in children than adults (White et al. 1988). Opthalmological changes of 
haemorrhage and oedema indicating the pathology deeper in the brain can be seen in 
the retina in around 15% of patients (Lewallen et al. 1999). Although the main 
pathogenic process is sequestration and microvascular obstruction, the underlying 
cause of the coma in cerebral malaria is still unknown (White and Ho 1992). The 
main mechanisms proposed previously were hypoxia although diffuse white matter 
multiple small haemorrhages with microglial reaction (Durck’s granulomas) are seen 
at post-mortem rather than infarcts or increased capillary permeability causing 
cerebral oedema and raised intracranial pressure (White and Ho 1992). These theories 
have not been validated and in fact the use of steroids in cerebral malaria to reduce 
supposed oedema was deleterious (Warrell et al. 1982). More recently various 
neurotransmitters have been implicated such as quinolinic acid and tryptophan 
metabolites (Dobbie et al 2000). In particular the effect of nitric oxide has been 
proposed by Clark (Clark, Rockett, and Cowden 1991; Clark, Rockett, and Cowden 
1992) to be the major component of coma through a mixture of hypoxia and its direct 
neuromodulatory effects (Clark and Cowden 1999). This is claimed to be important in 
the generation and maintenance of induction in general anaesthesia (Johns et al 1992). 
Although there has been in vitro evidence for the protective and deleterious effects of 
nitric oxide there have been few clinical studies performed. As part of our studies we 
measured total nitrites in age/sex matched control patients and patients with severe
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and uncomplicated malaria. These studies were performed both in children and in 
adults. We also for the first time measured nitrite in the cerebro-spinal fluid.
Anaemia As discussed previously the invasion of red blood cells by parasites 
inevitably results in their destruction. Potential causes of haemolysis include loss of 
infected cells by rupture (before or at schizogony) or phagocytosis, removal of 
uninfected cells due to antibody sensitization or other membrane changes, and 
increased reticuloendothelial activity, particularly in organs such as the spleen. 
Decreased production results from marrow hypoplasia seen in acute infections, and 
dyserythropoiesis (Weatherall and Abdalah 1982; Phillips and Pasvol 1992) possibly 
induced by cytokines. Ninety-four per cent of 169 patients with cerebral malaria in 
one study developed anaemia (haematocrit less than 35 per cent) and 30 per cent 
required blood transfusion to maintain the haematocrit at more than 21 per cent 
(Phillips et al. 1986). The haemolytic destruction of erythrocytes leads to jaundice, 
exacerbated by reductions in hepatic blood flow (Pukrittayakamee et al. 1991), 
haemoglobinuria (Blackwater fever) and subsequent renal tubular damage (van 
Velthuysen and Florquin 2000).
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Chapter 2, Study Sites and Statement o f Personal Contribution
2.1 Mae Sot District Hospital, Tak Province, Thailand. This is a 300-bedded 
hospital located on the Thai Burmese border. It has 5 medical wards; an 8 bedded 
intensive care unit with facilities for mechanical ventilation, peritoneal dialysis and 
care of central venous access. It also has two surgical theatres and an obstetric unit. It 
has basic X-ray capabilities, basic biochemistry and haematology including a Coulter 
counter and access to blood transfusion from Tak Provincial Hospital. The average 
life expectancy in Thailand is 66 years for men, the infant mortality rate is 29 per
1,000 live births, the maternal mortality rate is 200 per 1,000 live births and the 
expectation of dying before your fifth birthday is 3.7%. This is compared to the 
United Kingdom where the average life expectancy is 75 years, the infant mortality 
rate is 7 per 1,000 live births, the maternal mortality rate is 9 per 1,000 live births and 
the expectation of dying before your fifth birthday is 0.9% (World Health 
Organisation 1998).
As well as the local population, the hospital serves a large refugee population of 
Burmese people, particularly the Karen who live on either side of the border. Malaria 
transmission is low in this area with a seasonal peak during the rainy season that starts 
in late spring until late summer (Luxemburger et al. 1996). Severe disease occurs at 
all ages. Multiple drug resistance is an increasing problem in this area (Nosten et al. 
1991) and the main vectors are Anopheles minimus, A. maculatus and few A. darus 
(S.W. Lindsay, personal communication 2000). I worked together with Dr. Ronatrai 
Ruangveerayuth, the medical division director. This site had not previously been 
involved in studies run by the Wellcome Unit and so I was involved in setting up the 
studies from an early stage. The Wellcome Trust sponsored Shoklo Malaria Research
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Unit (SMRU) has been running large community based studies into new anti-malaria 
treatments in the area since 1986 under the supervision of Dr Francois Nosten. 
However there were no hospital-based studies in severe disease before my arrival.
My work involved planning studies, applying for ethical approval with the 
appropriate Thai authorities, ordering equipment and supplies and establishing a 
clinical laboratory in Mae Sot Hospital. As far as clinical work was concerned, I saw 
all patients admitted with a possible diagnosis of malaria, confirmed the diagnosis and 
resuscitated the patients, I then made arrangements for admission to one of the wards 
or the intensive care unit and was responsible for their continuing medical care. I 
randomised the patients where appropriate into treatment studies and took the relevant 
samples. I made thin blood films, counted and staged parasites, measured 
haematocrit, lactate and glucose using the YSI analysers and measured red cell 
deformability using the LORCA analyser. I entered data onto computer, analysed the 
results and was helped to write the final papers. The work on red cell deformability 
was done in conjunction with Dr. Arjen Dondorp, University of Amsterdam, 
Netherlands and clinical assistance came from Dr Yupin Supputamongkol, and Dr. 
Kenechanh Chanthapadith. More detailed laboratory work on culture of malaria 
parasites was done by Dr. Kesinee Chontavanich and Khun Kamolrat Silamut. 
Overall supervision was by Professors Nick White in Bangkok and Piet Kager in 
Amsterdam.
2.2 Komfe Anokye Teaching Hospital, Kumasi, Ghana. This is a 1,500- 
bedded teaching hospital in Kumasi, capital of the Ashanti area in North Western 
Ghana with a population of 700,000. The average life expectancy is Ghana is 58 
years, the infant mortality rate is 74 per 1,000 live births, the maternal mortality rate
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is 740 per 1,000 live births and the expectation of dying before your fifth birthday is 
10.7% (World Health Organisation 1998), It is linked to the Institute of Science and 
Technology (1ST) in Kumasi and has its own medical school. There were no reliable 
laboratory services in the hospital. I worked in the Department of Paediatrics with Dr 
Tsiri Agbenyega and Dr. Baffoe-Bonnie. Again there had been no previous studies at 
this site and I was involved from an early stage in its development. This was part of 
the St. George’s Tropical Medicine Research Programme under the supervision of 
Professor George Griffin and Dr, Sanjeev Krishna from the Division of 
Communicable Diseases, St. George’s Hospital, London.
We arranged for a special care unit to be built between two wards. I was 
responsible for ordering and transportation of equipment and drugs into Ghana. We 
used some equipment from the unit in Thailand. Since the peak malaria seasons are at 
different times of the year in Thailand and Ghana I was, rather uniquely, able to study 
severe malaria in both children and adults throughout the year. As far as clinical work 
was concerned I saw patients on the ward with malaria and confirmed the diagnosis of 
severe malaria. I measured haematocrit, glucose and lactate, resuscitated and then 
randomised patients into the trials. We had no access to mechanical ventilation. I 
collected samples from the patients, froze and then transported them back to the 
United Kingdom for analysis. The chromatography was done elsewhere and the 
mathematical and statistical modelling was done in Florida. Help with clinical work 
was by Dr. Krishna, Dr Agbenyega, Dr. Beddo-Addo in Ghana and Professor White 
in Bangkok, Prof. Griffin in London and Prof. Stacpoole in Florida were overall 
supervisors.
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Abstract
During acute falciparum malaria infection, red blood cells (RBC) containing abundant 
ring-infected erythrocyte surface antigen (Pf 155 or RESA), but no intracellular 
parasites, are present in the circulation. These RESA-positive parasite negative RBC 
are not seen in parasite cultures in vitro. This indicates that in acute falciparum 
malaria there is active removal of intraeiythrocytic parasites by a host mechanism in 
vivo (probably the spleen) without destruction of the parasitized RBC. This may 
explain the observed disparity between the drop in haematocrit and decrease in 
parasite count in some hyperparasitemic patients. The fate of these “once-parasitized” 
RBC in vivo is not known.
Introduction
The mechanisms of parasite clearance in human malaria in vivo are unclear. The 
spleen is considered the major site of parasite removal (World Health Organization 
1990) and splenic function is increased in acute malaria; the clearance thresholds for 
both mechanical filtration and Fe receptor-mediated parasitized erythrocyte clearance 
are lowered (Ho et al. 1990a; Looareesuwan et al, 1987). Parasite clearance is delayed 
considerably in splenectomized patients. Despite evidence from animal studies in the 
1960s that the spleen could remove intraerythrocytic parasites leaving the host 
erythrocyte intact, a process known as pitting, parasite clearance in human malaria 
has been considered generally to result in obligatory destruction of the parasitized 
RBC (Davis et al. 1990). Anemia is an inevitable consequence of malaria infection 
(World Health Organization 1990), but we have observed that the haematocrit in 
some patients with heavy parasitaemias does not decrease as much as would be 
expected from destruction of the parasitized RBC (unpublished observations, 1992).
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This is particularly evident with the rapid parasite clearance that follows treatment 
with artemisinin or one of its derivatives. To establish whether pitting occurs in 
human malaria, we have used detection of the Pf 155 or Ring Erythrocyte Surface 
antigen (RESA), which is expressed immediately following merozoite invasion, as a 
measure of parasitization and correlated this with the presence of intraerythrocytic 
parasites.
Materials and Methods
Preparation o f cells, Plasmodium falciparum-infQctQd RBC were obtained from 
admission blood samples from patients with uncomplicated (n = 22) and severe (n = 
26) falciparum malaria admitted to Mae Sot Hospital, Tak Province, western Thailand 
or the Hospital for Tropical Diseases. Bangkok. The World Health Organization 
criteria were used to define severe malaria. Patients requiring hospitalization, but 
without one of these criteria, were considered to have uncomplicated falciparum 
malaria. These patients had no previous antimalarial treatment and were enrolled in 
prospective studies of malaria treatment, which will be described in detail elsewhere. 
Blood samples were also taken for full blood count, routine biochemistry, glucose and 
lactate measurements. A laboratory strain of P. falciparum, TM267R, cultured in 
RBC (RBC) for longer than 3 years was used as a standard comparator (Trager and 
Jensen 1976). Blood samples containing ring-stage parasites were washed three times 
in isotonic saline solution, the Buffy coat was removed, and the packed RBCs were 
resuspended to 50% haematocrit in heat-inactivated fetal calf serum. Thin blood films 
were made from the RBC suspension, air-dried, and fixed with methanol. In some 
assays, the thin films were fixed with 1% glutaraldehyde in saline solution, washed, 
and air-dried. All fixed thin film slides were stored at -20°C until use. Admission
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samples from patients with P. vivax malaria infection and also samples from healthy 
donors were processed and stored as described above and used as negative controls.
In vitro culture. During the continuous in vitro culture, the patients’ RBCs were 
replaced progressively with normal erythrocytes from healthy 0  ^ donors, and ring- 
stage parasites in these normal RBCs were maintained in vitro using continuous 
culture conditions (Trager and Jensen 1976a). Ring-infected RBCs from these 
cultures were then used to prepare samples as described above. The following 
antibodies were tested: 1) pooled sera from P. falciparum- immune Thai donors 
(kindly provided by S. Thaithong, Chulalongkom University, Bangkok. Thailand); (2) 
a human monoclonal antibody (MoAb) 3362 recognizing the P. falciparum RESA 
antigen (RU 1986) (Udomsangpetch et al. 1986); (3) serum from a P. v/vox-infected 
Thai patient: and (4) serum from a healthy Thai donor with no previous malaria 
exposure. All sera were heat inactivated and absorbed twice against group AW RBCs 
to deplete antiRBC antibodies that might interfere in the assay.
Antibody staining. The antisera were used at 1:50 dilution. Each antibody (5 
pL) was placed on a demarcated area on the thin blood films, incubated in a 
humidified chamber for 30 minutes at room temperature, and washed twice in 
isotonic saline solution. Rabbit antihuman immunoglobulin - G (5 pi) conjugated with 
fluorescein isothiocyanate (FITC) was then added to the previously stained area on 
the thin films and incubated for 30 minutes under the same conditions. After washing, 
all thin films were mounted with 50% glycerol in saline solution containing 10 pg/ml 
ethidium bromide to visualize the intraerythrocytic parasite DNA. The stained thin 
films were then examined with an ultraviolet (UV) light microscope at l,000x 
magnification. The FITC-stained ring-infected RBCs and the number of FITC-stained
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uninfected RBCs (RESA-RBC) were determined and expressed as numbers/1,000 
RBCs.
In the patients whose RBCs were used for cell preparation, serum was also 
tested at a single dilution (1:50) for the presence of antibodies to RESA using the 
staining procedures as described above.
Statistical analysis. Data were analyzed using Statview 4.1 (Abacus Concepts Inc. 
Palo Alto, CA. 1994). Normally distributed data were compared by the Student’s t- 
test and non-normally distributed parameters were compared using Mann-Whitney U 
test. Correlations were assessed by Spearman’s method. The test with Yates’ 
correction was used for comparison of groups.
Results
Laboratory isolate, Glutaraldehyde-fixed or methanol-fixed thin blood films of 
ring-infected RBCs from a laboratory parasite strain TN4267R were tested with 
pooled sera of P. falciparum immune donors, and the human MoAb 3362 to RESA. 
Both antibodies reacted with only the membrane of ring-infected RBCs and gave 
similar intensity and pattern of staining. This indicated that fixation of blood films 
with either glutaraldehyde or methanol provided equal antibody access to the RESA 
and that immune sera could substitute for the MoAb in routine staining.
All sera preabsorbed with AB^ ± RBCs showed no reactivity with normal RBCs 
in the indirect immunofluorescence assay. Serum from a P. vivax—infected patient 
and a healthy donor did not stain the ring form-infected RBCs. None of the antibodies 
stained uninfected RBCs in the TN4267R parasite culture.
Acute malaria. Of the 48 patients studied, 26 had severe falciparum malaria (12 
cerebral malaria, 3 acute renal failure, 1 severe anemia, 2 jaundice, 8
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hyperparasitaemia) and the other 22 had uncomplicated malaria. Four patients with 
severe malaria (15%) died. The geometric mean (range) parasite counts were higher 
in the severe malaria group; 1,174,830/pL (3.010 to 1,210,920) compared with the 
uncomplicated group; 26,540/pL (2.070 to 221,560); P < .05. The mean (standard 
deviation [SD]) haematocrit was similar in the severe and uncomplicated malaria 
groups; 32 (9)% and 35 (8)%, respectively. The clinical and laboratory values for the 
patients with severe malaria are shown in Table 1. Thin blood films from malaria 
patients on admission that contained bright ethidium bromide-stained parasite nucleic 
acid were then stained with the pooled immune sera or MoAb 3362 and showed the 
typical RESA pattern of staining on the infected RBCs. This pattern was also seen on 
some uninfected RBCs (RESA-RBC) containing no ethidium bromide (Fig 4). The 
absolute number of RESA-RBC was higher in patients with severe malaria (geometric 
mean [range] 21,720/pL [5,650 to 166.5501 compared with 7,200/pL [2,390 to 
39,190] in patients with uncomplicated malaria. The median (range) ratio of parasit­
ized RBCs to RESA-RBCs was 8.63 (0.133 to 50) for severe patients and 2.917 
(0,278 to 20) for uncomplicated patients (P < .05). There was a significant positive 
correlation between absolute parasitaemia and absolute RESA-RBC numbers (r^ = 
.52. P = .0004), i.e. RESA-RBC accounted for 50% of the variation of parasitaemia 
(Fig 5). There were no significant correlations for any other markers of disease 
severity including spleen size, haematocrit, lactate, or glucose (Krishna et al. 1994b; 
World Health Organization 1990). There was no significant difference for duration of 
previous illness before presentation or for outcome.
Continuous in vitro culture. When all of the patients’ RBCs had been replaced 
by RBCs from a healthy donor in continuous culture, the infected RBCs stained as
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before with pooled immune sera or human MoAb 3362, but either no RESA-RBC was 
detected or, in eight patients’ cultures, very low numbers were seen (median, 100 
cells/mL. range. 100 to 500). There was no significant difference in the numbers of 
RESA-RBC between mild and severe patients in vitro.
Anti-RESA antibodies. Sera from P. falciparum-infQOiQd patients were tested 
for antibodies to RESA by indirect immunofluorescence assay. Thirteen sera showed 
reactivity with RESA at 1 in 25 dilution. Ten patients had uncomplicated disease and 
three had severe disease (P = .011) There was no significant difference in the number 
of RESA-RBC or measures of diseases severity between the antibody positive and 
antibody negative patients, although there was a significantly lower parasitaemia in 
the antibody positive patients (P ~ .009).
Discussion
The objective of these studies was to seek evidence of previous parasitization in 
unparasitized RBCs in acute falciparum malaria. The parasite-derived antigen Pf 155 
or RESA (Perlmann et al. 1984) was chosen because it is associated with dense 
granules in the apical part of the merozoite and is deposited in the erythrocyte 
membrane during invasion (Brown et al. 1985) (Aikawa et al. 1991a). RESA is, there­
fore, present in the RBC membrane from a very early stage of infection and acts as a 
“footprint” of RBC parasitization by a P. falciparum parasite. RESA is a well- 
characterized polypeptide antigen that is highly conserved and is immunogenic in 
man (Cowman 1984). Immune sera and MoAb 3362 gave a distinctive pattern of rim 
fluorescence over the glutaraldehyde-fixed erythrocyte membrane, but not on unfixed 
cells (Udomsangpetch et al. 1986). RESA is first synthesized within mature 
trophozoites and accumulates within merozoites. When RBCs from acute malaria
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patients were stained with pooled immune serum or MoAb3362, the pattern of 
antibody binding on some of the unparasitized RBCs was typical of RESA staining. 
Pooled immune serum is likely to have recognized a number of different parasite 
antigens, but the relative immunodominance of RESA was such that the two patterns 
of staining appeared identical.
There are three possible explanations for these observations. First, that in some 
cases, the merozoites invade the RBCs, then die spontaneously and are degraded 
rapidly within the cytoplasm. Second, that the young parasites are extruded actively 
by the RBC (either alive or dead), and third, that the parasites are somehow extracted 
from the RBC leaving it intact. If the parasites had simply died, then some DNA 
degradation products would still be expected to have stained by the ethidium bromide. 
This was not observed. The discrepancy between the numbers of RESA positive, 
parasite negative cells seen in vivo and in vitro suggests that active extrusion of 
parasites by the RBCs is unlikely to be quantitatively important. The most likely 
explanation is that host defense responses (probably the spleen) are involved in 
removal of intraerythrocytic parasites in vivo (Ferrante 1990; Nnalue and Freidman 
1988; Abdalla and Weatherall 1982; Phillips et al 1986). The spleen normally 
removes residual host nuclear material from erythrocytes, but how it recognizes 
damaged intraerythrocytic parasites is not known. The possibility that immature or 
killed intraerythrocytic parasites could he removed from within RBCs either by 
phagocytic cells or by active extrusion without their destruction, was first raised by 
observations in experimental simian malaria by Conrad and Dennis (Conrad and 
Dennis 1968). This was further supported by ultrastuctural studies of the spleen in 
Rhesus monkeys infected with P. knowlesi (Conrad and Dennis 1968) (Schnitzer et al.
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1971) (Schnitzer et al. 1972) (Schnitzer et al. 1973). Human neutrophils in vitro have 
also been shown to be capable of extracting P. falciparum parasites from RBCs, 
leaving the RBCs intact (Kumaratilake et al. 1994) and parasitized RBCs treated with 
antimalarial drugs have been recorded extruding dead trophozoites (Gu and Inselhurg 
1989). This evidence in experimental systems supports our findings that removal of 
intraerythrocytic parasites occurs naturally in vivo when the host immune system can 
act, but not under in vitro parasite culture conditions in the absence of leukocytes and 
the spleen. It is likely that the parasites removed were in the first 24 hours of their 48- 
hour asexual life cycle because the morphology of the RESA positive cells was 
normal. In the second half of the asexual life cycle, cytoadherence takes place, and 
these adherent RBCs would have remained sequestered in the microcirculation 
whether or not they were still parasitized (Molyneux et al. 1989). As most of the 
intraerythrocytic hemoglobin is consumed by more mature parasites, the hemoglobin 
concentration of the once parasitized cells was probably not reduced markedly. Thus, 
in the short-term, these once parasitized and antigenically marked RBCs. which occur 
in numbers approximately similar to the parasitized RBCs, will contribute to oxygen 
carriage and delivery, but their ultimate fate is not known. RESA is not expressed on 
the cell surface (Aikawa et al. 1991b), so increased antibody binding and thus immune 
recognition would not be expected, but it is associated with the RBC cytoskeleton 
(Ruangjirachupom et al. 1991) (through binding with spectrin) and could theoretically 
alter RBC deformability leading to splenic removal. Further study of the survival and 
the effects of different antimalarial drugs on the numbers of these cells in the 
circulation will be required.
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Table 1.
Summary of Clinical and Laboratory Variables in 26 Patients With Severe 
Falciparum Malaria (median, range unless indicated)
Temperature (®C) 38.8
(36 .5 -40)
Pulse 111
(beats/min) (8 8 -  140)
Systolic blood pressure 100
(mm Hg) (80 -  140)
Respiratory rate 35
(breaths/min) (20 -  48)
Glasgow Coma Score 15
(3 -1 5 )
Parasite count/mL 174,830
geometric mean (range) (3,010-1,210,910)
RESA-RBC count/pL 21,720
geometric mean (range) (5 ,650- 166,550)
Ratio parasite count to RESA-RBC 8.63
median (range) (0.2 -  75)
Lactate (mmol/L) 6.8
Mean, (SD) (5.3)
Blood urea nitrogen 27.5
(mg/dl) (1 2 -108)
Serum creatinine 1.15
30
(mg/dL) (0 .6 -7 .6 )
Total bilirubin 2.85
(mg/dL) (0 .6-23 .3)
SGOT 49
(U/L) (18 -335)
SGPT 20
(U/L) (5 -9 1 )
White cell count 7.6
(cells X 10^/L) (4.7 -  8.8)
Hemoglobin (g/dL) 9.9
(5 .5-15 .2)
Platelet count 93
(cells X 10^/L) (20 -191)
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Figure 4. Immunofluorescence photomicrograph (original magnification x 
1.000) stained with ethidium bromide and FITC-conjugated antiRESA 
demonstrating a parasitized RBC on the left and a RESA positive, parasite 
negative RBC on the right.
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Figure 5. Linear regression analysis of parasitaemia with the number of RESA 
positive, parasite negative RBCs (RESA-RBC) (mean. 95% confidence interval 
for the slope).
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Abstract
Red blood cells infected by mature stages of Plasmodium ovale obtained from a 
56-year-old Thai patient formed rosettes readily with uninfected erythrocytes. Ex vivo 
the ring stage-infected erythrocytes matured well under the in vitro conditions used 
for P. falciparum culture, and the infected erythrocytes formed rosettes when the 
parasites became mature trophozoites. These rosettes were stable and remained intact 
until completion of schizogony. Plasmodium ovale rosettes were similar to those 
formed by P. falciparum and P. vivax - infected erythrocytes. Rosette formation 
appears to be a common property of three species of human plasmodia.
Introduction
Four species of plasmodia cause malaria in humans. Of these, only Plasmodium 
falciparum infections are potentially lethal (World Health Organization 1990). The 
pathology of severe falciparum malaria is related to sequestration in which infected 
erythrocytes stick in the deep vasculature and the resultant slowing of blood flow and 
focusing of toxic damage causes vital organ dysfunction (White and Ho 1992). Two 
in vitro phenomena observed are thought to be related to this mechanism: 
cytoadherence or the adhesion of infected erythrocytes to vascular endothelial cells 
(Udienya et al. 1981) and rosette formation in which two or more uninfected 
erythrocytes adhere to an infected erythrocyte (Udomsangpetch et al. 1989). The 
ability of parasites to form rosettes has been considered a marker of pathogenic poten­
tial and those parasites with a greater potential for this phenomenon are considered 
inherently more pathogenic (Rowe et al. 1995). Rosette formation has been correlated 
with cerebral malaria and with other manifestations of severe falciparum malaria in
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studies in Africa (Carlson et al. 1990b; Hassler et al. 1990; Ringwald et al. 1993), but 
not in Southeast Asia or Oceania (Al-Yaman et al. 1995; Ho et al. 1991). The human 
malaria parasites causing benign malaria have been considered incapable of 
cytoadherence or rosette formation (Handunnetti et al, 1989), although we have 
recently reported that P. v^vax-infected erythrocytes readily form rosettes 
(Udomsangpetch et al. 1995), and now report here rosette fomiation by P. ovale- 
infected erythrocytes.
A 56-year-old woman from the northwestern border of Thailand originally 
diagnosed as having P. vivax infection was admitted to Sangklaburi Hospital in 
Kanchanaburi. The patient was febrile (temperature = 38°C) and mildly anemic 
(haematocrit = 28%) but was able to walk. A thin blood film made on admission 
showed a P. ovale infection. The parasitaemia was 1.4% with a predominance of ring 
forms (Figure 6A). The patient was blood group B, Rosette formation was then 
assessed by mounting one drop of a fresh EDTA-blood specimen diluted 1:10 with 
normal saline on a microscope slide and examined using a light microscope at 1,000X 
magnification. This showed no rosette formation nor aggregation of the erythrocytes. 
She was given a single dose of mefloquine (15 mg of base/kg) and a 14 day course of 
primaquine (0.15 mg of base/kg). A subsequent EDTA-blood specimen taken 15 hr 
later showed some pigment-containing trophozoites and schizonts on the thin blood 
film (Figure 6B and C) that formed rosettes readily (Figure 6D).
To document the development of rosette formation in vitro, a culture of the 
pretreatment parasites was prepared as described previously for P. falciparum in vitro 
(Trager and Jensen 1976b). An admission EDTA-blood specimen was washed three 
times with RPMI 1640 medium, the leukocytes in the Buffy layer removed, and the
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erythrocytes were then diluted to haematocrit in malaria culture medium containing 
RPMI 1640, pH 7.4, 10% heat-inactivated AB serum, 25 mM PES, and 20 pg/ml of 
gentamicin. This was then cultured at 37^C in air plus 5% CO2 for 45 hr. A thin blood 
film made after in vitro culture for 24 hr showed that the parasites had matured to the 
pigment-containing trophozoite stage. Infected erythrocytes with pigment-containing 
parasites formed rosettes with uninfected erythrocytes. No uninfected erythrocyte 
aggregations were seen. By 36 hr of culture parasites had matured to the schizont 
stages, and again the schizont-infected erythrocytes formed rosettes. Examination of 
the thin blood film after 45 hr of culture showed a few ring-infected erythrocytes 
while most of the schizonts had become pyknotic. The remaining schizont-infected 
erythrocytes all still formed rosettes.
The observations that two species of plasmodia infecting humans, P. ovale and 
P. vivax, which do not sequester and do not cause severe clinical disease, readily form 
rosettes (Udomsangpetch et al. 1995) challenges the hypothesis that rosette formation 
alone is a marker of parasite pathogenicity. This further emphasizes the differences 
between the properties of rosette formation and cytoadherence. It does not exclude the 
possibility that rosette formation contributes significantly to microvascular 
obstruction and thus pathogenicity in P. falciparum in vivo, but suggests that it would 
do so only in conjunction with cytoadherence leading to sequestration, and/or high 
parasite burdens. Rosette formation appears to be a common property of these three 
species o îPlasmodium under in vitro conditions.
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Figure 6.
Thin blood films of the patient showing A. a ring form of Plasmodium ovale (on 
admission), B, a pigmented trophozoite, C, a schizont (15-hr after admission), and D, 
a red blood suspension with rosette formation by a P. ovale infected erythrocyte 
(reversed Field’s staining, magnification X 1.000).
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Abstract
Severe falciparum malaria is associated with mierovascular obstruction 
resulting from sequestration of erythrocytes containing mature stages of the parasite. 
Since reduced red blood cell deformability (RBC-D) can contribute to impaired 
microcirculatory flow, RBC-D was measured in 23 patients with severe falciparum 
malaria (seven of whom subsequently died), 30 patients with uncomplicated malaria, 
and 17 healthy controls. The RBC-D, measured by ektacytometry, was significantly 
reduced in severe malaria and was particularly low in all fatal cases. At a low shear 
stress of 1.7 Pascal (Pa), a red blood cell elongation index less than 0.21 on admission 
to the hospital predicted fatal outcome with a sensitivity of 100% (confidence interval 
[Cl] 59— 100%) and a specificity of 88% (Cl = 61- 98%). The reduction in the RBC- 
D appeared to result mainly from changes in unparasitized erythrocytes. Reduced 
deformability of unparasitized red blood cells in severe malaria may contribute to 
impaired microcirculatory flow and a fatal outcome in severe falciparum malaria.
Introduction
Infection with Plasmodium falciparum remains a major cause of death in the 
tropics, with an annual global mortality of 1—2 million people and a mortality rate in 
severe malaria of 15—30% (World Health Organization 1990; World Health 
Organization 1993). The sequestration of red blood cells containing the mature forms 
of the parasite in the microcirculation of the vital organs is considered to be the 
essential pathologic feature of the infection, but precisely how this causes death is not 
known. Sequestration interferes with microcirculatory flow and tissue metabolism and 
may focus the release of host- or parasite-derived toxins to the vital organs (White
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and Ho 1992). The cytoadherent, parasitized red blood cells impede the passage of the 
uninfected red blood cells, which are forced to deform more than usual in their transit 
through the microcireulation. Since reduced red blood cell deformability (RBC-D) has 
been associated with impaired tissue perfusion in other conditions (Mokken et al. 
1992) we investigated the relationship between RBC-D and disease severity in 
falciparum malaria.
Patients and Methods
The study was carried out in May and June 1995 in the provincial hospital of 
Mae Sot, Tak Province, Thailand. Malaria transmission is low in this area with a 
seasonal peak during the rainy season that starts in late spring (Luxemburger et al. 
1996). Severe disease occurs at all ages. Multiple drug resistance is an increasing 
problem in this area.
Patients and clinical procedures.
Consecutive adult patients, admitted to Mae Sot Hospital with acute falciparum 
malaria were included provided that written informed consent was obtained from the 
patients or their attendant relatives. Disease severity was classified according to 
standard criteria (World Health Organization 1990). Exclusion criteria were an age 
less than 14 years, pregnancy, and a history of previous antimalarial drug treatment - 
within 24 hr of admission. Previous quinine treatment was checked in a baseline 
blood sample by a rapid quinine dipstick method in all patients (Silamut et al. 1995). 
A full clinical examination was performed on admission and all details were recorded 
in a standard form. In cases of cerebral malaria a lumbar puncture was performed to 
exclude other causes of altered consciousness. Patients were randomly assigned to 
treatment with either intravenous quinine dihydroehloride (20 mg of salt/kg infused
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over a 4-hr period followed by 10 mg/kg every 8 hr) followed by oral tetracycline or 
intravenous artesunate (2.4 mg/kg immediately, then 1.2 mg/kg at 12 and 24 hr and 
then daily) followed by mefloquine in a comparative study that will be published 
elsewhere. Full supportive care was given as described previously (World Health 
Organization 1990). If necessary, patients were transferred to an intensive care unit 
for mechanical ventilation, peritoneal dialysis, or haemodynamic support and 
monitoring. This investigation was part of studies approved by the Ethical and 
Scientific Review Subcommittee of the Ministry of Public Health, Thailand.
Laboratory methods.
Thick and thin films from peripheral blood were taken on admission and stained 
with Field’s stain for parasite counting (White and Silamut 1989). Baseline blood 
samples were taken for full blood count, glucose, lactate, and routine biochemistry. 
Hemoglobin (Hb) electrophoresis was assessed from stored frozen samples (—20^C). 
Mean red blood cell diameter (MCD) and red blood cell morphology were evaluated 
in a thin smear using a calibrated light microscope. The RBC-D was measured 
immediately by ektacytometry using a Laser-assisted Optical Rotational Cell 
Analyzer (LORCA;® Mechatronics, Hoorn, The Netherlands) (Hardeman et al. 1994). 
Blood samples from healthy Thai adults of the same age range were used as controls. 
With this method a defined shear stress is applied to a red blood cell suspension in a 
high viscous medium (5% polyvinylpyrrolidone in phosphate-buffered saline) at a 
constant temperature of 37^C, in a small gap between two concentric rotating 
cylinders. Because of the applied shear stress the cells elongate and align themselves 
in the fluid layer, thus forming a grid. A laser beam is directed through the fluid layer 
and forms a diffraction pattern behind it. The ellipticity of this diffraction pattern is
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directly proportional to the mean ellipticity of the red blood cells (i.e., the amount that 
the normally discoid erythrocyte is deformed). The unit of deformability is the 
elongation index (El), defined by the length of the long axis minus the short axis 
divided by the length of the long axis plus the short axis of the deformability pattern. 
This is determined by computer analysis of the diffraction pattern, using iso-intensity 
lines for curve fitting. Red blood cell defoimability was assessed at three shear 
stresses (1.7, 9.5, and 30 Pascal [Pa]) corresponding approximately to shear stresses 
encountered in vivo in the venules, the arterioles and capillaries, and in arteries with 
significant stenosis, respectively (Chien 1987). Reproducibility was a major drawback 
in former filtration methods for measuring RBC-D, but it is very good with ekta­
cytometry (Bessis, Mohandas, and Feo 1980; Hardeman et al. 1994; Mokken et al. 
1992).
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Table 2.
Admission clinical and laboratory variables in 23 patients with severe malaria in Mae 
Sot Hospital, Tak Province, Thailand
Variable* Survivors (n = 16) Fatal cases 
(n = 7)
P
Age (years) 28 ± 8 28 6 14 NS
Days with fever prior 
to admission
3.5 ± 1.8 4.3 6 1.8 NS
Pulse rate (per mm) 114 6 11 109 6 15 NS
Blood pressure(mm 
ofHg)
Systolic
Diastolic
108 6 12 
61 6 13
1046 14 
63 6 20
NS
NS
Temperature (C) 38.9 6 9 38.2 6 1.4 NS
Median coma score 15 8 0.004
Packed cell volume 
(%)
31 6 12 3 1 6 9 NS
Parasitaemia (%) 6 6 6 106 11 NS
Creatinine (mg/dl) 1.15 6 0.22 2.35 6  2.36 0.029
Lactate (mmol/liter) 4.4 6 2.4 13.1 6 9.2 0.019
Glueose (mmol/liter) 9.5 6 6.3 8.9 6 3.5 NS
MCD (pm) 6.2 6 0.5 6.2 6 0.2 NS
RBC-D at SS = 1.7 Pa 0.252 6 0.033 0.189 6 0.014 0.0001
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(El)
RBC-D at SS = 9.5 Pa 
(El)
0.507 6  0.035 0.450 6 0.034 0.0014
RBC-D at SS = 30 Pa 
(El)
0.588 6 0.029 0.547 6 0.033 0.0077
MCD mean eell diameter of red blood cells; RBC-D = red blood cell deformability; 
SS = shear stress; El = elongation index; Pa = Pascal.
Except for median coma score, values are the mean ± SD.
Comparisons by Mann-Whitney U test; all other comparisons by Student’s t-test.
Statistical methods.
Statistical analyses were carried out using SPSS 6.1 statistical programs (SPSS 
Corporation, Chicago, IL). Normally distributed data were analyzed using Student’s t- 
test and analysis of variance, with application of the least significant difference 
method for multiple comparisons. The Mann-Whitney test was used to compare non- 
normally distributed variables. Correlations were assessed by the method of Pearson 
for normally distributed variables, and the method of Spearman for the remainder. A 
multiple logistic regression model was used (Forward Logistic Regression; SPSS 6.1 
statistical programs) to determine the most discriminating prognostic indicators and 
their relative contributions in predicting outcome (death or survival).
Results
Clinical details.
A total of 23 patients with severe malaria were included in the study. The
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comparison groups comprised 30 adult patients with uncomplicated falciparum ma­
laria and 17 healthy volunteers. In the severe malaria group 12 had cerebral malaria, 
four developed pulmonary edema requiring assisted ventilation, one patient became 
anuric and was dialyzed, and one patient developed nosocomial pneumonia. Seven 
patients (30%) subsequently died (of whom four received quinine and three 
artesunate). There were no deaths in the group with uncomplicated malaria. Clinical 
and laboratory details are shown in Table 3. The mean (SD) time to fever clearance in 
severe malaria was 68.5 (54.8) hr and the corresponding time to parasite clearance 
was 63.4 (24.2) hr. Within the group of patients with severe malaria MCD of the red 
blood cells did not differ significantly between survivors and fatal cases. There were 
five patients with severe malaria and severe microcytosis (MCD < 6.0) all of whom 
survived. Of these five patients four likely to suffer from thalassemia because of high 
HbA2 levels and target cells in the thin smear. The RBC-D at 1.7 Pa varied between 
0.24 and 0.28 in this group. One patient who died was later shown to have had an 
HbE haemoglobinopathy. The MCD of the red blood cells was 6.0 pm and RBC 1.7 
at Pa was 0.20 in this patient. Six patients with intracellular haemolysis were found to 
be negative for glucose-6- phosphate dehydrogenase deficiency.
Red blood cell deformability.
Red blood cell deformability was reduced in proportion to disease severity 
(Table 3). The most striking difference was between fatal cases with severe malaria 
and survivors (Figure 7). Severely reduced RBC-D (El <0.21) at a shear stress of 1.7 
Pa predicted fatal outcome with a sensitivity of 100% (confidence interval [Cl] = 
59— 100%) and a specificity of 88% (Cl = 61—98%). Parasitaemia on admission did 
not correlate either with the RBC-D (correlation coefficient = —0.08, P  = 0.6) or with
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survival. In a multiple logistic regression analysis, with the parameters listed in Table 
2 as variables, RBC-D at a shear stress of 1.7 Pa was the strongest predictor of 
mortality (Wald statistic = 4.5). The only other variable that contributed significantly 
to the model was the Glasgow Coma Score on admission (Wald statistic = 2.1). There 
was a significant correlation between admission values for plasma lactate levels and 
RBC-D (correlation coefficient = —0.44, P  = 0.04). There was no relation between 
the MCD of the red blood cells and RBC-D at 1.7 Pa. In fatal eases, the RBC-D on 
admission was not significantly different from the RBC-D 2-12 hours before death 
(mean ± SD RBC-D at 1.7 Pa = 0.186 0.018 and 0.197 ± 0.039, respectively). There 
was no significant change in RBC-D during the time of admission (up to 168 hr).
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Table 3,
Mean ± SD red blood cell deformability (RBC-D) on admission in 30 patients with 
uncomplicated falciparum malaria, 23 patients with severe falciparum malaria, and 17 
healthy controls in Mae Sot Hospital, Tak Province, Thailand*
Study group
Variable Uncomplicated
malaria
Severe malaria Healthy controls
n 30 23 17
Age, years (mean ± 
SD)
27 6 10 28 6 10 32 6 7
RBC-D a t S S=  1.7 
Pa (El)
0.270 6  0.027 0.232 6 0.041 0.284 6 0.017
RBC-D at SS = 9.5 
Pa (El)
0.520 6 0.020 0.489 6 0.043 0.544 6 0.011
RBC-D at SS = 30 
Pa (El)
0.602 6  0.016 0.576 6 0.035 0.617 6 0.010
Differences in RBC-D at all levels of shear are significant (P < 0.05) between all 
study groups (analysis of variance), except for RBC-D at SS = 1.7 Pa in 
uncomplicated malaria patients compared with healthy controls.
•SS = shear stress; El = elongation index.
Discussion
During their passage through the microcirculation, red blood cells must undergo
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considerable deformation because their diameter (7.5 pm) exceeds the average 
midpoint diameter of the capillaries (3—7 pm). Red blood cell deformability is 
therefore an important determinant of mierovascular blood flow (Nash 1991), Red 
blood cells infected with P. falciparum parasites become progressively less 
deformable as the intra-erythroeytic parasites mature (Cranston et al. 1983a; Nash et 
al. 1989). Early studies showed that the filterability of red blood cells in 
uncomplicated malaria was reduced, suggesting that uninfected red blood cells might 
also be less deformable, although the relationship of red blood cells filterability to the 
rhéologie conditions encountered in vivo is uncertain (Areekul and Yamarat 1988; 
Lee et al. 1992). The present study shows that red blood cells in patients with acute 
falciparum malaria are less deformable than in healthy subjects and that this rigidity 
increases with increasing severity of the infection.
The red blood cells deformability estimate obtained by the LORCA is a 
summation of the RBC-D of all the red blood fractions, with contributions to the 
overall value that are proportional to their size (Streekstra GJ, A Biplane Rheoscope 
for the Measurement o f Red Cell Deformation and Orientation in a Couette Flow. 
Thesis, University of Utrecht, Utrecht, The Netherlands, August 1994). Since the 
majority of red blood cells even in severe malaria is uninfected, this reduction in 
RBC-D results mainly from changes in the unparasitized erythrocytes. The relative 
unimportance of the parasitized red blood cells to this measurement is supported by 
the lack of conclation between parasitaemia and RBC-D in this study. Moreover, the 
most rigid cells containing the mature parasites are usually sequestered in the 
microcireulation and are not present in the peripheral blood samples used.
Several prognostic factors have been identified in severe malaria including
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depth of coma, hyperparasitaemia, the predominance of late stages of parasite 
development or a high proportion of neutrophils containing malaria pigment, hy­
poglycemia, elevated plasma levels of tumor necrosis factor, elevated lactate levels in 
the blood and cerebrospinal fluid, and the severity of acidosis (Field and Niven 1937; 
Molyneux et al. 1989; Silamut and White 1993; White and Ho 1992; World Health 
Organization 1990; Phu et al, 1998; Grau et al. 1989; Krishna et al. 1994; Kwiatowski 
et al. 1990; Taylor, Borgstein, and Molyneux 1993; Taylor et al. 1988; White et al. 
1985). Multiple logistic regression analysis showed that a markedly reduced mean 
RBC-D was the strongest predictor of mortality in this small series. Severely reduced 
RBC-D lowers microcirculatory blood flow since red blood cells have to deform in 
order to pass through the smaller capillaries. In blood vessels lined by cytoadherent 
rigid parasitized erythrocytes, there must be considerable luminal obstruction. 
However, some flow is often maintained, presumably by even more than usual red 
blood cell deformation (White and Ho 1992). Any reduction in the deformability of 
uninfected erythrocytes would be expected to further compound the mierovascular 
obstruction caused by cytoadherent erythrocytes and inter-erythrocytic adhesion 
(rosette formation). This effect would be greatest in the tissues of vital organs such as 
the brain where sequestration is greatest. This mechanism could also contribute to the 
lactic acidosis by inducing anaerobic glycolysis. Host tissues are quantitatively the 
most important source of lactate in severe malaria (Krishna et al. 1994b; White and 
Ho 1992). The predictive value of lactic acidosis for mortality in malaria and the 
correlation between venous lactate concentrations and reduced mean RBC-D could be 
explained by this causal relationship. Reduced RBC-D is not an epiphenomenon 
related to direct effects of the lactate ion or acidaemia because acidification of the
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suspension medium (to pH 6.9) with laetate does not reduce RBC-D significantly at 
any shear stress as measured with the LORCA (Hardeman MR, unpublished data).
The mechanisms underlying the reduction in RBC-D of uninfected cells in 
severe malaria are not known. There was no significant increase in RBC-D during the 
time of admission, or shortly after recovery, suggesting irreversible damage to the 
uninfected red blood cells. In this study, we could not follow the patients after 
recovery. We have observed that normalization of the mean RBC-D in nonimmune 
Dutch travelers with falciparum malaria took 2—4 weeks (Dondorp AM, unpublished 
data). Reduction in RBC-D was most significant at the lower shear stresses. Changes 
in the flexibility of the red blood cell membrane are likely to be an important factor, 
since RBC-D at low shear stresses is very susceptible to membrane changes 
(Mohandas et al. 1980). Nauman and others have identified a heat-labile exoantigen 
produced by in vitro cultures of P. falciparum that binds reversibly to normal red 
blood cells and reduces their deformability (Nauman et al. 1991). We have also found 
that soluble products of P, falciparum in culture reduce the RBC-D of normal 
erythrocytes (Unpublished data). Red blood cell morphology and mean red blood cell 
diameter were not important parameters of RBC-D in this study. Although RBC-D is 
diminished in thalassemia (Vasselon et al. 1981), in the present study the level of dis­
turbance is smaller than found in the fatal cases. An increase in temperature up to 
41°C did not reduce RBC-D of normal erythrocytes in vitro as measured by LORCA, 
suggesting that fever was not a major contributor to this effect. The role of systemic 
host factors or endothelial eell malfunction in reducing RBC-D is not known.
If reduced RBC-D is a cause rather than an effect of potentially lethal organ 
dysfunction in severe malaria, then measures to correct this abnormality may save
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lives. Exchange transfusion is widely used in the management of severe malaria, 
although it has never been clear how it might be of benefit (Editorial 1990). The 
parasitized red blood cells causing pathology are sequestered and not available for 
exehange. However, removal of rigid unparasitized cells and their replacement by 
more deformable new erythrocytes would provide a plausible explanation for the 
apparent benefit from this treatment. Patients with severely reduced RBC-D form a 
subgroup that might benefit from exchange transfusion. In conclusion, this study 
shows that the mean RBC-D is an important predictor of and may be a contributor to 
mortality in severe falciparum malaria. This reduction in mean RBC-D is mainly due 
to a reduction in the RBC-D of unparasitized erythrocytes.
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Abstract
Decreased erythropoiesis and increased clearance of both parasitized and 
noninfected erythrocytes both contribute to the pathogenesis of anemia in falciparum 
malaria. Erythrocytes with reduced deformability are more likely to be cleared from 
the circulation by the spleen, a process that is augmented in aeute malaria. Using a 
laser diffraction technique, we measured red blood cell (RBC) deformability over a 
range of shear stresses and related this to the severity of anemia in 36 adults with 
severe falciparum malaria. The RBC deformability at a high shear stress of 30 Pa, 
similar to that encountered in the splenic sinusoids, showed a significant positive 
correlation with the nadir hemoglobin concentration during hospitalization (r = 0.49, 
P < 0.002). Exclusion of five patients with microcytic anemia strengthened this 
relationship (r = 0.64, P < 0.001). Reduction in RBC deformability resulted mainly 
from changes in unparasitized erythrocytes. Reduced deformability of uninfected 
erythrocytes at high shear stresses and subsequent splenic removal of these cells may 
be an important contributor to the anemia of severe malaria.
Introduction
Anemia is an important cause of morbidity and mortality in falciparum malaria 
(Phillips et al. 1986; World Health Organization 1990). The pathogenesis of anemia in 
malaria is multifactorial and incompletely understood. It is thought to result from a 
combination of parasitized erythrocyte destruction at schizont rupture, accelerated 
removal of parasitized and unparasitized red blood cells, and defective erythropoiesis 
(Looareesuwan et al. 1987b; White and Ho 1992). Of these factors, removal of un­
parasitized red blood cells is the most important, accounting for approximately 90%
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of the reduction in the haematocrit in malaria (Price RN et al, Am. J. Trop. Med. in 
press). We have shown previously that the threshold for splenic removal of 
complement-damaged or antibody-coated erythrocytes in acute malaria is lowered, 
suggesting enhancement of both mechanical filtrative function and Fc receptor- 
mediated clearance (Looareesuwan, 1987b; Nash et al. 1988). Reduced red blood cell 
(RBC) deformability is thought to play an important role in the removal of senescent 
blood eells from the circulation by the spleen (Nash et al. 1988). Since reduced RBC 
deformability might also play a role in the clearance of both parasitized and 
unparasitized red blood cells in malaria, we have measured RBC deformability in 
relation to the development of anemia in severe falciparum.
Patients and Methods
Study site.
The study was carried out during the rainy season months from May until July 
in both 1995 and 1996, in the provineial hospital of Mae Sot, Tak province, in 
western Thailand. Malaria transmission is low in this area with a seasonal peak during 
the rainy season that starts in late spring (Luxemburger et al. 1996). Severe disease 
occurs at all ages. Multiple drug resistance is an increasing problem in this area.
Patients and clinical procedures.
Consecutive adult patients admitted to Mae Sot Hospital with severe falciparum 
malaria were included, providing that written informed consent for blood sampling 
was obtained from the patients or attendant relatives. Disease severity was classified 
according to standard criteria (World Health Organization 1990). Exclusion criteria 
were an age less than 14 years, pregnancy, and previous antimalarial drug treatment
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within 24 hr of admission. Previous quinine treatment was checked in a baseline 
blood sample by the rapid dipstick method in all patients (Silamut et al. 1995). 
Patients were randomly assigned to treatment with either intravenous quinine 
dihydroehloride (20 mg salt/kg infused over a 4-hr period followed by 10 mg/kg 
every 8 hr) followed by oral tetracycline, or intravenous artesunate (2.4 mg/kg 
initially, then 1.2 mg/kg at 12 and 24 hr and then daily), followed by mefloquine in a 
comparative study, the results of which will be published elsewhere. Full supportive 
care was given as described previously (World Health Organization 1990). A control 
group of 22 healthy age- and sex-matched Thai volunteers provided a blood sample 
for measurement of RBC deformability.
A second control group comprised 12 adult Duteh travellers who presented with 
uncomplicated falciparum malaria at the Academic Medical Centre in Amsterdam. 
This group was treated with either oral sulfadoxine/pyrimethamine or halofantrine. A 
blood sample was taken on admission and at days 3, 7, 14, 21, and 28 after start of the 
treatment for assessment of parasitaemia, haemoglobin level, and RBC deformability.
This investigation was part of studies approved by the Ethical and Scientifîe 
Review Sub-committee of the Ministry of Public Health, Thailand. The study in 
Dutch travellers was approved by the Medical Ethical Committee of the Academic 
Medical Centre in Amsterdam.
Laboratory methods.
Thick and thin films from peripheral blood were taken on admission and stained 
with Field’s stain for parasite counting (White and Silamut 1989). Blood samples 
were taken every 12 hr for a full blood eount, routine biochemistry, laetate, glucose 
(assessed daily), and assessment of RBC deformability. Immediately after
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venepuncture, RBC deformability was measured with a laser-assisted optical 
rotational cell analyzer (LORCA®; Mechatronics, Hoorn, The Netherlands) 
(Hardeman et al. 1994). With this method a defined shear stress is applied to an RBC 
suspension in a high viscous medium (5% polyvinylpyrrolidone in phosphate- 
buffered saline buffer, viscosity = 30 mPa.sec at 37nC) at a constant temperature of 
37^C in a small gap between two eoncentric cylinders. Because of the applied shear 
stress caused by rotation of the outer cylinder, the cells elongate and align themselves 
in the fluid layer.
A laser beam is directed through the fluid layer and forms a diffraction pattern 
on a screen behind it. The ellipticity of this diffraction pattern is directly proportional 
to the mean ellipticity of the red blood cells. This ellipticity is described by the 
elongation index (El) defined by the formula El = (length of the long axis — length of 
the short axis)/(length of the long axis + length of the short axis). This is determined 
by computer analysis of the diffraction pattern. Red blood cell deformability was 
assessed at a range of shear stresses from 1.7 Pa to 30 Pa. Shear stresses of 1.7 Pa and 
above are eneountered in the capillaries (Chien 1987). Higher shear stresses are also 
likely to occur in the sinusoids of the spleen where red blood cells have to squeeze 
through the small intercellular gaps. Poor reproducibility has been a major drawback 
in earlier methods of measuring RBC deformability by filtration, but it appears to be 
very good with ektacytometry (Bessis, Mohandas, and Feo 1980; Mokken et al. 
1992).
In the patients that were included in 1996, the mean cell volume (MCV) was 
measured with a Coulter Counter (Coulter, Inc., Hialeah, FL). Because of the lack of 
availability of the Coulter machine in 1995, the MCV were calculated from the mean
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cell diameter (MCD) during this year. The MCD was assessed by light microscopy by 
averaging 200 red blood cells in a thin smear. The MCV was calculated from these 
values by using a nomogram (England 1982). The thin smear was also checked for the 
appearance of target cells and other RBC abnormalities. Hemoglobin electrophoresis 
was performed on the admission blood samples. Admission plasma samples were also 
stored at —20^C for subsequent measurement of bilirubin, transaminases, lactate 
dehydrogenase, and serum iron.
Statistical methods.
Statistieal analyses were carried out using SPSS 6.1 statistical programs (SPSS 
Corporation, Chicago, IL). Comparisons of means were made by Student’s test, with 
a Bonferroni correetion for multiple comparisons if applieable. Non-normally 
distributed parameters were compared by the Mann-Whitney U test. Correlations 
were assessed by the method of Pearson for normally distributed variables, and the 
method of Spearman for the remainder. A multiple regression analysis was performed 
to determine the most discriminating prognostic parameters in predieting the severity 
of the anemia, defined as the lowest hemoglobin level that was reached during 
admission.
Results
A total of 42 patients with severe malaria were included in the study. Six 
patients were excluded from further analysis because they were given blood 
transfusions shortly after admission: one was thalassaemic with a severe microcytic 
anaemia (haemoglobin level = 3.3 g/dl), another (haemoglobin level = 7.8 g/dl) 
received a blood transfusion 24 hr after admission because of unstable
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haemodynamics partly related to atrial fibrillation. Four patients received exchange 
transfusion because of severe illness. Six patients (17%) subsequently died. Clinical 
and laboratory details are shown in Table 4. The mean (± SD) time to fever clearanee 
in severe malaria was 67 (6 30) hr and the corresponding time to parasite clearance 
was 68 (6 19) hours. The mean RBC deformability at admission at a shear stress of 30 
Pa of patients, expressed as El (SD), was 0.586 (0.030) (range 0.508—0.624), and 
was significantly lower than the RBC deformability in healthy controls (El [SDI = 
0.608 [0.005 <0.05).
Red blood cell deformability and anemia.
Figure 7 shows the correlation between the mean RBC deformability on 
admission and the nadir value in the hemoglobin level during hospitalization. The 
admission RBC deformability at a stress of 30 Pa correlated significantly with the 
degree of anemia (defined as the absolute hemoglobin concentration that developed 
during admission (n = 36, Pearson r = 0.49, P< 0.002). This correlation was strongest 
when the RBC deformability was measured at a high level of shear. At a lower shear 
stress of 1.7 Pa, the correlation coefficient between RBC deformability and the degree 
of anemia was 0.38 {P <0.02) for all patients (Figure 8).
The correlation between admission RBC deformability at high shear and the severity 
of subsequent anemia was even stronger (r = 0.64, P < 0.001) when five cases with 
microcytic anemia (MCV < 80 fl) were excluded from the regression analysis (Figure 
7). All patients with microcytic anemia had a hemoglobin concentration < 9.0 g/dl 
and showed relatively more deformable red blood cells at these low hemoglobin 
levels than did the remaining patients. The cause of the microcytic anemia was iron 
deficiency (serum iron level = 2.3 mmol/L, iron binding capacity = 75 mmol/L) in
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one case, and thalassemia in the other four, who had normal serum iron levels, target 
eells in the blood smear, and (in two cases) high hemoglobin K% levels on 
electrophoresis.
There was no significant correlation between the change in hemoglobin 
concentration and the change in RBC deformability over the same period of time. Red 
blood cell deformability at the time of the nadir in the hemoglobin level was not 
significantly different from the RBC deformability on admission (Table 4). Six 
patients with macroscopic haemoglobinuria had similar RBC deformability values at 
a shear stress of 30 Pa as the remaining patients (mean [SD] RBC deformability = 
0.588 [0.0191] compared with 0.586 [0.032]). None of these haemoglobinuric patients 
were deficient for glucose-6-phosphate dehydrogenase.
The group of 12 Dutch travellers that returned from the tropics with 
uncomplicated malaria did not have high parasitaemias (mean [SD] = 1.5% [1.3%]) 
and developed only mild anemia, with a mean (SD) nadir in hemoglobin con­
centration of 12.5 (1.3) g/dl. The RBC deformability was only slightly decreased with 
a mean (SD) El of 0.595 (0.009) at a shear stress of 30 Pa. Nevertheless, in this group 
the percentage improvement in hemoglobin eoncentration during the four-weeks 
follow-up correlated significantly with the percentage improvement in the RBC 
deformability over the same time period (r = 0.67, P  = 0.018). Moreover, the linear 
regression line describing the correlation between these two parameters nearly 
crossed the zero point (% improvement in hemoglobin level = 1.5% + 3.5 X % 
improvement in RBC deformability). The RBC deformability started to normalize two 
weeks after the start of treatment.
Factors related to anemia.
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Besides RBC deformability, none of the other clinical or laboratory variables 
listed in Table 4 showed a significant correlation with the degree of anemia during the 
course of the disease. In particular, the admission parasitaemia was not a predictor of 
anemia (correlation coefficient = 0.13, not significant). In a multiple regression 
analysis (forward stepwise regression) with the variables listed in Table I as 
explanatory variables, the RBC deformability at admission (at a shear stress = 30 Pa) 
was the only parameter that contributed significantly to the model (adjusted R  ^= 0.39, 
B = 45.1, SE(B) = 10.1, P  = 0.0001, F = 20.0).
Discussion
Anemia in acute falciparum malaria is caused by increased destruction of both 
infected and noninfected erythrocytes and decreased erythropoiesis. In severe malaria, 
anemia develops rapidly. The decrease in hemoglobin concentration is often 
considerably greater than could be accounted for by destruction of parasitized eells 
only. Anemia results largely from accelerated RBC destruction (Davis et al. 1990; 
Lee et al. 1992; Looareesuwan et al. 1987b; Phillips et al. 1986; White and Ho 1992). 
Labeling studies have shown rapid clearance of uninfected red blood cells by the 
spleen (Looareesuwan et al. 1987b). The importance of the enhanced clearance of 
uninfected cells is illustrated by the lack of correlation between parasitaemia and the 
severity of the anemia evident in this and previous studies (Molyneux et al. 1989; 
Phillips et al. 1986). The mechanism for this enhanced clearance of uninfected red 
blood cells remains to be elucidated. Evidence of an immune-mediated meehanism is 
unconvineing, although a role for antibody-mediated clearance cannot be ruled out 
since the spleen in acute malaria shows a lowered threshold for clearance of
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erythrocytes coated with immunoglobulins, and it therefore may be difficult to 
demonstrate inereased antibody binding in eirculating erythrocytes (Abdalla and 
Weatherall 1982; Ho et al. 1990b; Lee et al. 1992; Looareesuwan et al. 1987a).
In this study, the RBC deformability on admission in patients with severe 
falciparum malaria was significantly lower than in healthy controls. Red blood cells 
infected with Plasmodium falciparum parasites become progressively less deformable 
as the intra-erythroeytic parasites mature (Cranston et al. 1983b; Nash et al. 1989). 
However, the mean RBC deformability obtained with LORCA is a summation of the 
RBC deformability of all the RBC fractions in the peripheral blood, with 
contributions to the overall value that are proportional to their size (Streekstra GJ, 
1994. A Bi Plane Rheoscope for the Measurement o f Red Cell Deformation and 
Orientation in a Couette Flow. Thesis, University of Utrecht, Utrecht, The 
Netherlands). Since the majority of red blood cells even in severe malaria is unin­
fected, the reduction in RBC deformability in the patients in this study results mainly 
from changes in the unparasitized erythrocytes.
Reduced RBC deformability does not result from a nonspecific response to 
severe infections. In a group of 14 septicaemia patients in the intensive care unit of 
the Academic Medical Centre in Amsterdam, there was no correlation between RBC 
deformability and severity of anemia and the mean (SD) RBC deformability at 30 Pa, 
expressed as the El, was 0.594 (0.020) (range = 0.574—0.614).
This study shows a clear correlation between the RBC deformability on 
admission and subsequent anemia in severe falciparum malaria. Reduced RBC 
deformability and anemia could both be independent markers of overall disease sever­
ity, but a causal relationship seems more likely, i.e., clearance of less deformable red
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blood cells from the circulation by the spleen, a mechanism that is also thought to 
account for the clearance of senescent erythrocytes (Nash et al. 1988). The 
relationship between reduced RBC deformability and anemia was most prominent at 
the shear stresses encountered normally in the spleen where red blood cells have to 
squeeze through the small intercellular gaps in the sinusoids of the spleen (width = 
0.5—2m) (Chen and Weiss 1973). In a recent study, we showed that in severe 
falciparum malaria, RBC deformability at a lower shear stress of 1.7 Pa correlated 
strongly with mortality, suggesting impairment of microcirculatory flow by rigid red 
blood cells (Dondorp et al. 1997). This shear stress corresponds with that encountered 
in the capillaries (average diameter = 3— 5 mm) (Chien 1987).
The mean RBC deformability did not change significantly during 
hospitalisation, which was generally up to seven days after the start of treatment. 
Longer follow-up, to study if the improvement in RBC deformability is related to 
recovery from anaemia, was unfortunately not possible in the Thai patients. However, 
follow-up in a group of 12 Dutch travellers with uncomplicated falciparum malaria 
showed that the improvement in haemoglobin levels over a four-week period 
correlated closely with the improvement in RBC deformability over the same time 
period. These findings further support a causal relationship between the two 
parameters.
The correlation between RBC-D and the severity of anaemia that developed in 
patients with severe malaria was even stronger when the patients with microcytic 
anaemia, resulting from either a haemoglobinopathy or iron deflcieney, were 
excluded. The few patients with microcytic anaemia showed a slight but 
nonsignificant decrease in RBC deformability at 30 Pa compared with healthy
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controls (mean [SD] = 0.600 [0.020] and 0.608 [0.005], respectively, Figure 7). The 
RBC deformability can be reduced in both iron deficiency and thalassemia (Schrier, 
Rachmilewitz, and Mohandas 1989; Yip et al. 1983). We were not able to genotype 
all patients but it is unlikely that thalassemia was a significant confounder in the 
normocytic malaria patients. Of 95 well-defined patients with various forms of a- and 
P“ thalassaemia and haemoglobin E and haemoglobin Constant Spring (hemoglobin - 
CS) disease studied in Bangkok, only 10 had a normal MCV > 80 fl. Seven had 
haemoglobin CS (4) or haemoglobin thalassaemia (3) with a normal RBC 
deformability at 30 and slight or no anaemia (mean haemoglobin levels Hb 11.5 g/dl 
and 13.4 g/dl, respectively) (Dondorp AM, unpublished data).
The mechanisms underlying the reduction in RBC deformability of uninfected 
cells in severe malaria are known. Mohan and others showed damage of the 
uninfected erythrocyte membrane through lipid peroxidation in P. falciparum co 
cultured with blood monocytes (Mohan et al. 1995). Nauman and others have reported 
on a heat-labile exoantigen produced by in vitro cultures of P. falciparum  that binds 
reversibly to normal red blood cells and reduces their deformability (Nauman et al. 
1991). We also think that a soluble factor produced by the parasite the most likely 
cause of a reduction in RBC deformability in patients with falciparum malaria. 
Preliminary data shows that plasma from patients with acute falciparum malaria 
mixed with healthy donor red blood cells can rigidify these cells. Also, supernatant 
from a P. falciparum culture seems to be able to rigidify healthy donor red blood 
cells, but the exact mechanism remains to be elucidated (Unpublished observations). 
Although heat damages red blood cells, an increase in temperature up 41^C did not 
reduce the RBC deformability of normal erythrocytes in vitro as measured by
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LORCA, suggesting that fever was not a major contributor to this effect. The relative 
roles of systemic host factors or endothelial cell dysfunction in reducing RBC 
deformability is not known.
In conclusion, this study shows a strong predictive value of admission RBC 
deformability at a high shear level the severity of the anaemia that develops in the 
course of severe falciparum malaria. Since the reduction in RBC deformability is 
caused mainly by rigidifîcation of nonparasitized erythrocytes, this correlation could 
be an explanation for the increased splenic clearance of noninfected erythrocytes.
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Table 4.
Mean (SD) clinical and laboratory variables in patients with severe falciparum 
malaria according to the severity of anaemias* Group 1 - Severe anemia (Hb 
<9.0g/dl)(all patients), Group 2 - Severe anemia (Hb < 9.0 g/d l) (micro cy to sis excluded), 
Group 3 - Mild anemia (Hb > 9.0 g/dl)
Group 1 
(n=  17)
Group 2 
(n = 12)
Group 3 
(n=  19)
P
Age (years) 27(13) 28(14) 26 (10) NS
Fatal cases (n) 3 3 3 NS
Artesunate (n) 9 6 8 NS
Quinine (n) 8 6 11 NS
Parasitaemia (%) 6.3 (5.1) 7.4 (5.4) 9.1 (7.5) NS
Hb (g/dl) 9.1 (2.4) 9.4 (2.6) 13.9(1.7) 0.03
MCV (fl) 84.4 (8.7) 88.5(6.1) 88.6 (6.6) NS
Nadir Hb (g/dl) 7.1 (1.2) 7.3 (1.2) 10.9(1.4) 0.001
Time after admission to nadir in Hb 
(hr)
41 (42) 53 (48) 83 (26) NS
RCD at 30 Pa (El) 0.574
(0.034)
0.564
(0.036)
0.597
(0.020)
0.002
RCD at 1.7 Pa (El) 0.233
(0.032)
0.227
(0.032)
0.251
(0.031)
0.05
RCD (30 Pa) at time of lowest Hb 0.574 0.567 0.598 NS
(El) (0.032) (0.033) (0.025)
LDH (mmol/L) 672 (153) 717(137) 548 (364) NS
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Total bilirubin (pmol/L) 47.0 (46.0) 57.7 (53.7) 70.1 (114.3) NS
Direct bilirubin (pmol/L) 27.4 (35.9) 35.9(41.7) 46.2 (93.2) NS
Haptoglobin (g/L) 0.2 (0.6) 0.0 (0.0) 0.1 (0.2) NS
Serum iron (pmol/L) 10.4 (9.4) 12.7(10.4) 6.4 (7.8) NS
ASAT (U/L) 69 (27) 66 (12) 79 (94) NS
Creatinine (pmol/L) 101 (35) 108(42) 94 (59) NS
Glucose mmol/L) 4.5 (1.8) 4.6 (2.0) 3.6 (0.6) NS
Lactate (mmol/L) 4.8 (3.1) 5.0 (2.7) 3.9 (1.8) NS
Hb = hemoglobin; MCV mean cell volume; RCD = red blood cell deformability; Pa 
Pascal; El elongation index; LDH lactate dehydrogenase; ASAT aspartate 
aminotransferase P  values for significance of difference between patients with severe 
and mild anemia, with the exclusion of patients with microcytic anemia.
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Figure 7. Correlation between admission values of mean red blood cell deformability 
(RCD) at a shear stress (SS) of 30 Pa and the lowest hemoglobin (Hb) level reached 
during the time of hospitalization in patients with severe falciparum malaria, (n = 36, 
correlation coefficient = 0.49, P  = 0.002). When patients with a microcytic anaemia 
(mean red blood cell volume < 80 fl, open circles) are excluded, the correlation 
coefficient between the two variables becomes much stronger (n = 31, correlation 
coefficient = 0.64, P < 0.001). MCV = mean cell volume.
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Figure 8. Correlation between admission values of mean red blood cell deformability 
(RCD) at a shear stress (SS) of 1.7 Pa and the lowest hemoglobin (Hb) level reached 
during the time of hospitalization in patients with severe falciparum malaria, (n = 36, 
correlation coefficient = 0,38, P  = 0.02). MCV = mean cell volume.
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Abstract
Nitric oxide is an important host defence molecule as well as being a mediator 
in many pathophysiological processes. To investigate its role in severe malaria, we 
measured plasma nitrate and nitrite concentrations in 70 children with malaria (54 
with severe malaria) and 48 control subjects (33 with medical conditions and 15 
surgical patients). We related these measurements to plasma lactate concentrations, an 
established marker of disease severity in malaria. Plasma lactate levels were 
significantly elevated in patients with deep coma (P=0-0007) and those with a fatal 
outcome, but mean nitrogen oxide concentrations were not significantly different in 
the 2 outcome categories and were not related to depth of coma (P>0*5). In patients 
whose cerebrospinal fluid (CSF) was examined, lactate concentrations were elevated 
in fatal cases (geometric mean 8-2 mmol/L, n=5) compared with survivors (3-4 
mmol/L, n=13; P=0-032); corresponding CSF nitrogen oxide concentrations were 
10*7 pM in fatal cases compared with 12-5 pM in survivors (B=0 5). Plasma nitrogen 
oxide concentrations were negatively correlated with admission parasitaemia {r=- 
0 41, n=70; P<0'Q001). In our population, elevations of plasma lactate, but not nitrite 
or nitrate, reflected disease severity in malaria.
Introduction
Nitric oxide (NO) is an important host defence molecule synthesized from L- 
arginine in a reaction catalysed by the inducible isoform of nitric oxide synthase 
(N0S2). Expression of NOS2 in murine macrophages occurs after they are exposed to 
bacterial endotoxin, or to ‘pro-inflammatory’ cytokines including interleukin 1, 
tumour necrosis factor (TNF) and interferon y. The NO synthesized by NOS2 is toxic
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to many fungi and protozoa, and certain bacteria and viruses (Anggard 1994; Vallance 
and Moncada 1994), This potentially important defensive role has been supported by 
the observation that mice lacking a normal NOS2 gene cannot suppress the 
proliferation of Leishmania (Wei et ah 1995). Human monocytes, after appropriate 
activation, also express NOS2 and produce sufficient NO to kill intracellular 
Leishmania (Vouldoukis et al. 1995). The role of NO in the pathophysiology of 
human malaria, however, is still unclear. A recent study in Tanzanian children with 
malaria suggested that decreased NO synthesis may predispose to cerebral malaria 
and also to a fatal outcome (Anstey et al. 1996). This study also suggested that TNF 
or other proinflammatory cytokine synthesis in severe malaria infection may have 
been up-regulated because of relatively decreased NO production.
In contrast, others have argued that increased NO synthesis may contribute to 
cerebral symptoms in malaria (Clark, Rockett, and Cowden 1992), and have found 
that elevated concentrations of plasma reactive nitrogen intermediates are associated 
with coma (Al-Yaman et ah 1996). This latter role implies increased local (cerebral 
endothelial) synthesis of NO in patients with cerebral malaria, but does not exclude 
other potential roles for NO such as host defence.
We measured plasma nitrate and nitrite concentrations in Ghanaian children 
with uncomplicated and severe malaria, and related these measurements to elevations 
in plasma lactate concentration, a recognised marker of severe disease (Allen et ah 
1996; Krishna et ah 1994b). We also compared these indices to those obtained from 
children recovering from elective surgery and other non-malarial disease processes. 
Plasma nitrate and nitrite are breakdown products arising from the short lived parent
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compound NO, and increased concentrations in plasma reflect increased NO 
production through inducible pathways.
Material and Methods
Patients
Patients were studied as part of published and cuiTent studies on lactic acidosis 
in malaria carried out between October and December in 1993 and 1995 (Krishna et 
al. 1995). We defined severe malaria as asexual Plasmodium falciparum parasitaemia 
associated with hyperlactataemia (whole blood or plasma lactate when screened >5 
mmol/L), and we included a further 5 patients with cerebral malaria (Blantyre coma 
score <2) and one with a fatal outcome. When our metabolic definition of severe 
malaria was compared with the World Health Organization classification of severe 
disease, all except one patient fulfilled at least one stipulated criterion and >80% 
fulfilled 2 or more criteria (World Health Organization 1990). Children with malaria 
without hyperlactataemia (screening lactate concentration <5 mmol/L) or cerebral 
malaria were classified as having non-severe malaria. The lactate values presented 
here were those obtained simultaneously with sampling for nitrogen oxides (NOx; 
nitrate plus nitrite). For baseline values, this was approximately 1 h after screening. 
Patients with hyperlactataemia and malaria were managed by the study team and their 
parasitological and clinical measures of recovery 'were estimated as reported 
previously (Krishna et al. 1995). In some children with severe malaria, measurements 
of plasma NO x were also carried out one and 12 h after admission.
Control subjects were children with other severe medical illnesses (meningitis, 
encephalitis, septicaemia, pneumonia, Burkitf s lymphoma, tetanus, or jaundice) or
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children in a surgical ward (with head or limb injuries, appendicitis, or cellulitis) at 
the study site. Cerebrospinal fluid (CSF) samples obtained from children undergoing 
lumbar puncture when clinically indicated were also examined for lactate, glucose 
and nitrogen oxides.
Assay for plasma nitrite  ^nitrate and lactate
Plasma nitrate and nitrite concentrations were assayed using capillary 
electrophoresis with reported inter-assay coefficients of variation of 4 6% and 1-2% 
for nitrite and nitrate (50 pM), respectively (Leone et al. 1994). Lactate and glucose 
were assayed using YSI glucose and lactate analysers (model 1600) or a combined 
analyser (model 2300, YSI Instruments, Yellow Springs, Ohio, USA).
Statistical analyses
Statistical analysis was carried out using SYSTAT™ v. 5-2 (SYSTAT Inc., 
Evanston, Illinois, USA) or Statistica™ v. 3 (StatSoft Inc., Tulsa, Oklahoma, USA). 
Normally distributed variables were compared by Student’s t test and linear 
regression analysis and non-normally distributed variables were normalized by log 
transformation before analysis by ANOVA and Bonferroni’s post-hoc test. 
Correlations were analysed by Spearman’s rank correlation. Non-normal measures 
were compared by the Mann-Whitney U or Wilcoxon tests. Trend analysis was 
carried out with SPSS^* .^
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Results
One hundred and eighteen children were studied, 70 children with malaria and 
48 control subjects; 54 children had severe malaria, 9 of whom (17%) died, and 16 
had uncomplicated malaria, all of whom recovered. Fifteen control patients were 
either recuperating from surgical procedures (studied at least 5 d after surgery) or 
awaiting surgery. The remaining 33 control patients included 5 with bacteriologically 
confirmed meningitis (3 fatal cases), 4 with febrile convulsions, and 4 with Burkitt’s 
lymphoma. The admission clinical and laboratory findings in the study groups are 
given in the Table 5.
Table 5.
Clinical and laboratory characteristics of patients with malaria and control 
subjects
Malaria patients Controls
Variable a Uncomplicated Severe Surgical Medical
No. 16 54 15 33
Age (months) 63(53) 42(26) 98(50) 100(164)
Body mass 
index (kg/m^ )
0-154(0-037) 0-153(0-032) 0-137(0-032) 0-153(0-03)
Oral
temperature
CC)
37-8(0-8) 38(1) 36-8(0-6) 37-8(1)
Pulse (per min) 122(20) 144(21) 83(6) 123(27)
Systolic blood 101(9) 102(22) 93(11) 102(19)
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pressure (mm 
Hg)
Diastolic blood 
pressure (mm 
Hg)
63(12) 57(14) 64(7) 64(15)
Respiratory rate 
(per min)
37(12) 51(15) 24(4) 42(17)
Packed cell 
volume (%)
29(8) 23(8) 32(12) 27(9)
Parasitaemia 
(per pL)b
66,171(10,050-
443,300)
100,300(10-
1,799,470)
Plasma NO 2 
(pM)b
l'06(0'5-2'2) 1 06(0-4-2 63) 1 3(067-22) 1(0-5-24)
Plasma NO 3 
(pM)b
39(14*7-183) 33-8(10-6-197) 42(12-6-153) 41(16-208)
Blood lactate 
(mM) b
2 3(0'9-3'8) 6-4(1-2-17-3) 3-87(1-14)
Blood glucose 
(mM) b
6 54(3 9-11 4) 6-5(37) 5-8(2)
a All values are means (with standard deviation in parentheses) except where shown, b Geometric 
mean (range in parentheses).
In the whole study population, there was no difference between survivors and 
the 14 fatal cases (12%) in individual or summed plasma NO x concentrations (for
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survivors, geometric mean NO x value=37-3 |iM; for fatal cases, it was 43 juM; 
P=0 4; Fig. 9). However, lactate concentrations were significantly elevated in fatal 
cases (geometric mean=8*2 mM) compared with survivors (geometric mean=4 mM; 
f< 0  0001). Nitrate and nitrite levels were not correlated with each other (r=0*003, 
%=118; P=0-56) or with clinical and biochemical correlates of disease, including 
temperature, blood pressure, tachypnea, pulse rate, lactate and glucose.
Figure 9. Plasma concentrations of nitrogen oxides (NOx) in patients with malaria 
and control subjects. Clinical details are given in the Table 5.
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Figure 10. Relationship between admission parasitaemia and plasma concentrations 
of nitrogen oxides (NOx); the linear regression line is shown, with 95% confidence 
intervals.
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Figure 11. Relationship between (A) admission plasma lactate concentration, and (B) 
plasma concentration of nitrogen oxides (NO x), and the Blantyre coma score; open 
circles represent survivors and filled circles show fatal cases.
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Patients with malaria
Patients with severe malaria had higher admission pulse rates (P=0-002) and 
respiration rates (P=0-002), and were more anaemic (P=0-019) than uncomplicated 
cases (Table 5). Parasitaemia was marginally higher in severe cases (P=0*05) but it 
was not correlated with lactate levels. Parasitaemia was significantly negatively 
correlated with summed NO x levels (r=-0-4l, n-70; P<0-0001; Fig. 10). Thirty-four 
patients (49%) had coma scores <2 on admission and, overall, lactate levels were 
negatively correlated with coma scores (Fig. 11 A, %2 for trend=21-32, d.f.=5; 
F=0-0007) as well as fatal outcome. In contrast, NO x levels were not associated with 
admission coma scores (Fig. IIB; P>0-5) or fatal outcome.
For some patients studied in greater detail, there was no relationship between 
clinical measures of recovery such as time to recovery of consciousness (n=23), time
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to eat («=26), time to sit («=21) and time to walk («=18), parasitological indices of 
improvement (50%, 90% and 100% parasite clearance times; «=29-31) (White and 
Krishna 1989), fever clearance data («=27) and the admission nitrite, nitrate or 
summed NO x levels. There was no significant difference between the 4 study groups 
(Table 5) in admission nitrite, nitrate or NO x levels (Fig. 1; P>0-5). One and 12 h 
following admission, there was no significant change in nitrate concentration in a 
subset of 19 patients with severe malaria.
Nitrite concentrations increased significantly at 12 h from a mean of IT to a 
mean of 1*8 pM («=13; P=0-002) in this group of patients.
Cerebrospinal fluid findings
In no patient was there a relationship between nitrite, nitrate or NO x levels in 
CSF and the corresponding plasma levels (r=0-32, «=19; P=0T9), nor any 
relationship between nitrite and nitrate concentrations in the CSF. In fatal cases, CSF 
lactate concentrations were significantly elevated compared with those of survivors 
(geometric mean CSF lactate concentration=8 2 mM («=5) vs. 3*4 mM («=13); 
F=0*032), but no difference was observed for corresponding CSF NO x levels 
between the 2 outcome categories (fatal cases, geometric mean NO x level=10-7 pM 
(range 5-7-17-7) vs. 21-5 pM (range 5 9-23 9); P=0*5). Neither was there any 
difference in CSF NO x level between patients with cerebral malaria and those with 
other conditions (P>0-7). CSF nitrite levels were never above 3-4 pM in any patient. 
Discussion
There was no significant difference between admission plasma nitrate or nitrate 
concentrations in malaria patients and control subjects. Neither was any relationship 
observed between clinical and laboratory markers of disease severity in malaria (apart
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from parasitaemia, discussed below) and concentrations of NO x in the plasma. In 
contrast, blood lactate concentrations were clearly associated with disease severity 
and a fatal outcome in these patients. There are several potential confounding factors 
in interpreting measurements of plasma nitrate and nitrite in our patient population. 
Dietary ingestion of nitrate may lead to elevation of plasma nitrate for a few hours. 
However, this elevation does not exceed 50% of fasting nitrate levels (Leone et al.
1994) and it would have tended to increase levels in the children with uncomplicated 
malaria or the surgical controls, rather than those in severely ill children who had not 
eaten or drunk for some hours before admission. The median time when the 35 
children severely ill with malaria for whom data were available had last eaten was 
lOh (range 2-72) previously. Nitrite levels are unaffected by fasting.
Renal impairment (assessed by a single measurement of plasma creatinine 
levels) is infrequent and relatively mild in West as well as East African children with 
malaria (Anstey et al. 1996; Waller et al. 1995). As nitrate is excreted by the kidneys, 
correction for minor elevations in plasma creatinine concentrations may have lowered 
our values for plasma NO x in severely ill children. We were not able to measure 
plasma creatinine, but the magnitude of the correction required would be small as 
none of the children developed clinical evidence of renal failure. No relationship was 
observed between plasma NO x concentrations and depth of malarial coma, and there 
was no difference in plasma NO x concentrations between patients with malaria and 
surgical control subjects. Our findings are consistent with observations from 
Yaounde, where children with cerebral malaria had mean plasma NO x concentrations 
of 44*3+36-5 pM and no statistically significant relationship between depth of coma, 
disease severity and NO x level was noted (Cot et al. 1994). In our study, mean
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concentrations of nitrogen oxides in the plasma (37-5+22 pM) were not elevated to 
the degree seen in septic adults (63-1+6-5 pM, «=72) (Ochoa et al. 1991) or septic 
neonates with shock (582+385 pM, range 242-1230) (Shi et al. 1993), even though 
our severely ill malaria patients were at high risk of mortality. In a small study in Viet 
Nam, higher plasma concentrations of NO x were reported in severe malaria, although 
levels in fatal cases did not differ from those in survivors (Nussler, Eling, and 
Kremsner 1994). More recently, in a series from Papua New Guinea, relatively 
elevated serum levels of reactive nitrogen intermediates were noted in children with 
cerebral malaria compared with those who were not comatose, and significantly 
higher levels in fatal cases compared with survivors (Al-Yaman et al. 1996). 
Peripheral parasitaemia and NO x were negatively correlated (r^O-22) in that study, 
as they were in this one (r=-0-4. Fig. 1). Although parasitaemia correlates poorly with 
other indices of disease severity (Krishna et al. 1994b), this negative association 
between peripheral parasitaemia and NO x levels may suggest a protective role for 
NO in patients with malaria. In a separate study from Papua New Guinea, admission 
lactic acidosis, not coma, was predictive of a fatal outcome, and parasitaemia was 
considerably lower than in children in Africa presenting with disease of similar 
metabolic severity to our patients, highlighting geographical variation in the clinical 
features of malaria (Allen et al. 1996). The absence of a strong correlation between 
plasma nitrite and nitrate concentrations in our patients probably reflected the 
instability of nitrite in whole blood, where it is particularly susceptible to the action of 
haemoglobin (Leone et al. 1994). The inconsistent associations between circulating 
NO X and disease status and severity of malaria in several reports may reflect not only 
methodological differences but also differences between geographically distinct
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patient populations. Control populations in some studies may themselves have been 
significantly exposed to malaria, and this may have influenced interpretation of NO x 
values, although this does not mitigate against examining the role of NO x in different 
malaria syndromes within a population (Al-Yaman et al. 1996; Anstey et al. 1996). 
Furthermore, plasma estimations of NO metabolites may not represent important 
changes in local concentrations of NO, and the precise cellular source of the NO 
detected in malaria is uncertain. Thus changes in endothelial or cerebral NO 
metabolism may still be undetected because of the insensitivity of plasma based 
assays. We therefore also measured CSF nitrate concentrations in a subset of patients 
with cerebral malaria and did not find any difference between fatal cases and 
survivors. Interestingly, the normal CSF concentration of reactive nitrogen 
intermediates has a mean of 5-1 pM (SD=0*8) (Milstien et al. 1994). In another series, 
mean CSF nitrate and nitrite levels were 6*3 pM and O-SpM, respectively, in patients 
with noninflammatory neurological disease.
These levels were significantly elevated in patients with meningococcal 
meningitis to mean values for nitrate of 18 4 pM and nitrite of 25-8 pM (Visser, 
Scholten, and Hoekman 1994). In our patients, elevations of CSF nitrate were 
relatively modest, with geometric mean concentrations approximately twice those 
reported for normal individuals and no disproportionate increase in CSF nitrite in 
patients with cerebral malaria or meningitis. Disease severity in our study was 
mirrored by elevations in plasma or CSF lactate concentrations and not by changes in 
plasma or CSF NO x. Clearly, more sophisticated techniques designed to measure 
N0S2 expression (of both encoding messenger ribonucleic acid and protein) in 
cerebral endothelial cells obtained from patients dying of cerebral malaria will
83
provide a more sensitive method than measurement in CSF of examining the 
hypothesis that local derangements in NO metabolism are contributory to the cerebral 
syndrome. The role of changes in NO metabolism in malaria, and the effects of such 
changes on host defence or disease pathophysiology, clearly require further 
investigation.
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Abstract.
It has been suggested that nitric oxide (NO) plays an important role in the 
pathogenesis of severe falciparum malaria. Since NO has a very short half-life, nitrate 
and nitrite (NOx) levels, stable metabolites of NO, are used as measures of NO 
production. We measured plasma NOx levels in 24 adults with severe falciparum 
malaria on the Thai-Burmese border. After correction for renal function, there was no 
correlation between plasma NOx levels, or the total amount of NOx excreted in the 
urine, and disease severity. Plasma NOx levels decreased after the first 48 hr in all 
patients (P 0.007), suggesting decreased NO production. The NOx levels in 
cerebrospinal fluid (CSF) correlated well with plasma NOx levels, but these did not 
show a correlation with coma depth, and were not significantly different from those in 
a healthy control group. These findings do not support the hypothesis that excessive 
NO production contributes to the pathogenesis of severe falciparum malaria. 
However, local changes in NO production, e.g., in the central nervous system might 
not be reflected in the total NOx production or NOx levels in the CSF.
Introduction
Severe falciparum malaria remains an important cause of mortality in the 
tropical world with an annual global mortality of 1 - 2  million people and a mortality 
rate as high as 15 - 30% despite effective anti-malarial treatment (World Health 
Organization 1990; World Health Organization 1993). It has been proposed that nitric 
oxide (NO) plays a central role in the pathogenesis of severe, and in particular 
cerebral malaria (Clark, Rockett, and Cowden 1991). Nitric oxide is an important 
mediator of many homeostatic processes and host defense mechanisms, and may also
8 6
have a function as neurotransmitter (Moncada and Higgs 1993). The production of 
NO is increased by proinflammatory cytokines such as tumor necrosis factor a  and 
interleukin-1, which reach high levels in severe falciparum (Rockett et al. 1992). 
Excessive synthesis of NO by cerebrovascular endothelial cells might alter 
neurotransmission and thus contribute to the pathogenesis of cerebral malaria (Clark, 
Rockett, and Cowden 1991). On the other hand, NO is thought to play a role in 
parasite killing (Green et al. 1994; Mellouk et al. 1994). It also reduces the induction 
of endothelium-bound adhesive molecules such as intercellular adhesion molecule-1, 
which are thought to play an important role in the intracerebral sequestration of 
parasitized erythrocytes (Decaterina et al. 1995).
Study of NO production in vivo is difficult because of its very short plasma 
half-life of less than 10 sec (Kelm and Schrader 1990). In plasma, NO is almost 
immediately oxidized to nitrite and subsequently converted to nitrate, and this seems 
to be the most important fate of the molecule (Kelm et al. 1992; Westfelt et al. 1995). 
As a consequence, all clinical information about the possible role of NO in falciparum 
malaria derives from the measurements of plasma and urine levels of nitrites and 
nitrates (Anstey et al. 1996; Cot et al. 1994; Kremsner et al. 1996; Nussler, Eling, and 
Kremsner 1994; Prada and Kremsner 1995). These studies have produced sometimes 
contradictory results. In the present study, we measured nitrate and nitrite (NOx) 
levels in patients with severe falciparum malaria, both in plasma and urine, to provide 
a better estimate of total body NOx production. In addition, we measured NOx levels 
in cerebrospinal fluid (CSF) in patients with cerebral malaria and compared these 
with NOx values obtained in CSF from controls.
87
Patients and Methods
Consecutive adult patients admitted to Mae Sot Hospital, Tak Province, 
Thailand with acute falciparum malaria were included in this study, provided that 
written informed consent was obtained from the patients or their attendant relatives. 
Malaria transmission is low in this area with a seasonal peak during the rainy season, 
which starts in late spring (Luxemburger et al. 1996). Disease severity was classified 
according to standard criteria (World Health Organization 1990). Exclusion criteria 
were an age less than 14 years, pregnancy, and previous antimalarial drug treatment 
within 24 hr of admission. Previous quinine treatment was checked in a baseline 
blood sample by a rapid quinine dipstick method in all patients (Silamut et al. 1995). 
A full clinical examination was performed on admission and all details were recorded 
on a standard form. Patients were randomly assigned to treatment with either in­
travenous quinine dihydrochloride or intravenous artesunate in a comparative study, 
the results of which will be published elsewhere. Full supportive care was given as 
described previously (World Health Organization 1990). If necessary, patients were 
transferred to an intensive care unit for mechanical ventilation, peritoneal dialysis, or 
haemodynamic support and monitoring. Postmortem examinations of the fatal cases 
were not performed. This investigation was part of studies approved by the Ethical 
and Scientific Review Subcommittee of the Ministry of Public Health, Thailand. 
Laboratory methods.
Baseline blood samples were taken for a full blood count, glucose, lactate and 
routine biochemistry. Thick and thin films from peripheral blood were taken on 
admission and stained with Field’s stain for parasite counting (White and Silamut 
1989). Blood samples for plasma NOx and creatinine measurements were taken every
12 hr. Urine was collected every 12 hr from the time of admission for NOx and cre­
atinine measurements. Chlorhexidine was added to the collection containers to 
prevent bacterial growth. In cases of cerebral malaria, a lumbar puncture was 
performed, and routine laboratory measurements were done to exclude other causes of 
altered consciousness. Five patients undergoing a lumbar puncture for anesthesia 
served as a control group for this part of the study. All samples were immediately 
stored at -20^C for later analysis.
Table 6.
Admission clinical and laboratory variables in patients with severe 
malaria*
Variable Survivors 
(n = 7)
Fatal cases 
(n=7)
Significance of 
difference (P)
Age (years) 26±8 28±14 NS
Pulse rate (per mm) 114±11 109 1 15 NS
Blood pressure (mm o f t [g)
Systolic 109±12 104±14 NS
Diastolic 64±16 63±20 NS
Temperature (°C) 38,8 ±1.1 38.2 ± 1.4 NS
Median coma score 15 8 0.004 $
Packed cell volume (%) 34 ± 11 31±9 NS
Parasitaemia (%) 6±6 10± 11 NS
Plasma creatinine 
(pmol/L)
81 ± 18 148 ± 97 0.01
Plasma lactate 4.2 ±2.6 13.1 ±9.2 0.02
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(mmol/L)
Plasma glucose 
(mmol/L)
9.0 ±6.1 8.8 ±3.5 NS
Plasma NOx (pmol/L) 
Median (range)
33.6
(15.2—
151.1)
117.4
(20.2—935.0)
N S$
Plasma
NOx/creatininepiasma 
(pmol/L/pmol/L) 
Median (range)
0.51
(0.16—
1.78)
0.63
(0.26—3.08)
NS
Urine NOx (pmol) in 
first 12 hr after 
admission 
Median (range)
422.9 
(204.3— 
2311.5) 
(n=  14)
85.3
(22.4—561.8)
(n -7 )
0.03 $
Urine
NOx/creatinineurine 
(pmol/mmol) 
Median (range)
82.8 
(27.7— 
360.7) 
(n = 14)
47.1 
(38.5— 179.3) 
(n = 7)
N S$
CSF NOx (pmol/L) 
Median (range)
4.8 
(2.5—7.7) 
(n = 6)
13.8 
(1.5—61.4) 
(n = 5)
N S$
* NS = not significant; NOx = nitrate and nitrite; CSF = cerebrospinal fluid. 
Values, where indicated are the mean ± SD.
$ Comparison by Mann-Whitney U test; all other comparisons by Students t-test.
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The NOx levels were assessed by ion-pair chromatography. To precipitate proteins in 
plasma or CSF, 500 pA of water, 100 pi of 0.35 M ZnS04 , and 100 p i of 0.75 M 
NaOH was added to a 100-pl sample. Urines were treated in the same way after a 1:4 
dilution in water. The precipitates of protein were removed by centrifugation at 1,500 
X g for 10 min. Standards were processed in the same way as the samples. A volume 
of 20 p i of the deproteinized sample was injected on a 100 x 3.0 mm Chromsphere 
c l8 column (Chrompack, Bergen op Zoom, The Netherlands). Separation was 
achieved by ion-pair chromatography with 0.01 M n-octylamine as eluent (Stein and 
Classen 1988). The pH of the eluent was brought to 6 with sulfuric acid and then 
adjusted to pH 6.5 with 2 mmol/L of ammonium acetate. Detection was measured at 
215 nm. The flow rate was 0.65 ml/min. The coefficient of variation of duplicate 
determinations was less than 2%. Plasma NOx levels were corrected for kidney 
function by taking the ratio of NOx concentration and plasma creatinine con­
centration. Similarly total urinary NOx values were corrected for renal function by 
taking the ratio of NOx and total urinary creatinine values in the same sample (Anstey 
et al. 1996). Fractional NOx excretion (the fraction of filtered NOx that is excreted) 
was calculated with the formula total NOx in urine (pmol/12 hr)/[NOx] in plasma 
(pmol/L) divided by total creatinine in urine (pmol/1 2 hr)/[creatinine] in plasma 
(pmoi/L).
In one patient who died 2 hr after urine collections were started, the total 
amount of NOx excretion in the urine in the first 12 hr was obtained by extrapolation 
of the excretion in the first 2 hr after admission.
Statistical methods.
Statistical analyses were carried out using SPSS 6.1 statistical programs (SPSS
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Corporation, Chicago, IL). Normally distributed data were analyzed using Student’s t- 
test. The Mann-Whitney test was used to compare non-normally distributed variables. 
Correlations were assessed by the method of Pearson for normally distributed 
variables, and by the method of Spearman for the remainder. The Wilcoxon matched 
pairs rank test was used to compare changes in NOx levels between two time points. 
Results
Twenty-four consecutive patients with severe falciparum malaria, 11 of whom 
had cerebral malaria, were studied. Seven patients died. One patient who was 
included initially because of severe anemia accompanying her malaria was excluded 
subsequently when it became apparent that her anemia resulted from thalassemia. 
Complete, sequential, 12-hr urine samples were collected from 21 of these patients.
Clinical and laboratory findings are summarized in Table 6. There was no 
significant difference between fatal cases and survivors in the NOx levels in plasma 
or CSF, although values tended to be lower in survivors. This tendency disappeared 
when plasma nitrate levels were corrected for renal function by dividing plasma NOx 
by plasma creatinine. There was a significant correlation between plasma nitrate and 
plasma creatinine levels at admission (r = 0.47, P  = 0.03). The total amount of NOx 
excreted in the first 12 hr following admission was greater in survivors than in the 
fatal cases (P 0.03. by Wilcoxon rank test). This difference also disappeared when the 
NOx levels in the urine were corrected for renal function by dividing them by the total 
creatinine level in the same sample. The mean fractional clearance of NOx in the 
survivors was 17% compared with 12% in the fatal cases (not significant). Admission 
parasitaemia did not correlate significantly with either plasma, urine, or CSF nitrate 
levels.
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Figure 12.
Plasma nitrate and nitrite (NOx) levels over time corrected for kidney function in 
patients with severe falciparum malaria in survivors and fatal cases. The two 
patients with elevated plasma NOx levels in the group with fatal cases both had 
severe kidney insufficiency, with calculated creatinine (creat) clearances of 4.0 
ml/min (*) and 8.0 ml/min (*), respectively, at admission. Despite the correction of 
plasma NOx for kidney function by taking the ratio with plasma creatinine, this 
measure is still likely to be an overestimation of NOx production since fractional 
NOx excretion (F-NOx) decreases with deteriorating kidney function (Westfelt et al.
1995). In these patients, F-NOx at admission was 1.3% (*) and 10.5% (k), 
respectively, versus a mean F-NOx of 15.5% for all patients, h = hours.
plasma [NOx] / [creat] 
(p M /p M ) survivors fatal cases
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Figure 13.
Urinary nitrate and nitrite (NOx) levels over time corrected for kidney function in 
patients with severe falciparum malaria in survivors and fatal cases. The sharp 
increase in urinary NOx in one patients in the fatal group (*) could be attributed to a 
urinary tract infection, creatinine; h hours.
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Plasma NOx levels were lower 48 hr after admission (Figure 12) (median value 
= 0.63 pM/pM versus 0.38 pM/pM; P = 0.007, by Wilcoxon matched pairs rank test) 
and also if the data were not corrected for kidney function (median value = 38.4
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pmol/L versus 32.4 pmol/L; P -  0.04). The two patients with elevated plasma NOx 
levels in the group with fatal cases both had renal failure, with an estimated creatinine 
clearance on admission of < 5.0 mL/min and 8.0 mL/min, respectively. Correction of 
plasma NOx levels for renal function by taking the ratio with plasma creatinine may 
still overestimate NOx production since fractional NOx excretion (F-NOx) decreases 
with deteriorating kidney function (Anstey et al. 1996). In these patients, admission F- 
NOx values were 1.3% and 10.5%, respectively, versus a mean F-NOx of 15.5% for 
all patients.
Urinary NOx tended to decrease following admission (Figure 13). One patient 
who died showed a sharp increase in urinary NOx, but this was attributed to a 
coincident urinary tract infection. There was a significant correlation between nitrate 
levels in the CSF and the plasma. (Spearman correlation coefficient = 0.59, P =
0.045). We did not find a significant correlation between nitrate levels in the CSF and 
the Glasgow coma scale, nor with coma recovery time or survival. The CSF nitrate 
levels did not differ significantly between healthy controls (n = 5) and patients with 
severe malaria (n = 11), with median values of 2.4 pmol/L (range = 0 - 8 . 9  pmol/L) 
and 4.8 pmol/L (range 1.5 - 61.4 pmol/ L), respectively.
Discussion
In this study, we did not show a correlation between either plasma NOx levels 
or the total amount of NOx excreted in the urine, and disease severity or outcome in 
patients with severe falciparum malaria after correction of the values for renal 
function. From studies with inhaled NO in humans, it has become clear that about 
70% of the NO is converted to NOx, and a smaller amount to methaemoglobin and
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other molecules (Kelm et al. 1992; Westfelt et al. 1995). The NOx levels are therefore 
taken as a measure for total NO production, since NO itself has a very short half-life 
(Kelm and Schrader 1990). Although the sample size was rather small, the present 
study shows that overall NO production does not seem to be a predictor of disease 
outcome or severity in nonimmune adult patients. This study group differs from those 
in several recent studies performed on malarial patients in highly endemic areas. In 
these latter studies, the highest serum NOx levels were found in healthy controls or 
patients with asymptomatic parasitaemia, and it was concluded that high NOx levels 
might be associated with malarial tolerance rather than with disease severity (Anstey 
et al. 1996; Clark et al. 1996; Kremsner et al. 1996).
In our study, we showed a significant correlation between plasma NOx and 
creatinine levels. Patients with renal failure showed very high plasma NOx levels with 
only little NOx excreted in the urine. Because NOx excretion is dependent on renal 
function and severe malaria is associated with renal impairment, severe malaria can 
be associated with higher levels of plasma NOx, As F-NOx secretion decreases as re­
nal function deteriorates, correction of plasma NOx levels by taking the ratio with 
plasma creatinine may still overestimate NOx production in patients with renal 
insufficiency (Anstey et al. 1996). Our results contrast with those of the study of Al- 
Yaman and others, who did not find a correlation between kidney function and 
plasma NOx levels in children with cerebral malaria in Papua New Guinea (Al- 
Yaman et al. 1997). However, of the 41 patients in their study who were evaluated for 
both plasma NOx levels and plasma creatinine, only four children had a slightly 
disturbed kidney function.
Nutritional status may also confound the interpretation of plasma NOx levels
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(Granger, Miller, and Hibbs 1996; Mitchel, Shonl, and Grindley 1916). In our study, 
bias from exogenous nutritional sources of NOx also cannot be excluded, but most 
patients had probably eaten very little before admission. Since gastric or parenterally 
feeding is never started immediately, patients with severe malaria, such as those 
reported here, almost invariably have a period of starvation during the first days after 
admission. This period of starvation was associated with a decrease in plasma NOx 
levels. Since the plasma half-life of nitrates is approximately 8 hr when kidney 
function is normal, a much sharper decrease in NOx levels would be expected if 
levels on admission were only elevated because of NOx derived from food taken 
before admission (Jungertsen et al. 1993; Radomski, Palmiri, and Hearn 1978). It is 
likely that a decrease in endogenous NO production after treatment contributed to the 
decrease in plasma NOx levels.
The NOx levels in the CSF were all much lower than blood levels, suggesting 
that NO production in the central nervous system is much lower than in the blood 
compartment. There was a clear correlation between plasma and CSF levels of NOx. 
This can be interpreted either as reflecting free diffusion of nitrites and nitrates across 
the blood-brain barrier or that cerebral NO production is a reflection of NO 
production elsewhere in the body. Moreover, NOx levels in CSF did not correlate 
with the coma depth in our patients. This is in accordance with the findings in 
Ghanaian children, where transmission of falciparum malaria is high (Agbenyega et 
al. 1997).These findings do not support the hypothesis that high levels of intracerebral 
NO production impair neurotransmission in the fatal cases brain in severe falciparum 
malaria (Clark, Rockett, and Cowden 1991; Kremsner et al. 1996). This hypothesis 
was formulated without data on NOx levels in the CSF. The CSF levels of NOx,
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however, might not be a good indicator of the local NO concentrations at the cerebral 
tissue level. For instance, in Alzheimer’s disease, increased activity of inducible nitric 
oxide synthase (iNOS) can be measured in postmortem—obtained brain microvessels, 
without evidence of increased NOx levels in the CSF (Dorheim et al. 1994; Milstien 
et al. 1994). Similarly, micro vascular iNOS in the brain could be increased in 
cerebral malaria, thus influencing nearby synapses, without increased NOx levels in 
the CSF, but this hypothesis will be difficult to prove in vivo.
In conclusion, there was no correlation between NOx levels in plasma, urine, or 
CSF and disease severity in nonimmune patients with severe falciparum malaria in 
this study. Plasma NOx levels are dependent on renal function. High NOx levels in 
CSF did not correlate with coma depth in cerebral malaria and the CSF-levels were 
much lower than those found in the blood compartment. These findings do not 
support a pivotal role for NO in the pathogenesis of cerebral malaria. However, local 
overproduction of NO might not be reflected in total NOx production or CSF levels of 
NOx. Therefore, the role of NO in severe falciparum malaria remains to be 
elucidated.
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A b s tr a c t
Lactic acidosis frequently complicates severe malaria in African children, and is 
a strong independent predictor of mortality. We tested the hypothesis that sodium 
dichloroacetate (DCA), an activator of pyruvate dehydrogenase, rapidly reduces 
hyperlactataemia in this patient population. Eighteen children with severe malaria and 
capillary plasma lactate > 5 mM were randomised to receive either intramuscular 
quinine plus a single 50 mg/kg intravenous infusion of DCA in saline, or quinine plus 
intravenous saline alone. Two patients in each treatment group died following 
randomisation. Thirty minutes after treatment, the mean plasma lactate was 28% 
below pre-treatment baseline values in the DCA group, but was unchanged in the 
placebo group. Throughout the first 4 h after treatment, mean plasma lactate in the 
DCA-treated patients was significantly less than that in controls (p= 0.003). 
Thereafter, mean plasma lactate declined in both groups and was <2 mM 10 h after 
treatment. DCA was well tolerated and did not alter quinine pharmacokinetics, A 
single intravenous dose of DCA rapidly improved lactic acidosis in African children 
with severe malaria, suggesting that DCA may be a useful adjunct in the initial 
treatment of these patients, and may increase their chance of survival by improving a 
major complication of their illness.
In tr o d u c tio n
Lactic acidosis is frequently associated with severe malaria and independently 
predicts a mortality of over 30% (Krishna et al. 1994b; Taylor, Borgstein, and 
Molyneux 1993). The treatment of lactic acidosis complicating P, falciparum 
infection relies on the rapid initiation of antimalarial therapy and correction of
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exacerbating factors such as intravascular volume depletion, seizures and anaemia. 
No specific treatment of lactic acidosis has been assessed in children with malaria, 
although African children are the largest group at risk of death from this complication 
(Taylor, Borgstein, and Molyneux 1993).
Sodium dichloroacetate (DCA) stimulates aerobic consumption of lactate by 
activating pyruvate dehydrogenase, the mitochondrial enzyme that catalyses the rate- 
limiting step in the oxidation of lactate (via pyruvate) to acetyl CoA2 (Stacpoole 
1993). The usefulness of DCA in children with malaria-associated lactic acidosis was 
anticipated on the basis that it rapidly corrects lactic acidosis in adults with severe 
malaria (Krishna et al. 1994a). The objectives of this study were therefore to carry out 
a detailed pharmacokinetic and pharmacodynamic study of DCA in children with 
lactic acidosis due to malaria, using a study design appropriate to circumstances 
prevailing in many African hospitals.
M e th o d s
This study was approved by the Committee of Research, Publication and Ethics 
of the School of Medical Sciences, University of Science and Technology, Kumasi, 
Ghana. Fully informed written consent was obtained from attending relatives of 
enrolled patients. This was an open, randomized comparison of DCA vs. saline 
placebo given as an adjunct to conventional treatment in children with severe malaria 
aged 18 months to 10 years. Initially, 12 children were randomized in pairs to receive 
either one dose of DCA or an equivalent volume of normal saline. To ensure 
comparability between DCA- and placebo-treated groups, the six remaining patients 
were stratified for treatment on the basis of entry lactate concentrations. Criteria for
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admission to the study were a confirmed diagnosis of severe falciparum malaria 
(asexual parasitaemia in a patient who either had strictly defined cerebral malaria or 
who looked severely ill, was unable to sit unaided, and required parenteral treatment) 
and an admission capillary blood lactate concentration ~5 mmol/1. To exclude 
confounding causes of coma, hypoglycaemia was corrected, a blood culture was taken 
and a lumbar puncture was performed to examine the cerebrospinal fluid.
M a n a g e m e n t
Patients admitted to the Department of Paediatrics at Komfo-Anokye Teaching 
Hospital Kumasi, Ghana, in November and December 1993 with the suspected 
diagnosis of severe malaria were referred to the study team. All patients received 
intravenous fluids while the diagnosis of malaria was confirmed by blood film 
examination. Hypoglycaemia was excluded by capillary glucose measurement (BM 
stix) and the patient was weighed. Two flne-gauge (22 or 23 G) intravenous cannulae 
were inserted, one for the administration of intravenous fluids and DCAI placebo, and 
the other for sampling purposes.
A n tim a la r ia l  a n d  D C A  tr e a tm e n t
After a rapid history and examination, and taking of baseline venous blood 
samples (250 pi for the immediate measurement of glucose, lactate and PCV), 
antimalarial treatment was begun (Waller et al. 1990). In patients who had not 
received previous quinine treatment, 20 mg salt/kg of quinine dihydrochloride (BP80, 
Rotexmedich) was injected intramuscularly, half into each thigh, after dilution (1:1 
v/v with sterile water for injection). Patients who had been pretreated with quinine 
received a maintenance dose (10 mg salt/kg diluted as before). Subsequent doses of 
quinine (lOmg salt/kg i.m., also diluted as before) were repeated every 12 h in
1 0 2
alternate thighs from the commencement of the first dose until the patient recovered 
sufficiently to tolerate oral quinine, which was continued for a total of 7 days. DCA 
(Tokyo Kasei Kyogo) was formulated as a 10% solution (w/v) in saline and sterilized 
by filtration (Stacpoole et al. 1992). DCA was administered by intravenous infusion 
(50 mg/kg, over 10 mm) or an equivalent volume of saline was administered to those 
subjects randomized to receive placebo. DCA and placebo were administered imme­
diately after quinine treatment had begun and venous access was established.
S u p p o r tiv e  tr e a tm e n t
An infusion of 5% glucose was administered at a rate of 3 mg/kg/mm for a 
minimum of 24 h. All patients received a single dose of intravenous thiamine (100 
mg, North wick Park Hospital, Harrow) and comatose patients received a single 
intramuscular dose of phenobarbitone (7 mg/kg, Biomedicine SPRI) at the start of the 
study. Seizures occurring after admission were treated with intravenous diazepam (0.3 
mg/kg, Diazemuls, Dumex), high temperatures (>38.5 ^C) were treated with rectal 
paracetamol (120 mg paracetamol suppositories) and severe anaemia (PCV <15%) 
was treated with transfusions of HIV- and hepatitis-B-virus-screened packed cells 
given with frusemide (1 mg/kg, Antigen Pharmaceuticals). Secondary bacterial 
infections were managed with gentamicin (20 mg/2ml, Roussel 2 Labs) and 
ampicillin (Berk Pharmaceuticals).
M o n ito r in g  a n d  sa m p lin g
Vital signs (respiratory rate, pulse, blood pressure) and the coma score assessed 
on the Blantyre scale (Molyneux et al. 1989) were monitored every 5 mm during the 
DCA infusion, then at 15 mm, 30 mm and 60 mm, followed by every 2 h for 12 h, and 
then at 16, 20 and 24 h after admission. Subsequent monitoring of vital signs was
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every 6 h until patients recovered, and other clinical measures, such as time to sit and 
time to drink, were also noted as endpoints. Temperature was monitored at 30 and 60 
mm, at 4 h and then with the other vital signs. The packed cell volume (PCV) and 
parasitaemia were monitored every 4— 6 h for the first 24 h and then every 6 h until 
resolution of infection.
Whole blood (400 pi) was collected into chilled heparinised (10 lU) 
microcentrifuge tubes each time vital signs were obtained, and was transported on ice 
before separation and processing of plasma. Plasma glucose and lactate assays (50 pi) 
were carried out on site immediately after collection using YSI glucose and lactate 
analysers, as reported previously (Krishna et al. 1994a). The lactate assay uses lactate 
dehydrogenase, and is stereospecific for L(±)-lactate. Plasma for DCA and quinine 
measurements (200 pi) was stored at —20 °C, and transported on dry ice for assay.
Q u in in e  a n d  D C A  a ssa ys
DCA in plasma was analysed by gas chromatography, as described (Curry et al. 
1991). Briefly, plasma (100 pi) and trichloracetic acid (TCA, 50 pi of a 50 pg/mL 
solution as an internal standard) were mixed in a 16 x 100mm screw cap culture tube 
(Klimax), and BF3 (1 ml, 14% solution in methanol) was added. The tube was 
vortexed, heated to lOO^C for 15 mm and cooled to room temperature. Cyclohexane 
(1 ml) and water (1 ml) were added to the mixture and the tube was agitated 
vigorously for 10 mm. After centrifugation (10 mm, 2500 g), the organic layer (top, 1 
pi) was injected into a Varian 3600 gas chromatograph equipped with a 6 ft x 2 mm
i.d. Chromosorb 101 column, a ^^Ni electron capture detector, and a PE Nelson 
Turbochrom 3 chromatographic integrator. The column temperature was 160 ^C. 
DCA and TCA had retention times of 1.96 and 3.18 mm, respectively. The peak areas
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obtained from the integrator were used in the determination of the ratio DCA:TCA. 
Every batch of DCA analysis involved calibration with known mixtures of DCA in 
plasma (2.5 to 200 pg/ml) and TCA. The coefficients of variation on the assay were 
2.02% (intraday) and 3.52% (interday), and the calibration graph was linear. DCA in 
the treatment vials was also measured by gas chromatography, after 1000-fold 
dilution with deionised water.
Quinine was measured using high performance liquid chromatography as 
described previously (Mhoru et al. 1991). An aliquot of plasma (200 pi) with internal 
standard added (quinidine, 200 ng) was mixed with ammonia (0.5 ml) and incubated 
at room temperature (5 mm). Samples were extracted by vortexing (30 s) with a 
mixture of hexane:ethylacetate (5 ml, 1:1 v/v). After centrifugation (5 mm, 2000 g) 
the organic phases were discarded, and contents of the tubes evaporated under N2 to 
dryness at 37 ^C. After reconstitution in the mobile phase (150 pi), 20 pi was injected 
into the column. The inter- and intra-assay coefficients of variation for the assay were 
< 8%.
Data analysis
One- and two-compartment pharmacokinetic analysis of DCA was carried out 
using PCNONLIN (v4, Statistical Consultants), and the most appropriate model 
selected on the basis of the Aikake Information Criterion and simplicity. Quinine 
profiles were analysed using Topfit (Schering) and a one-compartment model.
Statistical analysis used SYSTAT (v5.2, Evanston) or SAS programmes (SAS 
System Release 6.09, SAS Institute). Normally distributed data were analysed by 
Student’s t test, and non-normally distributed data were analysed by the Kruskall- 
Wallis test or logarithmically transformed to a normal distribution before analysis.
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Relative changes in lactate from baseline were analysed using the equation:
dtij= log2(ytij/yoij) (1)
where yti is the venous plasma lactate concentration measured at time t for patient i.
For patients who received quinine only, (j=0) and for patients who received DCA and 
quinine (j = 1).
To estimate and test the effects of adding DCA to quinine therapy, repeated 
measures data (for lactate and vital signs) were analysed using the randomized 
coefficient regression modelling methods in Proc Mixed in the SAS system. We used 
maximum likelihood estimation without assumption of the pattern for the structure of 
the common within-group covariance matrix.
These models tested the effects of treatment (DCA plus quinine vs. quinine 
alone), the effects of time and the effects of interactions between treatment category 
and time. The early phase of changes in lactate concentrations (Phase 1, up to 4 h, see 
Results) required the addition of a quadratic component to the model to achieve an 
adequate goodness of fit, and the model is represented in the following equation:
dtij==(a + aij) + (pj + bij)log2time + yj(log2time — 0.5)^ + eÿ (2)
where Si = ay =0, Si = by =  0
The following simpler mixed linear model describes the later changes in lactate 
concentrations (Phases II and III, 4 h and subsequently):
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dtij=(a +  ay) +  (Pj +  by)log2tim e +  ey (3)
In these models, the fixed effects for group j are the intercept aj, the slope pj, 
and the quadratic coefficient yj. The random effects, ay and by allow individual 
patients to have intercepts and slopes that deviate from their groups’ fixed values. A 
test of the primary hypothesis (that the addition of DCA produces differences in fixed 
effects from the recipients of quinine alone), was tested with standard log-likelihood 
tests comparing the above models with their null counterparts. For example, for 
the model described in (2), the null counterpart would be:
dtij=(a + ap + (Pj + bi)log2time + yj(log2time — 0.5)^ + ety (4)
From these models we also computed estimates and 95% Cls for the differences 
between the groups’ means on d at each time point.
R e s u lts
Patients
During the study period, 72 children suspected of having severe malaria were 
referred to the study team. The diagnosis of severe malaria was confirmed in 43 
(60%), and 18 (42%) with capillary venous lactate concentrations >5 mM were 
entered into this study. Fourteen patients (78%) presented with a history of vomiting. 
The median(range) duration of fever (n= 18) before admission was 48(1 —96) h, the 
time after the last meal was 14(2—72) h, and time after the last drink was 4(2—72) h. 
Fourteen patients (78%) had a history of convulsions, 8(44%) in the DCA-treated
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group. Five patients (28%) had opisthotonus, and one patient was hypoglycaemic 
(blood glucose ~2.2 mM) on admission. The two treatment groups were comparable 
for these variables (Table 7).
Table 7. Clinical characteristics of patients
Variable Placebo (n=9) DCA (n=9)
Sex (M/F) 5/4 4/5
Age (months) 49 ±29 39 ±22
Weight (kg) 14.9 ±5.7 11.7±3.4
Pulse (/min) 148±11 150 ±25
Respirations (1mm) 44± 11 55± 17
Blood pressure
(mmHg)
Systolic 122 ±37 111 ±16
Diastolic 62±  14 62± 11
Temperature (“C) 38 ± 1.0 37.8 ±1.2
Liver (cm)s* 3.5(2—5) 3.5(0— 5.5)
Spleen (cm)** 0.5(0—3) 1.0(0—3.5)
Cerebral malaria 5/9(56%) 4/9(44%)
Parasitaemia* (/pi) 
range
41 520 
10—778 500
63215 
10—758 600
Haematocrit (^/o) 21±9 22±7
Data are median (range), proportion or mean ± SD, except 
* geometric mean.
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** Measured from the costal margin in the midclavicular line.
Clinical course o f infection
Two patients in each treatment group died, all within 24 h of admission, giving 
an overall mortality of 22%. Eleven patients (61%) had seizures after admission 
which were often recurrent, partial motor in character, and sometimes difficult to 
distinguish from opisthotonus and decerebrate rigidity. Nine patients (50%) received 
blood transfusions, and in three patients (2 DCA, 1 placebo) a partial exchange 
transfusion was carried out because of high parasitaemia and/or severe anaemia. 
Clinical and parasitological measures of recovery in the two treatment groups are 
summarized in Table 8. There were no significant differences in these measures 
between treatment groups, except for the time to sit, which was slightly shorter in the 
placebo group (p=0.048) because of one patient with particularly prolonged 
measures of recovery (Table 8).
Table 8. Clinical measures of recovery
Variable (h) Placebo 
(n=5— 8)
DCA 
(n=5— 8)
Time for parasitaemia to fall by 50% of baseline 
(PC50)
18(2.5—34) 21(2.5—36)
Time for parasitaemia to fall by 90% of baseline 
(PC90)
23(19—36) 28(15—46)
Parasite clearance time (PCT) 37.5(20-^8) 48(36—60)
Fever clearance time (FCTb) 26(5—44) 36(5—54)
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Time to drink 18(10—42) 32.25(2— 68.4)
Time to eat 18(12—44) 40.8(5— 112)
Time to sit unaided 42.5
(23.3—66.3)
67
(34— 112)
Time to stand unaided 49(37.5—
119.5)
114(49— 191)
All values are medians (ranges).
Efficacy o f dichloroacetate
The baseline geometric mean venous plasma L(+)-lactate concentrations in the 
two treatment groups were 8.2 mM in the placebo group, and 7.6 mM in the DCA 
group. Corresponding logzlactate mean ± SD values were 3.03 ± 0.72 and 2.92 + 1.06 
(p>0.1). Because venous lactate concentrations were analysed after logztransformation 
(equation 1), a difference of 1 is a two-fold difference in concentration, and values of 
d=0, -0.5, -1, -1.5, and -2 correspond to reductions from baseline of r=0%, 29%, 50%, 
65%, and 75% (r=2^ - 1). Inspection of profile plots of the means of d (changes in 
lactate from baseline) relative to logztime in the two treatment groups revealed a 
nonlinear pattern characterized by phases (Figure 13 and Table 9). The effects on 
lactate profiles of adding DCA to quinine therapy were analysed separately for these 
phases, as described in Methods. These procedures used all the available data, and 
assumed that censoring due to death is not informative.
Phase 0 (time=5 min, 10 min) was too soon after the DCA infusion to discern 
differences between the DCA and control groups, and was therefore not analysed 
further. Phase I (t=30 min, 1 h, 2 h, 4 h) describes the clinically important reductions
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in lactate concentrations in the two treatment categories because in this phase overall 
geometric mean lactate concentrations exceeded 4.5 mM (i.e. patients were grossly 
hyperlactataemic). There were no deaths in Phase I, and DCA recipients had 
significantly greater lactate reductions than controls (p=0.003, two-tailed), especially 
at 30 min and 1 h.
In Phase II (t=6 h, 8 h, 10 h, 12 h), geometric mean lactate concentrations fell 
below 3 mM , and the rate of fall in lactate concentrations increased compared with 
Phase I (i.e. the slope of decline in lactate concentrations was steeper). In this phase, 
lactate concentrations in the control group (quinine alone) declined more rapidly than 
DCA-treated patients (p=0.021). However, lactate concentrations had already fallen 
considerably at the start of Phase II, and mean lactate at 8 h was 2 mM in controls, 
and 2.6 mM in DCA recipients.
Phase III (t = 16 h, 20 h, 24 h) contained groups whose mean lactate 
concentrations were below 1.8 mM. There was considerable inter-patient variation in 
lactate profiles, without any apparent overall reductions, and no significant 
differences between groups (p=0.09). The four patients who died had the highest 
baseline venous lactate concentrations (p<0.001). A fatal outcome was associated 
with both higher lactate concentrations (p=0.001) and smaller reductions in lactate 
from baseline (p= 0.05) for the lactate measurement taken immediately prior to death 
(see footnote Table 9).
There was no evidence of toxicity with DCA. Using the same mixed linear 
models described above, no DCA effects were inferred for changes in glucose, pulse, 
respiratory rate and blood pressure.
I l l
Figure 14. Lactate profiles in a DCA-treated and b placebo-treated children with 
severe malaria.
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Figure Î .  Lactate profiles in a DCA-treated and b placebo-treated children with severe malaria.
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Table 9. Lactate levels and changes from baseline in children with severe malaria 
treated with quinine-only (Q) or DCA plus quinine (DCA + Q)
Table 3 Lactate levels and changes from baseline in children with severe malaria treated with quinine-only (Q) or DCA 
plus quinine (DCA +  Q) (both n =  9)
Time Lactate (mM) change from baseline % Change Mean DCA effect on d
(geometric mean) (d: mean ±SD) from baseline (from mixed model)
Q DCA-PQ Q DCA +  Q Q DCA +  Q Estimate 95% Cl
Baseline 0 min 8.2 7.6
Phase 0 5 min 8.2 7.4 -0 .0 2 + 0 .1 4 -0 .0 3 + 0 .1 0 - 1  - 2
(not tested) 10 min 7.2 7.2 -0 .0 5 + 0 .0 9 - 0 .0 9  +  0.14 - 3  - 6
Phase 1 30 min 8.1 5.5 -0 .0 2 + 0 .1 9 - 0 .4 7  +  0.39 - 1  - 2 8 -0 .4 3 1-0 .74 ,
-0 .1 2 )
(p =  0.003) 1 h 7.1 4.9 -0 .2 0 ± 0 .3 1 -0 .6 3 + 0 .4 5 - 1 3  - 3 5 -0 .4 9 1-0.83,
-0 .1 6 ]
2 h 6.8 4.6 -0 .2 7  +  0.42 -0 .7 1  +0.52 - 1 7  - 3 9 -0 .3 8 (-0 .7 9 , 
+  0.03]
4 h 4.9(1) 4.3 -0 .7 5 + 0 .6 8 " ' -0 .8 2 + 0 .4 9 -4 1  - 4 3 -0 .0 9 [-0 .6 1 , 
+  0.42]
Phase 11 6 h 3.1 3.9"' -1 .2 7 + 0 .5 3 -0 .9 5  ±0 .52" ' - 5 9  - 4 8 +  0,36 [-0 .1 2 , 
+  0.83]
(p =  0.021) 8 h 2.0 2.6"' -1 .8 7  +  0.39 -1 .3 7  ± 0 .4 6 " ' - 7 3  -6 1 +  0.48 ( +  0.13,
+  0.831
10 h 1.7 1.8 -2 .1 5 + 0 .3 4 -1 .6 6  ±0.42 - 7 7  - 6 8 +  0.57 1 +  0.19, 
+  0.96]
12 h 1.5 1.7 -2 .3 5  ±0,67 -1 .7 6 ± 0 .3 7 - 8 0  - 7 0 +  0,65 [ +  0.17, 
+  1.13]
Phase III 16 h 1.4 1.8 -2 .4 0  +  0.69 -1 .7 1  ±0.62 - 8 1  - 6 9 +  0.72 1 +  0.04, 
+  1.401
(p =  0.093) 20 h 1.5'"' 1.8 - 2 .3 2 + 0 .9 2 ” ' -1 .7 0  ±0.56 - 8 0  - 6 9 +  0.55 1-0.19, 
+  1.28]
24 h 1.5 1.6 -2 .1 4  +  0.88 -1 .8 3  ±0.90 - 7 7  - 7 2 +  0.40 1-0.52, 
+  1.33]
n.i-î.-n pçjf gach patient who died, the baseline lactate (rank/18, where 1/18 =  minimum value), the time of final 
measurement, final lactate (rank/N, where 1/N =  minimum value among N survivors at that time), and final d value 
(rank/N) are: 17.4 mM (15/18), 4 h,16.4 mM (18/18), d =  -0 .0 9  (17/18); 19.4 mM (17/18), 6 h, 15.0 mM (17/17),
d =  -0 .3 7  (15/17); 19.8 mM (18/18), 8 h, 11.2 mM (16/16), d =  - 0 .8 2  (16/16); 18.6 mM (16/18), 20 h, 2.8 mM
(14/15), d =  -2 .7 3  (4/15).
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Table 10. Pharmacokinetic parameters for DCA and quinine
Variable DCA (n=8) Quinine (n= 13)
Volume of distribution (Vd) (1/kg) 0.323 ±0.097(0.1 6— 
0.5)
1.07 ±0.27(0.75— 1.71)
Area under the concentration-time 
curve (mg/l.h)
378 ± 6 5 (2 3 7 ^ 4 1 ) 517 + 360(1 50— 1 630)
Peak concentration (Cmin) (mg/I) 170 ±52(93—264) 15.5 + 3.26(9.6—21.6)
Half-life (ti/2p) (h) 1.8±0.4(1.4—2.5) 23.5 + 16.97(6.6—69.1)
Clearance (CL) (ml/min/kg) 2.68 ±0.83(1.87—3.88) 0.725 + 0.43(0.17— 
1.84)
Mean residence time (h) 2.11 ±0.73(1.45—3.72)
Pharmacokinetics o f  DCA
Table 10 summarizes the pharmacokinetic parameters from eight patients who 
received DCA, and Figure 14 summarizes the changes in mean plasma concentrations 
of DCA with time, Spearman-correlations were computed between the individual 
slope values (bij) in Phases I and II for patients’ lactate kinetics, and the following 
pharmacokinetic parameters: plasma half-life (ti/2p)), apparent volume of distribution 
(Vd), area under the plasma concentrations curve (AUC), and peak plasma DCA 
concentration (Cmax). The strongest relationship was between Phase I slope and AUC 
(r= -0.71), p=0.046). However, this result is not significant, given that only eight 
correlations were tested, and in this small study, no relationship was found between 
the derived pharmacokinetic and pharmacodynamic parameters for DCA.
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Figure 15. Mean and individual DCA concentration-time profiles in eight patients a 
and quinine profiles 6 in 16 patients with severe malaria.
(a)
DCA concentration (m g/L)
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Figure 2. Mean (bold line with circles) and individual DCA concentration-time profiles in eight patients a and individual 
quinine profiles b in 16 patients with severe malaria.
Pharmacokinetics o f  quinine
Quinine was administered a mean ± SD of 16±4 mm before the DCA infusion 
was begun. Detailed pharmacokinetic evaluation was only available for 13 patients, 
and absorption kinetics on six patients, because in others the sampling schedule was
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infrequent. The mean absorption half-time was 10.4 + 9 mm. Quinine was absorbed 
relatively rapidly, without evidence of excessively high peak levels, and therefore 
gave satisfactory overall profiles (Figure 14). There were no significant differences in 
quinine pharmacokinetic parameters between DCA (n= 7) and placebo (n=6) 
recipients (p>0.1). The pharmacokinetic properties of this regimen of intramuscular 
quinine are summarized in Table 10. On discharge, three patients had small, non­
tender, non-infected indurated lesions at the injection sites, and in one child similar 
lesions were tender to palpation. There was no other evidence of local toxicity. 
Discussion
Lactic acidosis vies in frequency with cerebral malaria as a potentially lethal 
complication of severe P. falciparum infection (Waller et al. 1995). In children who 
survive an episode of severe malaria, lactic acidosis resolves rapidly with antimalarial 
and supportive treatment. In fatal cases, however, systemic lactic acidosis often 
persists, or worsens, up to the time of death (Krishna et al. 1994b). This sustained 
hyperlactataemia is the measurable endpoint of many processes that probably vary in 
their relative contributions from patient to patient. Such processes include diminished 
oxygen delivery to vital organs because of anaemia (Krishna et al. 1983; Krishna et 
al. 1994b) and microvascular obstruction by infected red cells (White and Ho 1992), 
increased tissue output of lactate due to seizures (Taylor, Borgstein, and Molyneux 
1993), decreased lactate clearance by the liver (Pukrittayakamee et al. 1991), and the 
effects of increases in endogenous mediators, such as ' pro -inflammatory ' cytokines 
(e.g. TNF and IL-la) (Krishna et al. 1994b).
There is no established treatment for lactic acidosis associated with malaria. In 
this context, the use of DCA is based on the premise that it may prevent early deaths
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from lactic acidosis and therefore allow antimalarial treatment time to reverse the 
underlying cause(s) of acidosis. Our studies have therefore focused on DCA as an 
adjunct to quinine therapy. In preliminary work, DCA attenuated hyperlactataemia in 
a P, berghei-mÎQCtQé/yomig Wistar rat model of severe malaria (Holloway, Krishna, 
and White 1991), and DCA was also effective in correcting lactic acidosis in Thai 
adults with severe malaria (Krishna et al. 1994a). To evaluate the efficacy of DCA in 
prolonging survival when lactic acidosis complicates malaria, DCA was added to 
quinine therapy in a large prospective study using the previously characterized rodent 
model of severe infection. A single dose of DCA given with quinine significantly pro­
longed survival of rats with severe malaria, compared with controls receiving quinine 
alone (Holloway et al. 1995). These initial studies have established the efficacy of 
DCA in severe malaria and suggest that it is a promising drug for further studies.
Most deaths in children with severe malaria occur in the first 24 h after 
admission. The first 4— 8 h are therefore crucial in stabilizing a sick child, instituting 
antimalarial treatment, and treating complications (Waller et al. 1995). The current 
study confirms that within the first 4 h of admission, DCA corrects hyperlactataemia 
in children with lactic acidosis due to malaria more rapidly than supportive therapy 
alone. Hyperlactataemia predicted death in this study as well as in a previous larger 
investigation (Krishna et al. 1994b). The magnitude of the fall in lactate 
concentrations from baseline was smaller in patients who died than in survivors.
Four hours after admission, mean lactate concentrations had also fallen in the 
placebo group to relatively low levels (Phase II). Although the differences between 
placebo and DCA-treated patients were statistically significant during this period, 
they were small and not considered to be clinically important, as plasma lactate
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concentrations were no longer grossly elevated. From 12 h after admission, 
differences in plasma lactate were no longer discernible between the treatment and 
placebo groups.
A single 10 mm infusion of DCA gave reproducible plasma concentration- 
time profiles (Figure 15). DCA was easily administered, rapidly effective and, when 
given in conjunction with a glucose infusion, non-toxic in this study. A glucose 
infusion was considered to be necessary, because glucose concentrations may also fall 
as pyruvate dehydrogenase is activated by DCA (Stacpoole 1989). The mean apparent 
volume of distribution (Vd=0.32 1/kg) of DCA in this study is lower than that 
observed in adults with severe malaria (Vd= 0.75 1/kg and Vd=0.44 1/kg in a further
11 adult patients with very severe malaria, unpublished observations) and the mean 
elimination half-life (ti/2p= 1.8 h) is shorter (compared with adults ti/2p= 2.3 h and 
ti/2p= 3.4 h, unpublished). A single dose of DCA is probably sufficient to lower blood 
lactate in children with severe malaria, as conventional antimalarial and supportive 
treatment tend to normalize derangements in lactic acid metabolism within a few 
hours after admission. We have also studied two doses of DCA (46 mg/kg each) given
12 h apart to adults with very severe malaria, and shown that no significant additional 
metabolic improvement is observed when the effects of the second dose are compared 
with the hypolactataemic effects observed after the first dose (Krishna et al, 
submitted).
In a previous study, undiluted intramuscular quinine (300 mg/ml, administered 
as an intramuscular loading dose of 20 mg/kg quinine salt, followed by 10 mg/kg 
every 12 h) produced acceptable plasma concentration-time profiles (Waller et al. 
1990). In this study, similar profiles were observed for quinine given in the same dose
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and frequency after 1:1 dilution. There were no significant differences between the 
mean elimination half-lives ( t i / 2 p ) ,  peak quinine concentrations (Cmax) and clearances 
estimated in this study and those in the earlier one which used undiluted quinine 
(p>0.5 for all three pharmacokinetic parameters). The absorption half-times of 
quinine from the intramuscular site were, however, significantly more rapid when 
compared with undiluted quinine (ti/2abs= 10.4+9 mm vs. 38+25 mm, respectively; p=
0.0031) and were similar to those observed after 1:5 (v/v) dilution of quinine 
( t ] / 2 a b s = 8 . 7 + 7 . 8  min (Winstanley et al. 1993). There was no evidence of major toxicity 
with quinine, or of interaction with DCA (Figure 15). Thus quinine diluted in an equal 
volume of sterile water and given intramuscularly is an appropriate regimen for 
children with severe malaria complicated by lactic acidosis. In summary, a single 
intravenous dose of DCA is an effective adjunct therapy to conventional antimalarial 
treatment for children with severe malaria complicated by lactic acidosis. As lactic 
acidosis frequently accompanies severe malaria and contributes to a fatal outcome, 
and DCA ameliorates lactic acidosis more rapidly than supportive treatment, DCA 
should now be evaluated in larger studies designed to assess its impact on mortality.
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Abstract
Children with severe malaria often present with lactic acidosis and hypoglycaemia. 
Although both complications independently predict mortality, mechanisms underlying 
their development are poorly understood. To study these metabolic derangements we 
sequentially allocated 21 children with falciparum malaria and capillary lactate 
concentrations >5mmol/1 to receive either quinine or artesunate as antimalarial therapy, 
and dichloroacetate or saline placebo for lactic acidosis. We then administered a primed
infusion (90 min) of L-[3-^^Ci] sodium lactate and D-[6,6-Dz] glucose to determine the 
kinetics of these substrates. Nineteen surviving children were comparable at entry to the 
study. The mean (SD) glucose disposal rate in all patients was 56(16) pmol/kg/min and 
geometric mean (range) lactate disposal rate was 100(66-177) pmol/kg/min. Glucose and 
lactate disposal rates were positively correlated (r=0.62, p=0.005). Artesunate was 
associated with faster parasite clearance, lower insulin/glucose ratios and higher glucose 
disposal rates than quinine. Lactate disposal was positively correlated with plasma lactate 
concentrations (r=0.66; p=0.002) and time to recovery from coma (r=0.82, p<0.001; 
n=15). Basal lactate disposal rates increased with dichloroacetate. Elevated glucose 
turnover in severe malaria mainly results from enhanced anaerobic glycolysis. Quinine 
differs from artesunate in its effects on glucose kinetics. Increased lactate production is 
the most important determinant of lactic acidosis.
Introduction
Malaria kills approximately 2 million African children a year. Many of these 
children die with metabolic complications of infection. Lactic acidosis complicates 35% 
of severe childhood malaria (Krishna et al. 1994b) and hypoglycaemia is present in 20%
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of children with cerebral malaria (Newton and Krishna 1998). Both metabolic 
derangements commonly coexist, and each independently defines severe disease and 
predicts fatality in children (Allen et al. 1996; Krishna et al. 1994b; Newton and Krishna 
1998; Taylor, Borgstein, and Molyneux 1993) and in adults (Hien et al. 1996; Krishna et 
al. 1994a; White et al. 1983).
The causes of hypoglycaemia in African children with malaria are incompletely 
understood. Hyperinsulinaemia rarely accompanies hypoglycaemia in children presenting 
to hospitals with severe malaria (Krishna et al. 1994b; White et al. 1987; White et al. 
1983) although hyperinsulinaemia can complicate the treatment of children who receive 
quinine (Hensbroek et al. 1996; Krishna and White 1996). The kinetics of glucose has 
not been investigated in these populations despite the high risk of hypoglycaemia and the 
metabolic consequences of quinine have not been defined.
Although quinine is the preferred treatment for severe malaria in most geographic 
areas, artemisinin derivatives, such as artesunate, are an increasingly valuable therapeutic 
option (Hensbroek et al. 1996; Pukrittayakamee et al. 1994a). Artesunate is currently 
being investigated as an alternative to quinine in the management of African children with 
severe malaria, particularly when it is given by the intrarectal route in primary health care 
settings. However, artesunate’s effects on intermediary metabolism and insulin dynamics 
in children with severe malaria have not been investigated.
Sustained lactic acidosis may be the only clinically attributable cause of death in 
some children (Krishna et al. 1994b), but its causes and management are not established. 
Dichloroacetate (DCA) improves lactic acidosis in children with severe malaria (Krishna 
et al. 1994a) and increases survival in a rodent model of lactic acidosis caused by
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Plasmodium berghei infection (Holloway et al. 1995). However, the mechanism of action 
of DCA has not been studied in children with severe malaria.
We used stable isotopes to examine the kinetics of glucose and lactate in African 
children with malaria-associated lactic acidosis, and examined the effects of drugs used in 
the management of severe malaria. Children received quinine or artesunate as antimalarial 
therapy, and either DCA or placebo for hyperlactataemia. We hypothesised that quinine 
would have important effects on glucose metabolism, and that DCA would influence 
lactate kinetics.
Materials and Methods
The Committee of Research, Publication and Ethics of the School of Medical 
Sciences, University of Science and Technology, Kumasi, Ghana and the Institutional 
Review Board of the University of Florida approved this study. Informed consent was 
obtained from relatives of enrolled patients. This was a parallel, open-label comparison of 
quinine versus artesunate as antimalarial treatment, and DCA versus saline placebo given 
as an adjunctive treatment to children aged 11 months to 10 years who had severe 
malaria. Twenty-one children were allocated in strict sequence to one of four treatment 
categories: quinine and saline placebo (n=6), quinine and DCA (n=5), artesunate and 
placebo (n=5), or artesunate and DCA (n=5) if they had severe falciparum malaria 
(defined as asexual parasitaemia in a patient who either had strictly defined cerebral 
malaria or who looked severely ill, was unable to sit unaided, and required parenteral 
treatment (Waller et al. 1995)) and a capillary blood lactate concentration equal to or 
greater than 5mmol/1 at the time of screening (Krishna et al. 1995). To exclude
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confounding causes of other illnesses, a blood culture was obtained in all subjects and a 
lumbar puncture was performed in comatose patients.
Management
Patients who were referred for study were admitted to the Department of Paediatrics 
at Komfo-Anokye Teaching Hospital, Kumasi, Ghana, in October-November 1995 with 
the suspected diagnosis of severe malaria. The diagnosis of malaria was confirmed by 
examination of a blood film. Hypoglycaemia (glucose <2.2 mmol/1) was excluded by 
capillary glucose measurement (BM stix™) at the time of screening but all glucose 
estimations were confirmed as described below. Two intravenous cannulae were inserted. 
One peripheral line was to administer intravenous fluids and either DCA or placebo, and a 
second central line (5Fr 2 lumen or 5.5Fr multi-lumen catheter, Arrow-Howesf^^, Arrow 
International) was to administer 50% glucose to treat hypoglycaemia, to monitor 
circulating intravascular volume and to administer fluids and obtain samples for analyses.
Antimalarial and dichloroacetate treatment
Antimalarial treatment was begun immediately (Waller et al. 1990) after venous 
blood was obtained to measure glucose, lactate and haematocrit. In previously untreated 
patients who were randomised to receive quinine, 20 mg salt/kg of quinine 
dihydrochloride (BP 1980, Martindale Pharmaceuticals Ltd, Romford, Essex, UK) was 
injected intramuscularly, half into each thigh after dilution 1:1 (v/v) with water or normal 
saline (Krishna et al. 1995). Patients pre-treated with quinine received a maintenance dose 
(10 mg salt/kg diluted as before) thereafter. Subsequent injections of quinine (10 mg 
salt/kg, diluted) were repeated every 12 hours in alternate thighs from the commencement 
of the first dose until the patient recovered sufficiently to tolerate oral quinine (quinine
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sulphate suspension, 50 mg/5ml, Edikay Pharmacy Ltd, Kumasi, Ghana), which was 
administered as a lOmg/kg dose every eight hours for a total of seven days.
Patients who were randomised to receive artesunate (Guilin No 2 Pharmaceutical 
Factory, Guangxi, China) were given an intramuscular injection of 2.4 mg/kg (60 mg/ml) 
that was made up immediately before use in a 5% sodium bicarbonate solution that was 
supplied with drug. This dose was followed by intramuscular injections of 1.2 mg/kg 
artesunate 12 hours and 24 hours after admission, and subsequently 1.2 mg/kg daily, for a 
total of seven days (total dose of artesunate, 10.8 mg/kg). Treatment was changed to oral 
artesunate (nearest 1/4 tablet equivalent; 50 mg/tablet) as soon as patients could swallow 
oral medication. Sodium dichloroacetate (Tokyo Kasei Kyogo Ltd., Tokyo, Japan) was 
formulated as described previously (Stacpoole et al. 1992) and 50 mg/kg was 
administered by intravenous infusion over 10 minutes. Normal saline instead of DCA was 
administered to subjects who were randomised to receive placebo.
Supportive treatment
To minimise the risk of hypoglycaemia, all subjects received an infusion of 5% 
glucose in water, using a syringe pump, at a rate of 1 mg/kg/min for the duration of the 
stable isotope study. All patients received a single dose of intravenous thiamine (100 mg. 
North wick Park Hospital, Harrow, UK) to correct possible sub-clinical thiamine 
deficiency (Krishna et al. 1999)(17). Patients who were comatose patients or who had 
seizures received a single intramuscular dose of phenobarbitone (7 mg/kg, Biomedicine 
SPRI, Brussels, Belgium) at the start of the study. Seizures after admission were treated 
with intravenous diazepam (0.3 mg/kg, Diazemuls, Dumex Ltd., Princes Risborough, 
Bucks, UK), high temperatures (>38.5°C) were treated with rectal paracetamol (120 mg 
paracetamol suppositories, WHA, South West Thames Pharmacy Services Production
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Unit, St. George's Hospital, London, UK) and severe anaemia (haematocrit less than or 
equal to 15%) was treated with transfusions of packed cells screened for HIV- and 
hepatitis B virus. Frusemide (1 mg/kg. Antigen Pharmaceuticals Ltd., Rosivia, Ireland) 
was also administered during each transfusion. Patients with secondary bacterial 
infections received gentamicin (20 mg/2ml, Roussel 2 Labs Ltd., Uxbridge, UK) and 
ampicillin (Berk Pharmaceuticals Ltd., Eastbourne, UK). Intravascular volume depletion 
was monitored measuring central venous pressure and corrected with intravenous saline 
infusions.
Assay for antimalarials
Previous treatment with antimalarials was determined in pre-treatment plasma 
samples by dipstick ELISA tests that detect the presence of chloroquine, quinine, 
mefloquine and pyrimethamine (Silamut et al. 1995)(18).
Infusion o f L-[3-^^Cj] lactate and D-[6y6-D2]  glucose and sampling for stable 
isotopes
Stable isotope solutions were formulated in sterile water (15 ml) by mixing L-[3- 
l^Ci] sodium lactate and D-[6,6-D2] glucose to final concentrations of 2 .22% and 2.78% 
respectively (i.e. 0.333 g sodium lactate, and 0.417 g glucose per bottle). Patients were 
resuscitated and stabilised, and antimalarial and supportive therapies were begun. 
Baseline venous blood samples were obtained to determine the natural abundance of 
stable isotopes, and to quantitate glucose, lactate and insulin concentrations (-10 min, -5 
min and just before DCA or placebo infusion was begun). An intravenous priming bolus 
of 0.135 ml/kg of stable isotope was then injected after the DCA/placebo infusion had 
stopped and an infusion of 0.404 ml/kg/h of isotope solution was administered by syringe 
pump (Graseby 3200, Graseby Medical Ltd., Herts. UK) immediately after the loading
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dose of isotope was given. This infusion was continued for 90 minutes (13.48 mg/kg of 
lactate and 16.8885 mg/kg of glucose were infused for the duration of the study). Sixty 
minutes after the end of the DCA infusion, four samples (2 ml each) were taken at 10 
minute intervals (i.e. 60, 70, 80 and 90 minutes after isotope infusion had begun) to 
measure glucose, lactate and insulin concentrations, and an aliquot of each sample at the 
last three time points was used to determine enrichment with stable isotopes. The study 
protocol is illustrated in Fig 14.
Monitoring and sampling
Vital signs (respiratory rate, pulse, blood pressure) and coma score (Blantyre scale 
(Molyneux et al. 1989)), were monitored every five minutes during the DCA infusion, 
then at 15, 30, 60, 70, 80 and 90 minutes during stable isotope infusion, then every six 
hours until patients recovered. Other clinical measures, such as time to sit and time to 
drink, were also noted as endpoints. Temperature was monitored at 30 and 60 minutes, 
then with the other vital signs. Haematocrit and parasitaemia were quantified every six 
hours until parasites were undetectable by blood smear examination.
Whole blood (400 pi) was collected in chilled, heparinised (20 lU) micro centrifuge 
tubes each time vital signs were obtained, and was transported on ice and centrifuged to 
isolate plasma. Venous glucose and lactate (50 pi whole blood) were measured 
immediately after sample collection, using YSI 2300 glucose and lactate analysers 
(Yellow Springs Instruments, Youngtown, OH). For consistency, aliquots of plasma 
samples collected for isotope analysis were reassayed on a YSI 2300 ST AT combined 
glucose/lactate analyser. These data were used for analyses of glucose and lactate 
kinetics. Plasma (600 pi) was stored at -20°C and transported on dry ice for stable isotope 
measurements.
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Analysis o f stable isotopes
To determinate lactate enrichment of blood, plasma (100 pi) was made acidic by 
adding 50 pi of O.IM HCl. The mixture was passed through a Dowex AG-50 x 8 
exchange column (Sigma, St. Louis, MO), washed with 0.5 ml distilled water and 
collected in a silianized test tube. The solution was reduced under vacuum until almost 
dry and drying was completed under nitrogen. After preparing the t-butyldemethylsilyl 
derivative (Guyton et al. 1993) the lactate enrichment was determined using a Hewlett 
Packard 5790 gas chromatograph/5790 MSD fitted with a 30 mm x 0.25 mm x 0.25 I.D. x 
0.25 pm SPB fused silica capillary column (Supelco, Bellefonte, PA). The derivatised 
lactate had a molecular mass of 318 amu. The electron impact spectrum at 70 ev had a 
mass spectrum with a weak M-15 peak at 303 amu (without a methyl group) and a strong 
M-57 peak at 261 (without a t-butyl group). Using selective ion monitoring, we monitored 
ion channels 261 and 262 for lactate enrichment. Each sample was analysed in triplicate. 
The coefficient of variation was less than 1.5%.
To determine glucose enrichment, 50 pi plasma samples were made acidic by 
adding 25 pi of O.IM HCl. The mixture was passed through a Dowex AG-50 x 8 column, 
washed with distilled water, collected and dried completely under vacuum. The 
pentaacetate derivative of glucose was prepared by mixing acetic anhydride (200 pi) and 
pyridine (200 pi) and by incubating at room temperature overnight. The derivatised 
glucose was analysed using the same gas chromatograph/mass spectrometer as for lactate, 
under electron impact conditions. The derivatised glucose produced two peaks in the mass 
spectrometry analysis: a- and p-D-glucopyranose pentaacetate. The spectrum of each 
compound had a fragment of mass 242 amu, due to the loss of C-1 carbon of glucose 
(Biemann, DeJongh, and Schnoes 1963). Using selective ion monitoring of the a-D-
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glucopyranose pentaacetate, three ion channels, 242, 243 and 244, were monitored for 
glucose enrichment. Each sample was analysed in triplicate. The coefficient of variation 
was less than 3%. The results were confirmed by also monitoring (3 -D-glucopyranose 
pentaacetate.
Calculations
The lactate mole percent excess (MPE) was calculated using the 262/261 ratio for 
samples obtained after 60 minutes of infusion (Rs) and the time zero (Ro), as shown in 
the following equation.
MPE
1 + {Rs -  Ro)
For D-[6,6-D2] glucose, the 244/242 tracer ratio was corrected for contribution of 
singly enriched molecules, as suggested by Rosenblatt and Wolfe (Rosenblatt et al. 1992). 
Lactate and glucose disposal rates were calculated by a formula (Rosenblatt and Wolfe 
1988) that corrects for the change in pool size from the exogenous lactate or glucose, 
natural abundance, and the enrichment of infusate. The rate of gluconeogenesis was 
obtained by assuming that, in fasted children such as those with severe malaria, the rate of 
appearance of glucose from glycogenolysis was negligible (White et al. 1987). Hence, 
gluconeogenesis becomes the glucose disposal rate minus the rate of exogenous glucose 
administration.
Data analysis
S Y ST AT (v5.2, Evanston, II) and Stata (v5. College Station, TX) was used for 
statistical analysis. Normally distributed data (assessed by Schapiro-Wilk W test) were
129
analysed by Student's t test or ANOVA and Pearson’s correlation coefficient. Non- 
normally distributed data were analysed by the Wilcoxon Rank sum test, and correlations 
were determined by Spearman’s rho. The assumption of steady state was examined by a 
test for trend. Repeated measures data were analysed using MANOVA with specified 
linear general hypotheses. Insulin levels below the level of detection (<10 pmol/1) were 
coded as 1 pmol/1 for purposes of statistical analysis.
Results
Patients
During the study period 86 consecutive children were referred to the study team, 
and 54 of these had P. falciparum infection. The majority did not meet one of the study’s 
entry criteria (screening lactate > 5mM) leaving 24 with lactate concentration > 5 mM. 
Twenty-one of these 24 children were subsequently entered into this study. Of the 
remaining 3, 1 child’s parents refused consent and 2 children could not be studied because 
of difficulties with venous access. The clinical and laboratory characteristics of children 
in different treatment categories were comparable (Table 11). For all children, the median 
(range) duration of fever before admission was 48 (0.5-96) h, the time after food was last 
taken was 8.5 (4-24) h and the time after the last drink was 6 (2-15) h. Fifteen children 
(71%) presented with cerebral malaria (unrousable coma for at least 0.5 h following a 
seizure), five (24%) children were hypoglycaemic (glucose <2.2 mmol/1) on admission 
and five children (24%) presented with or subsequently developed retinal haemorrhages. 
All blood cultures and cerebrospinal fluid samples obtained on admission to the study 
were negative for pathogenic organisms.
Clinical course
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Two patients (one who received quinine and placebo, and one who received 
artesunate and DCA) died soon after randomisation, so 19 patients were included in 
metabolic studies. Another patient who received artesunate and DCA died 120 hours after 
entry into the study (overall mortality -  14%). Ten patients (48%) required transfusion, 
six patients (29%) had seizures after admission and two boys (10%) developed 
haemoglobinuria. At the time of admission, three patients had chloroquine detectable in 
plasma samples, but no subject had detectable plasma levels of quinine, mefloquine or 
pyrimethamine. Patients received DCA a mean (range) of 35 min (8 min-75 min) after 
antimalarial treatment began, and after correction of hypoglycaemia, when appropriate. 
Table 12 summarizes the clinical and parasitological measures of recovery for the two 
different antimalarial treatments.
Despite the relatively small number of patients in each category, parasite clearance 
(estimated as time to fall to 50% and 90% of admission values, Table 12) was 
significantly more rapid with artesunate than with quinine. However, more rapid parasite 
clearance was not reflected in median times to recover from coma, to eat, to sit unaided, 
to be discharged from hospital or to become afebrile. Parasite clearance times were not 
related to admission parasitaemia, hepatomegaly, haematocrit or fever.
The admission geometric mean plasma lactate concentration in patients who died 
was higher than in patients who survived (12.4 mmol/1 vs. 6.0 mmol/1; p<0.0001), and 
were also higher in those who presented with hypoglycaemia (geometric mean 10.7 
mmol/1 vs. 5.7; p=0.013). The parasite clearance time (PCT, Table 12) and the admission 
plasma lactate concentration were correlated (r=0.54, p=0.017; n=19), but parasitaemia 
and plasma lactate were not (r=0.35; p=0.12). Admission glucose levels were positively 
correlated with parasitaemia (r=0.501; p=0.02). There was no relationship between other
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clinical or parasitological estimates of recovery (Table 12) and admission lactate 
concentrations, and there were no effects of DCA on these variables when DCA was 
included as a covariate with either antimalarial drug.
Metabolic changes
To establish that kinetic measurements were carried out under steady state 
conditions, linear regression analysis of data points obtained at sampling times after 60 
min was used to estimate slopes for lactate and glucose disposal for each patient. The 
mean (95%CI) values of slopes for lactate and glucose disposal were -0.12(-0.62 to 0.38) 
and -0.08(-0.65 to 0.50), respectively, and were not significantly different (p >0.1) from 
zero. Admission plasma glucose and lactate levels were not correlated with each other 
(r=0.15, p=0.52), but glucose and lactate disposal rates were positively correlated (r=0.62, 
p=0.005). The mean (SD) Ra for glucose was 56(16) pmol/kg/min and the geometric 
mean (range) Ra for lactate was 100 (66-177) pmol/kg/min.
In all patients, glucose disposal was not related to admission glucose values (r=0.35; 
p=0.15) or admission insulin concentrations (r=0.04; p=0.86) or age of patient (r=0.025; 
p=0.92). By contrast, lactate disposal was positively correlated with admission lactate 
concentrations (r=0.66; p=0.002). Lactate disposal was also positively correlated with the 
time to recovery from coma in patients with cerebral malaria (r=0.84, p<0.001; n=15). 
There was no relationship between admission parasitaemia or temperature and measures 
of glucose or lactate kinetics (not shown).
Thirteen patients had sustained hyperlactataemia (lactate concentrations > 
5mmol/1), both at screening and at the time of admission to the study (six in the quinine or 
DCA treatment categories and seven in the artesunate or placebo categories) and 
represented children with the most severe metabolic derangement. The following results
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are therefore presented for 19 patients who were studied and separately for the subgroup 
of 13 more severely ill patients. Because the subgroup analysis was not specified 
prospectively, the results are exploratory.
Effects o f  antimalarials
Glucose
The plasma glucose and lactate concentrations obtained at the time of admission 
and during kinetic investigations were similar in patients who received quinine or 
artesunate (Table 11). Insulin levels at the start of the kinetic study were slightly higher in 
quinine-treated compared with artesunate-treated patients (p= 0.14) and were correlated 
with insulin levels measured after 60 min in the quinine group (r=0.99; p<0.001) but not 
the artesunate group (r=0.30; p=0.41). Insulin/glucose ratios were significantly higher in 
quinine-treated patients compared to subjects treated with artesunate during the study 
(F=4.45; p=0.05, with repeated measures analysis, Fig 16).
Glucose disposal was significantly lower in quinine-treated patients compared with 
those who received artesunate (Table 13, p=0.04). This difference was more obvious in 
the subgroup of patients who remained hyperlactataemic from the time of screening to the 
start of the study. In these individuals the mean ± SD glucose disposal was 49.2 ± 6.6 for 
subjects treated with quinine and was 70+15 pmol/kg/min for subjects administered 
artesunate (p=0.011. Fig 17). Gluconeogenesis, calculated from glucose disposal, was 
also significantly lower after treatment with quinine, compared with treatment with 
artesunate (Table 12), and accounted for a median (range) of 89.9% (83.7-93.6%) of the 
Ra values for glucose.
Lactate
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There were no differences in lactate disposal between the two antimalarial treatment 
groups as a whole (Figure 18), nor in the more severely ill patients with sustained 
acidosis.
Effects o f  dichloroacetate
Glucose
Glucose disposal was not significantly influenced by DCA, either in the group as a 
whole or in those patients with sustained hyperlactataemia.
Lactate
The mean (95% Cl) change in venous plasma lactate concentrations following DCA 
was -39(-55 to -22)% at the end of the study period (90 min) and was greater than the fall 
in plasma lactate after placebo administration -15(-55 to +50)%. However, within group 
variances obscured statistically significant differences in these two treatment groups. 
Lactate disposal was positively correlated with admission lactate levels (r=0.66, see 
above) and was not significantly different between patients who received DCA and those 
who did not (Table 12, p=0.6). However, in the 13 more severely ill patients with 
sustained hyperlactataemia, there was a highly significant difference in mean (95%CI) 
lactate disposal between DCA-treated patients (134(109-160) pmol/kg/min) and placebo- 
treated patients (97(80-114) pmol/kg/min; t=-3.2, p<0.01. Fig 18).
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Discussion
To optimise the management of hypoglycaemia and lactic acidosis in children with 
severe malaria, and to devise new treatment regimens, it is critical to understand the 
mechanisms that underlie these complications (White et al. 1987; White and Ho 1992). 
Studies in southeast Asian adults (White and Ho 1992), and in African children with 
uncomplicated malaria (Dekker et al. 1997a; Dekker et al. 1997b; Dekker et al. 1996) 
cannot be extrapolated to children with severe disease. Unravelling pathophysiological 
mechanisms in severely ill children is particularly complicated because both malaria itself 
and antimalarial drugs, such as quinine, contribute to metabolic derangements.
The Ra for glucose in our patients is approximately five times the value estimated in 
adults with severe malaria treated with quinine (Ra glucose-10 pmol/kg.min (Davis et al.
1993)). Glucose turnover is also much higher in children with severe malaria (Ra in this 
study = 56 pmol/kg.min), compared to children suffering uncomplicated infections with 
P. falciparum (Ra glucose ~ 26pmol/kg.min, (Dekker et al. 1997a)). Normal children 
have approximately threefold higher rates of glucose production (-35 pmol/kg.min) than 
do adults, and age influences these estimates significantly (Bier et al. 1977). We were 
unable to detect any influence of age on our glucose turnover estimates, as in our patients, 
the range of ages was relatively limited. To assess the metabolic effects of antimalarials, 
we allocated children to receive quinine or artesunate and evaluated their effects on 
glucose and lactate metabolism.
Quinine use is associated with higher mean insulin/glucose ratios and lower glucose 
turnover rates (by -30%) compared to artesunate (Table 12). In adults with severe 
malaria, there is a similar decrease (by -40%) in glucose turnover following treatment 
with quinine (Davis et al. 1993). Although insulin increases glucose utilisation by
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peripheral tissues and decreases gluconeogenesis by the liver, adults with severe malaria 
demonstrate peripheral resistance to insulin’s action (Binh et al. 1997). This suggests that 
the predominant effect of the relative hyperinsulinaemia {i.e. higher insulin/glucose 
ratios) in children who received quinine in our study was to decrease hepatic glucose 
production. Alternatively, there may be a significant non-insulin mediated component to 
glucose disposal in these patients, as was suggested to occur in adult patients with severe 
malaria who received quinine (Binh et al. 1997). Plasma levels of glucose did not fall to 
hypoglycaemic levels (< 2.2 mmol/1) partly because a constant infusion of glucose 
supplied approximately 10% of the total glucose requirements in these closely monitored 
individuals.
Our findings provide the first evidence that there are important differences in the 
effects of quinine and artesunate on glucose metabolism. Taken together with results from 
two large prospective studies (Hensbroek et al. 1996; Hien et al. 1996) that found 
artemether to be associated with fewer episodes of post-admission hypoglycaemia 
compared to quinine, our data indicate that wherever monitoring of plasma glucose is 
difficult, an artemisinin derivative may offer important advantages over quinine for 
children who are severely ill with malaria.
The fact that glucose and lactate kinetics are positively correlated in our subjects 
suggests that glucose is consumed predominantly through anaerobic pathways. This 
interpretation is consistent with our current understanding of the pathophysiology of lactic 
acidosis in severe malaria (Newton and Krishna 1998) and with the positive correlation 
we observed between Ra for lactate and plasma lactate concentrations. These results also 
suggest that increased production of lactate (rather than decreased disposal) is the most 
important determinant of hyperlactataemia in severe malaria in African children.
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Increased anaerobic glycolysis in severe malaria may be due to tissue hypoxia, to 
severe anaemia, enhanced skeletal muscle activity during seizures, the metabolic demands 
of parasitised erythrocytes, inhibition of mitochondrial glucose oxidation by host cells 
due to thiamine deficiency (Krishna et al. 1999), fever and associated increased cytokine 
production (Krishna et al. 1994b) and diminished clearance of lactate by the liver due to 
decreased hepatic blood flow (Pukrittayakamee et al. 1991; Pukrittayakamee et al. 
1994b).
The positive correlation between duration of coma and the lactate disposal rates is 
consistent with the hypothesis that microvascular obstruction, due to sequestration of 
infected erythrocytes, is an underlying mechanism that is common to the development of 
both cerebral malaria and lactic acidosis.
Overall, there was an elevated turnover of lactate in our study group when 
compared with similar measurements in other patient populations (e.g. 36 pmol/kg.min in 
healthy adults (Cowett and Wolfe 1991)). Values for lactate kinetics in our children were 
comparable to those obtained in non-acidotic adults with severe malaria who were treated 
with quinine (85pmol/kg.min, (Davis et al. 1996)).
DCA rapidly lowers plasma lactate concentrations in both adults and children with 
severe malaria (Krishna et al. 1995; Krishna et al. 1994a; Krishna et al. 1996). DCA 
treatment in patients who had sustained hyperlactataemia was also associated with a 
higher Ra for lactate. This suggests that basal lactate disposal is still capable of being 
augmented in these patients.
DCA stimulates pyruvate dehydrogenase and thus accelerates the oxidative removal 
of glucose, pyruvate and lactate (Krishna et al. 1996). It improved survival in an animal 
model of lactic acidosis due to malaria, when it was administered together with quinine
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(Holloway et al. 1995). DCA did not affect glucose concentrations or kinetics in our 
patients. This suggests that it is unlikely to cause hypoglycaemia in children with severe 
malaria who receive glucose supplementation. These effects, together with DCA’s 
stability and ease of use, make it a potentially important intervention to improve mortality 
in patients severe malaria complicated by lactic acidosis.
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Figure 16. Insulin/glucose ratios in patients receiving artesunate or quinine
The study protocol and sampling schedule are shown at the top of the graph. Mean (+ 
or - SEM) insulin/glucose ratios are given for patient who received artesunate (open 
circles) or quinine (filled squares) during the course of the study.
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Figure 17. Glucose disposal after treatment with artesunate and quinine
Glucose disposal rates were determined for patients who were hyperlactataemic (> 
5mmol/1) on admission to the study (filled circles) and for those whose lactates had 
fallen to <5mmol/1 from the time of screening to the time of admission to study (open 
circles).
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Figure 18. Lactate disposal after treatment with DCA or placebo
Lactate disposal rates were determined for patients who were hyperlactataemic (> 
5mmol/1) on admission to the study (filled circles) and for those whose lactates had 
fallen to <5mmol/1 from the time of screening to the time of admission to study (open 
circles).
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Table 11. A d m ission  clin ical and laboratory variables in patients.
Variable Quinine 
(n = 6)
Quinine + 
DCA (n = 5)
Artesunate 
(n = 5)
Artesunate + 
DCA (n = 5)
Sex (F/M) 5F/1M 2F/3M 2F/3M 2F/3M
Age (months) 39 (1 8 -7 2 ) 48 (1 8 -8 4 ) 1 8 (1 1 -6 9 ) 3 6 (1 8 -7 2 )
Body Mass 
Index (kg/m^)
15.7 (4.4) 15.1 (1.2) 15.5 (1) 15.8(1.2)
Heart rate 
(beats/min)
149(16) 161 (13) 146(16) 140 (28)
Respiratory
rate
(breaths/min)
56 (7.5) 50 (21 58 (15) 47 (12)
Mean arterial 
blood pressure 
(mmHg)
69(16) 73(5) 63 (13) 72 (22)
Axillary
temperature
CC)
37.8(1.6) 38.2 (0.3) 37.2 (0.8) 38.3 (0.6)
Liver (cm)^ 3.5 (3 -4 .5 ) 4 ( 0 - 6 ) 3 ( 0 - 5 ) 3 ( 0 - 4 )
Spleen (cm)^ 0 ( 0 - 3 ) 1 (0 -7 ) 1.5 (0 -6 ) 3 ( 0 - 8 )
Cerebral
malaria
3 3 4 5
Parasitaemia 
(no./pi)
602,050
298,930-
236,930
38,180-
168,380
42,700-411,470
153,060
26,380-960,590
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Range 1,798,840 761,140
Haematocrit
(%)
23 (9) 23(7) 19(6) 25 (5.5)
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Table 11 (continued). A d m ission  clin ica l and laboratory variables in  patients.
Variable All Quinine 
(n =11)
All artesunate 
(n = 10)
All placebo 
(n=  11)
All DCA 
(n=10)
Sex (F/M) lOF/lM 4F/6M 7F/4M 7F/3M
Age (months) 48 (1 8 -8 4 ) 3 0 (1 1 -7 2 ) 30(11 -7 2 ) 48 (1 8 -8 4 )
Body Mass 
Index (kg/m^)
15.4 (3.2) 16(1) 16(3) 15(1.2)
Heart rate 
(beats/min)
155(16) 143 (22) 148 (16) 151 (23)
Respiratory
rate
(breaths/min)
54(15) 52 (14) 57(11) 49 (16)
Mean arterial 
blood pressure 
(mmHg)
71(12) 68(18) 66 (14) 72(15)
Axillary
temperature
CC)
38(1.2) 37.7 (0.9) 37.6(1.3) 38.2 (0.4)
Liver (cm)^ 4 ( 0 - 6 ) 3 ( 0 - 5 ) 3 ( 0 - 5 ) 3.3 (0 -6 )
Spleen (cm)^ 0 ( 0 - 7 ) 2.5 (0 -8 ) 0 ( 0 - 6 ) 1.5 (0 -8 )
Cerebral
malaria
6 9 7 8
Parasitaemia 
(no./pi)
394,040
38,180-
159,740
26,380-
337,360
42,700-1,798,840
189,470
26,380-960,590
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Range 1,798,840 960,590
Haematocrit
(%)
23 (8) 22(6) 21(8) 24(6)
All data are presented as the mean (SD) or the median (range) values unless otherwise 
specified
 ^Measured from the intercostals margin in the mid-clavicular line.
Table 12. Clinical and parasitological measures of recovery after quinine and 
artesunate
Variable (h) Quinine
( n = l l )
Artesunate
(n=10)
Difference
iP)
P C 50 19.5 (7.8) 10.9(7.9) 0.025
P C 90 28.6(5.6) 18.7 (7.1) 0.003
P C X 48 (30 -  72) 3 6 (2 4 -7 2 ) 0.057
PCX 36.5 (0 -1 1 6 ) 1 8 (0 -8 9 ) 0.35
Coma recovery^ 8 ( 3 -  72) 12(1 .5 -72 ) 0.70
All data are the mean (SD) or the median (range) values. PC50 and PC90, Times for 
parasitaemia to fall to 50% and 90% from baseline values; PCX, parasite clearance 
time (i.e. the first time point at which blood films become negative for malarial 
parasites); PCX, time for axillary temperature to fall and remain below 37 °C.
 ^The numbers of patients with cerebral malaria are given in Table 13.
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Table 13, Metabolic data in patients according to treatment.
Variable Quinine (n = 6) Quinine ± DCA 
(n = 5)
Artesunate 
(n = 5)
Artesunate 
±DCA (n = 5)
- 5 min
Plasma glucose 
(mmol/L)
6.79 d= 4.01 
6.12(4.38-14.8)
7.32 ±5.15 
6.19(3-16,1)
5.59 ±0.5 
5.57(4.93-6.21)
7.03 ± 2.27 
6.76(4.54-10.7)
Plasma lactate 
(mmol/L)
9.12 ±4.3 
8.23(4.38-14.5)
5.93 ±3.06 
5.43(3.66-11.2)
5.47 ± 1.94 
5.15(2.66-8.06)
8.92 ± 4.02 
8.07(3.51-14.3)
Plasma insulin 
(pmol/L)
26(16-56) 44(16-230) 10.7(1-36) 8.9 (1-52)
Plasma insulin/ 
glucose ratio
4.9 ±2.6 9.1 ± 7 3 ±2.2 3.2 ±2.8
60 min
Plasma glucose 
(mmol/L)
6.57 ± 2.86 
6.15(4.34-11.2)
6.02 ±3.4 
5.4(3.17-11.8)
6.1 ±0.28 
6.08(5.6-6.93)
6.48 ±3.32 
5.95(3.85-12.2)
Plasma lactate 
(mmol/L)
7.62 ±4.41 
6.61(3.58-12.7)
4.52 ±3.97 
3.52(1.5-11.4)
4.49 ±2.41 
4(1.95-7.17)
7.25 ±4.61 
6(2.42-13.5)
Plasma insulin 
(pmol/L)
32 (1-72) 38 (13-201) 23 (12-42) 20 (1-38)
Plasma insulin/ 
glucose ratio
4.8 ±4.1 9.1 ± 7 4.1 ± 1.6 2.4 ±2.8
70 -  90 min
Lactate disposal 
(pmol/kg.min)
106 ±35 
101 (67-155)
89 ±28 
86 (66-129)
94±  16 
93 (73-113)
128 ±38 
123 (72-177)
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Glucose
disposal
(pmol/kg.min)
50 ±7.6 
50 
(42-62)
49 ± 9.3 
48 
(36-62)
57± 16 
56 
(42-79)
69 ±21 
65 
(33-84)
Glucose 45 ± 7.2 43 ±9.6 51 ± 16 63 ±21
production 45 42 49 59
(pmol/kg.min) (39-56) (30 -  57) (3 6 -7 3 ) (27-78)
Table 13 (continued). Metabolic data in patients according to treatment.
Variable All quinine 
(n=  11)
All artesunate 
(n=10)
All placebo 
(n = 11)
All DCA 
(n = 10)
- 5 min
Plasma glucose 
(mmol/L)
7.03 ±4.33 
6.15 
(3-16.1)
6.31 ± 1.73 
6.14 
(4.54-10.7)
6.3 ± 2.9 
5.86 
(4.38-14.8)
7.2 ±3.8 
6.47 
(3-16.1)
Plasma lactate 
(mmol/L)
7.67 ±3.97 
6.82 
(3.66-14.5)
7.19 ±3.49 
6.45 
(2.66-14.3)
7.46 ±3.8 
6.65 
(2.66-14.5)
7.42 ± 3.7 
6.63 
(3.51-14.3)
Plasma insulin 
(pmol/L)
33 (16-230) 9.8 (1-52) 17.4 (1-56) 19.7(1-230)
Plasma
insulin/glucose
ratio
6.8 ± 5.3 3.1 ±2.4 4.1 ±2.5 6.1 ± 6
60 min
Plasma glucose 6.3 ±3 6.29 ± 2.25 6.34 ± 2 6.3 ± 3.2
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(mmol/L) 5.8
(3.17-11.8)
6.01(3.85-
12.2)
6.12
(4.34-11.2)
5.67
(3.17-12.2)
Plasma lactate 
(mmol/L)
6.07 ±4.28 
4.82 
(1.55-12.7)
5.87 ±3.76 
4.87 
(1.95-13.5)
6.06 ±3.7 
5.12 
(1.95-12.7)
5.89 ±4.3 
4.59 
(1.55-13.5)
Plasma insulin 
(pmol/L)
36 (1-209) 22 (1-42) 26 (1-72) 30 (0-209)
Plasma
insulin/glucose
ratio
7.2 ± 6 3.2 ±2.3 4.4 ± 2.7 5.7 ±6.1
70 -  90 min
Lactate disposal 
(pmol/kg.min)
98 ±31 
94 (66-155)
113 ±34 
108 (72-177)
101 ±27 
98 (67-155)
109 ±38 
103 (66-176)
Glucose disposal 
(pmol/kg.min)
49 ±8*^  
49 (36-62)
64 ± 19b 
61(33-84)
53 ±12 
52 (42-79)
59± 19 
56 (33-84)
Glucose
production
(pmol/kg.min)
44±8b 
44 (30-57)
58 ± 19b 
55 (27-78)
48±  12 
47 (36-73)
53 ±19 
50 (27-78)
appropriate. DCA, dichloroacetate.
 ^ Five patients in the quinine and four in the artesunate group completed kinetic 
studies.  ^ p  < 0.005 between treatment groups.
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C o n c lu s io n s
The mortality in severe malaria has remained stubbornly high at 10 ~ 20% 
despite the use of intensive care (Warrell 1999). This is in spite of increasingly 
effective and rapidly acting anti-malarial drugs such as the artemisinin derivatives 
(Hensbroek et al. 1996; Hien et al. 1996) and has prompted the investigation of 
adjuvant therapies such as cytokine modifying drugs such as anti-TNF antibodies (van 
Hensbroek et al. 1996) and pentoxifylline (Looareesuwan et al. 1998). These 
unfortunately have proved as ineffective as did steroids and heparin some 20 years 
earlier (Warrell et al. 1982). New ideas are needed, based on what is known of the 
pathophysiology of severe malarial disease. My recent work has examined a few of 
these newer pathophysiological avenues with a view to developing new approaches to 
the care of the severely ill patient with malaria.
The pathophysiology of the anaemia of severe falciparum malaria is complex 
and multifactorial, and results in a condition that is a major cause of mortality and 
morbidity in patients living in malarial endemic areas. Falciparum malaria was the 
primary cause in 46 cases (46%) of children with severe anemia admitted to hospital 
in Kenya (Newton et al. 1997). The importance of anaemia as a cause of death in 
malaria may well be underestimated. The mortality rate in the children with severe 
malarial anemia was 8.6% compared with 3.6% in children with severe anemia due to 
other causes (Newton et al. 1997). There is undoubtedly an interaction between 
anaemia and acidosis (English et al. 1997; Marsh and Snow 1997). Some of the work 
detailed here has attempted to elucidate the steps in infected and uninfected 
erythrocyte destruction. The finding of erythrocytes that had malaria antigens 
incorporated into the red cell membrane but without plasmodial DNA suggested that
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there were methods for removal of parasites in vivo that did not necessarily result in 
the immediate loss of the erythrocyte (Angus et al, 1997). This may be a mechanism 
for salvaging some erythrocyte function until new erythrocytes can be generated. 
Other studies involving measurement of red cell deformability showed that changes in 
elongation index relate to the development of anaemia and implicate splenic clearance 
indirectly as the main mechanism for this (Dondorp et al, 1999).
Resetting was thought to be important in the process of microvascular 
obstruction in falciparum malaria and it may well be a contributing factor. Anti- 
rosetting antibodies were described as being disease modifying (Carlson et al. 1990a). 
Our reports of resetting in other species of plasmodia such as P. ovale (Angus et al,
1997) and P. vivax (Udomsangpetch et al. 1995) put this in doubt. Since this report 
resetting has also been described in Plasmodium malariae (Lowe, Mosobo, and Bull
1998), a finding that we have ourselves confirmed (unpublished data).
Exchange blood transfusion (ET) has been and is still used in many parts of the 
world for the treatment of severe falciparum malaria (Aquinas et al. 1996; 
Gulprasutdilog et al. 1999; Mathon et al. 1999). In general the consensus opinion is 
that exchange transfusion should be reserved for patients with hyperparasitaemia of 
>10% and with complications of multi-organ failure or with hyperparasitaemia >30% 
without complications. Since no randomised trials have been done the evidence for 
the indications, application and efficacy of its use are based on case reports and 
retrospective studies. Recent reports have been of automated exchange that may allow 
more rapid and predictable therapy (Macallan et al. 1999; Mainwaring et al. 1999). In 
the largest retrospective non-randomised study so far a 20% reduction in mortality 
was claimed (Hoontrakoon and Suputtamongkol 1998) although the control group
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mortality was high at 69%. The rationale put forward for this form of therapy is based 
on (1) rapid reduction in parasite load by exchange transfusion, (2) removal of toxic 
substances and (3) reducing microcirculatory sludging (Pasvol and Jacobs 1999; 
White 1999). There are some problems with these theories. It is the sequestrated 
parasites that are causing the damage and these are not removed by exchange 
transfusion. However mathematical modeling of the reduction of parasitaemia by 
exchange transfusion predicts a 25% smaller reduction in parasitaemia than is 
observed (Van den Ende et al. 1994; Wilkinson et al. 1994) implying that some 
sequestered parasites may be removed. At lower parasitaemias however the reduction 
in parasite count must follow an exponential curve and therefore be of increasingly 
diminishing returns. TNF has not been shown to be reduced by exchange transfusion 
(Chuncharunee et al. 1997). ET has been shown to increase oxygen delivery and 
improve cardiovascular work by an unknown mechanism (Beards, Joynt, and Lipman
1994). In practice, the amount of compatible blood required for total exchange is 
rarely available in areas endemic for malaria and the risks of the procedure including 
transfusion-related infections are high. Our recent work has suggested that changes in 
red cell deformability may be a further rationale for its use. There have been no 
randomized controlled trials of exchange transfusion and indeed these would be 
difficult to perform and need large numbers to show a significant effect on mortality. 
Our finding that red cell deformability in a subset of patients with severe disease was 
strongly predictive of death allows further studies to focus on this group. Power 
calculations for a further study to give a 25% reduction in mortality would require 
around 30 patients only. These studies are currently being done in Kenya in African 
children. This has several logistical advantages in that there are more patients with
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severe disease and they require less blood for the exchange. The other area that is still 
being pursued is the nature of the rigidifying factor that we have shown to cause 
changes in red cell deformability from the serum of severely ill patients that is also 
present in used malaria culture medium.
There has been a huge interest in the role of inducible nitric oxide in malaria 
recently. There is, however, still no consensus on the clinical significance as far as 
measuring serum or urinary nitrates are concerned. The lack of any difference 
between the groups studied in our two studies may be due to the inherent problems 
involved in measuring total nitrite excretion (Agbenyega et al, 1997; Dondorp et al,
1998). The hypotheses about associations between the pathophysiological effects of 
nitric oxide and severe malarial disease continue to be published predicting either 
benefit or harm (Al-Yaman et al. 1996; al-Yaman, Genton, and Clark 1998; Anstey et 
al. 1996; Burgner et al. 1998; Clark, Rockett, and Cowden 1991; Clark, Rockett, and 
Cowden 1992; Clark, Cowden, and Rockett 1993; Clark, Cowden, and Rockett 1995; 
Kremsner et al. 1996; Kun et al. 1998; Rockett et al. 1992; Taylor-Robinson and 
Looker 1998). This has more recently been extended to measuring inducible nitric 
oxide synthetase mRNA in patients but with similarly confused results (Burgner et al. 
1998; Chiwakata, Hemmer, and Dietrich 2000; Kun et al. 1998). Given that the role 
of nitric oxide is probably dichotomous, that is it is simultaneously protective and 
harmful (Taylor-Robinson and Smith 1999) this is not surprising and reminiscent of 
the situation with TNF (Tracey 1995). Previous clinical studies of nitric oxide 
synthesis inhibitors have not been encouraging (Avontuur et al. 1998) and so this does 
not look like a promising avenue for therapeutic intervention.
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Acidosis is an important contributor to mortality in malaria accounting for 43% 
of cases admitted to hospital in a study in Kenya (English et al. 1997). We have 
measured both lactate and glucose turnover in severe malaria and then have studied 
the utility of using dichloracetate as adjunctive therapy in severe malarial acidosis. 
Other approaches have been reported recently. In Vietnamese adults dopamine 
reduced whereas adrenaline infusion increased acidosis in severe disease (Day et al. 
1996) In animal models infusion of cross-linked haemoglobin reduced acidosis in 
mice again highlighting the interaction between anaemia and acidosis in malaria 
(Freilich et al. 1999). There is no doubt that another factor contributing to the 
generation and maintenance of acidosis is hypovolaemia (English et al. 1997). Fluid 
replacement using whatever is available be it blood or crystalloid is a priority in 
severe malaria and it was striking that even in the control groups that we studied the 
replacement of volume even if only by crystalloid caused great improvement in 
acidosis. The studies presented here have been used as the basis for a large 5-year 
study of the effect of DCA on mortality in African children at this study site funded 
by the National Institutes of Health.
The drug, artesunate, was used in the studies to measure lactate and glucose 
turnover. This is one of a group of new drugs called the artemisinin derivatives. These 
drugs, the sesquiterpene lactones have been shown to be of a unique structure, have a 
unique mechanism of action and are very potent in vitro (Klayman 1985). They have 
been widely used in South East Asia particularly China and Vietnam and have been 
well tolerated. Artesunate is the water soluble hemi-succinate form which is rapidly 
hydrolysed to the active compound dihydroartemisinin (DHA) with good 
bioavailablity, a rapid onset of action and a short half-life (around 45 minutes). It can
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be given as an intravenous or intramuscular injection as well as orally or per rectum. 
Recent studies comparing a sister compound the more lipid soluble artemether given 
intramuscularly with quinine have not shown a difference in mortality but have shown 
the artemisinin derivatives to be safe and well tolerated (Hensbroek et al. 1996; Hien 
et al. 1996; Pittler and Ernst 1999). In particular the main difference was in the 
occurrence of hypoglycaemia. Quinine is well known to induce hypoglycaemia 
(Taylor et al. 1988) while artesunate does not and these differences were highlighted 
in our studies. Since hypoglycaemia is itself a consequence of malaria obviously 
exacerbation of this is not a good thing particularly in situations where monitoring of 
the patient may not be all it should be. In view of the increasing resistance to 
commonly used antimalarial drugs including quinine the artemisinin derivatives are 
critical to “averting a malaria disaster” (White et al. 1999).
In conclusion, my studies have concentrated on pathophysiology in severe 
falciparum malaria. They have opened new avenues for trials for new adjunctive 
therapies in this disease. Red cell deformability may be the key to validating 
exchange transfusion in malaria, there is still no evidence for the exact role of nitric 
oxide as a mediator of disease and dichloroacetate has been shown to be safe and 
effective in reducing lactic acidosis in African children.
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Appendix 1. The intensive care units in Thailand (top) and Ghana (bottom). 
Central venous cannulation was performed for exchange transfusion.
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Appendix 2. A Ghanaian patient with typical features of cerebral malaria, comatose, 
fitting with extensor posturing and hepatomegaly. The patient recovered completely 
with no clinically detectable neurological deficit.
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